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Preface
Lower urinary tract dysfunction (LUTD) is an umbrella diagnosis that covers the
abnormalities of anatomy and function in the bladder, urethra, and, in men, the
prostate. People with LUTD face a number of social, mental, and physical health
effects due to the symptoms. Despite the increasing evidence in the assessment and 
management of lower urinary tract symptoms (LUTS), it remains a challenge to
bridge the gap between research evidence and clinical practice. In this book, the
authors demonstrate their understanding of how to apply the evidence to clinical 
practice from different aspects.
Based on epidemiological evidence, LUTS are heterogeneous between men and 
women, which is ascribed to the anatomical difference in the urethra between
genders. Generally, pelvic organ prolapse (POP) is a common cause for elderly
women to experience LUTS, while benign prostatic hyperplasia is the common
cause for elderly men. Accurate evaluation and classification of POP is an important
part of physical examination, which is certainly helpful for the development of a
therapeutic strategy. Dr Priyanka Bhadana illustrates the assessment approaches of
POP. This chapter includes many pictures that will help the readers understand POP.
Besides physical examination, urodynamic study has been playing an important
role in the accurate assessment of LUTD. However, the majority of patients tend 
to prefer a noninvasive assessment compared to invasive urodynamics. Dr George
Asafu Adjaye Frimpong and his colleagues present the infeasibility in using 
imaging modalities, including MRI, CT scan, ultrasound, PET, and fMRI, to assess
the function of the lower urinary tract, instead of urodynamics. Not only are the
innovative imaging techniques introduced, but also the advantages of each imaging 
modality for diagnosis of LUTD is interpreted in detail. Although these imaging 
modalities may not replace urodynamics completely, these approaches can be a
substitute for urodynamics and provide useful information for clinicians.
Stress urinary incontinence (SUI) is one of the most common storage LUTS in
females. Although the mid-urethral sling results in therapeutic success, it is still 
unclear how to predict the risk of SUI for individuals. Goran Mitulović introduces
an innovative approach to detect potential SUI using proteomic analysis of the urine
protein. Once a specific population group susceptible to SUI is identified, active
surveillance could be provided as early as possible. In addition, behavior therapy, 
pelvic floor muscle training, and biofeedback, as a prevention strategy, may also be
considered.
Nocturnal enuresis (NE) is a common condition in children. In general, the
pathogenesis of NE mainly includes nocturnal polyuria, bladder capacity decline
during nighttime, and arousal disorder. With the development of pharmacotherapy, 
a number of medications can be used to solve these problems. However, how to
accurately assess and achieve precision medicine for each patient is still not easy. 
To help readers develop a proper therapeutic strategy for children with NE, Dr
Zhou and her colleagues present current evidence in management of NE. Besides
modern medicine, the complementary and alternative medicine approaches are also
II
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introduced. It is worth mentioning that Dr Zhou et al. show their research results in 
the chapter, which demonstrates the high level of evidence in the effectiveness of 
acupuncture in managing NE.
Urethral stricture is a common cause for men to experience lower urinary tract 
obstruction. Basically, the male urethra consists of the prostatic, membranous, 
bulbar, and penile urethra. In comparison with other segments, the penile urethral 
stricture is more complex to reconstruct. Prof. Martins uses a chapter to sketch out 
an overall perspective on penile urethroplasty. In it, he demonstrates both historical 
and innovative surgical procedures, which allows readers to obtain an outline of 
the surgery. Furthermore, he presents an algorithm of surgical reconstruction for 
different stricture sites, which provides a practical guide for clinicians.
Comorbidity has been the focus in the intervention studies for LUTS. Some recent 
surveys show a strong association between LUTS and male sexual dysfunction. 
Understanding the relationship may allow physicians to manage LUTS and sexual 
dysfunction simultaneously. Dr Konstantinidis and his colleagues bring us a chapter 
that discusses the comorbidity in the male population. Not only are the involved 
biochemical pathways described, but the therapeutic strategy is discussed based on 
current evidence.
In this book, experts and researchers from different countries present the latest 
evidence in diagnosis and treatment of LUTD. Although these chapters cannot 
cover all aspects of LUTD, they provide readers with important updates on LUTD. 
I believe that the more the doctors understand an disease, the more benefit the 
patients receive. This book is a key to help readers to open the door to LUTD. I hope 
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Lower urinary tract symptoms (LUTS) refer to a series of symptoms due to 
bladder or urethral dysfunction and are basically divided into three groups: storage, 
voiding, and post-micturition symptoms [1]. Of those, storage symptoms include 
urinary urgency, increased daytime frequency, nocturia, and different types of 
urinary incontinence. Voiding symptoms include slow stream, splitting or spraying 
of the urine stream, intermittency, hesitancy, straining to void, and terminal dribble. 
Post-micturition symptoms include feeling of incomplete emptying and post-mictu-
rition dribble. A number of epidemiological studies reported the prevalence of LUTS 
that varies from country to country. EPIC study performed a population-based, 
cross-sectional survey in Canada, Germany, Italy, Sweden, and the United Kingdom 
using computer-assisted telephone interview and showed the overall prevalence of 
LUTS was approximate 64.3% [2]. The EpiLUTS study investigated the prevalence 
of LUTS in the USA, United Kingdom, and Sweden according to an Internet-based 
survey. The results revealed that the prevalence of at least one LUTS in male and 
female population was 72.3 and 76.3%, respectively [3]. Another study demonstrated 
that the prevalence in South Korea was 68.5%, which is higher than 59% in Mainland 
China and 58.5% in Taiwan [4]. The heterogeneity in LUTS prevalence may derive 
from the difference in genetic, diet, and lifestyle factors for people in different 
countries. In terms of the gender difference, some studies showed that storage LUTS 
were more common in women than in men, while voiding and post-micturition 
LUTS were more common in men than in women [3, 4]. Furthermore, women have 
a higher proportion to experience storage and voiding LUTS simultaneously in 
comparison with men. The difference in LUTS between male and female may result 
from the different anatomy of urethra. Men have an additional organ, prostate, and a 
longer urethra compared to women, which means men are more likely to experience 
bladder outlet obstruction than women. Due to the gender difference, it appears to be 
reasonable to only focus on single-gender population when designing a clinical trial 
or research about LUTS. Recently a number of clinical trials and research studies have 
emerged in the assessment and management of LUTS. With the evidence increas-
ing, it is worth considering how to apply these findings to clinical practice. We try to 
introduce the emerged evidence based on clinical practice from different aspects.
2. Clinical assessment for LUTS
It remains a challenge how to make an accurate assessment for LUTS and iden-
tify the potential causes since the etiology of LUTS is diverse. According to EAU 
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guideline, a number of conditions, including detrusor overactivity, underactive 
bladder, nocturnal polyuria, urethral stricture, etc., may contribute to male LUTS 
besides benign prostatic obstruction [5]. For female LUTS, increasing evidence 
shows that bladder outlet obstruction may play an important role in addition to 
pelvic floor dysfunction [6].
In general, physical examination can provide the helpful information for the 
etiological diagnosis of LUTS. Besides regular ones, bulbocavernosus reflex test 
is really useful to check the intactness of S2–S4 spinal reflex arc. Because sacral 
micturition center is located in S2–S4, this test is helpful to recognize the LUTS 
secondary to sacral or pudendal neuropathy. Additionally, the evaluation for pelvic 
floor function is essential for women with LUTS since it can identify the pelvic floor 
muscle tone, as well as the pelvic organ prolapse.
Traditionally, urodynamic study has been considered as a standard diagnostic 
tool for lower urinary tract dysfunction. Basically, urodynamic test contains filling 
cystometry (CMG) and pressure-flow studies (PFSs). The former is used to assess 
the storage function of the lower urinary tract, whereas the latter is used to evaluate 
the voiding function. Besides detecting bladder sensitivity, compliance, and detru-
sor overactivity, CMG can distinguish stress and urgency urinary incontinence. 
PFSs are normally used to diagnose bladder outlet obstruction. Furthermore, PFSs 
can also evaluate detrusor contraction, which is useful to find underactive bladder, 
a common cause of LUTS.
Despite advantages of urodynamic study, majority of patients tend to accept a 
noninvasive assessment compared to invasive urodynamic test. With the emergence 
of innovative imaging techniques, both anatomy and function of lower urinary 
tract can be assessed by noninvasive imaging approaches. In general, ultrasound 
is the most common technique to diagnose the lower urinary tract dysfunction. 
Some studies have shown that increased resistance of bladder contraction during 
the voiding phase in patients with bladder outlet obstruction (BOO) can result in an 
increase of bladder wall thickness (BWT), so can frequent detrusor overactive (DO) 
during the storage phase in patients with overactive bladder (OAB) [7, 8]. Based on 
this finding, a series of ultrasonographic parameters, including BWT, detrusor wall 
thickness (DWT), and ultrasound-estimated bladder weight (UEBW), have been 
used to diagnose BOO and DO. Furthermore, ultrasound strain imaging is also a suc-
cessful method to evaluate LUTS since it can monitor the change in the BWT during 
micturition in real time. In addition, near-infrared spectroscopy is a functional 
imaging technique which can detect changes in the concentration of oxygenated 
hemoglobin and deoxygenated hemoglobin in the bladder wall and consequently 
identify the DO and BOO. In comparison with ultrasound, MRI may provide 
additional important clue for the diagnosis of lower urinary tract dysfunction. Brain 
functional MRI is helpful to detect the neurologic lesions demerging bladder control. 
Dynamic MRI is able to detect the pelvic organ prolapse, as well as the urethral 
hypermobility, which cannot be found by physical examination or static MRI.
3. Management of LUTS
Successful management for LUTS is based on the deep understanding on specific 
symptoms and accurate diagnosis on potential cause of LUTS. For patients with 
predominant voiding LUTS, it is essential to distinguish between BOO and underac-
tive bladder (UAB). Once BOO is diagnosed clearly, α-blockers could be considered 
as the initial treatment. For male patients, if the BOO is secondary to significant 
enlarged prostate (>40 ml), 5α-reductase inhibitor is recommended to be added to 
shrink the prostate volume [5]. Moreover, there is increasing evidence to suggest 
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phosphodiesterase type 5 inhibitors (PDE5-Is) can relieve LUTS secondary to benign 
prostatic obstruction effectively though nitric oxide/cyclic guanosine monophosphate 
pathway (NO/cGMP). For patients who fail to respond to pharmacotherapy, minimal 
invasive surgical intervention, such as transurethral resection, could be an optional 
treatment. It is worth mentioning that urethral stricture is also a common cause of 
BOO and can be treated by urethral dilatation, internal urethrotomy, or urethroplasty 
depending on the characteristics of the stricture. The management of UAB, by con-
trast, is controversial because no regulatory approved specific therapy is available so 
far. Currently, the potential optional treatments for UAB include muscarinic agonists, 
regenerative therapy with mesenchymal stem cells or autologous muscle derived cells, 
gene therapy with myoblast injection, and neuromodulation [9].
In terms of patients with predominant storage LUTS, OAB is the most common con-
dition. Although behavioral interventions are recommended to be first-line treatment 
for OAB by guidelines, muscarinic antagonists and β3 agonists are normally used as the 
initial treatment in clinical practice. Once pharmacotherapy is unable to improve LUTS 
effectively, some invasive approaches including sacral neuromodulation, botulinum 
toxin type A intradetrusor injection, and posterior tibial nerve stimulation can be con-
sidered as the advanced therapeutic strategy. Urinary incontinence (UI) is another con-
dition related to storage LUTS, and successful management mainly relies on the precise 
identification for different types. Urgency UI can be managed by the approaches similar 
with the ones for OAB. Mid-urethral sling has been mainstream intervention for stress 
UI since the consolidated theory was proposed by Dr. DeLancey in 1996. Compared to 
pure stress or urgency UI, mixed UI is more difficult to treat since its complex etiol-
ogy. Today, the treatment only focuses on the main component of mixed UI. Besides 
conventional therapy, increasing high-level evidence demonstrates the effectiveness of 
complementary and alternative medicine on different types of UI [10, 11]. Nocturia is 
also a bothersome storage LUTS which not only can weaken patients’ quality of life but 
also may increase the risk of mortality. Management of nocturia had been a contro-
versial issue until the classification of nocturia was proposed, which allows clinicians 
to provide precision treatment for patients. It is reported that the main factors con-
tributing to nocturia include nocturnal polyuria and bladder capacity decline during 
nighttime. The former can be managed by desmopressin or diuretics, whereas the latter 
can be treated by muscarinic antagonists and β3 agonists. It is important to differenti-
ate nocturnal enuresis from nocturia in clinical practice, because both of them occur 
during the nighttime. The main difference between the two symptoms is whether the 
patient is accompanied by sleep arousal. Nocturnal enuresis occurs during sleep, while 
nocturia is presented in arousal. Moreover, nocturnal enuresis, also known as bed-wet-
ting, is more likely to present in children, while nocturia is common in adults. Similar to 
the pathogenesis of nocturia, nocturnal polyuria, and bladder capacity decline during 
nighttime are the potential pathogenesis of nocturnal enuresis too. Besides, arousal 
disorder also plays an important role for the occurrence of nocturnal enuresis. For this 
factor, alarm therapy could be helpful in waking the children up.
In summary, accurate clinical assessment is the prerequisite to manage LUTS 
successfully. Only with the sufficient understanding in characteristics and potential 
causes of LUTS can an individual management strategy be developed, which may 
optimize the treatment effect.
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Pelvic organ prolapse (POP) is a common, benign condition in women, and 
patient can present with complaints of vaginal bulge and pressure, voiding and 
defecatory, and sexual dysfunction, which may adversely affect quality of life. 
Although POP can occur in younger women, it is commonly seen in aging popula-
tion with a prevalence of 45–50%. Older terms describing pelvic organ prolapse 
(e.g., cystocele, urethrocele, rectocele) have been replaced because they do not 
provide complete information regarding the structures on the other side of the 
vaginal bulge, especially in women who have had previous pelvic organ prolapse 
surgery. Therefore, a thorough history and performing a careful physical examina-
tion with dignity and care, using some basic tools that aid in the accurate evaluation 
of anatomical and functional defects, should be conducted. A standardized assess-
ment system has been used to document findings which should explain everything 
in understandable terms.
Keywords: uterovaginal prolapse, POP-Q
1. Introduction
Pelvic organ prolapse (POP) is the herniation of the pelvic organs to or 
beyond the vaginal walls. Many women with prolapse experience symptoms 
that impact daily activities, sexual function, and exercise. The presence of 
POP can have a detrimental impact on body image and sexuality. Pelvic organ 
prolapse is an increasingly common condition seen with aging population with 
a prevalence of 41–50% of women above 40 years. The annual incidence of 
surgery for POP is within the range of 15–49 cases per 10,000 women years 
[1]. Pelvic floor defects result from attenuation of the supportive structures 
or by neuromuscular dysfunction due to obstetric trauma. Pregnancy itself, 
without vaginal birth, has been cited as a risk factor as well. Genital atrophy 
and hypoestrogenism also play important contributory roles in the pathogenesis 
of prolapse. However, the exact mechanisms are not completely understood. 
Prolapse may potentially result from pelvic tumors, sacral nerve disorders, and 
diabetic neuropathy [2].
Older terms describing pelvic organ prolapse (e.g., cystocele, urethrocele, 
rectocele) have been replaced because they do not provide complete information 
regarding the structures on the other side of the vaginal bulge, especially in women 
who have had previous pelvic organ prolapse surgery.
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Presently, the pelvis is divided into anterior, posterior, and middle or apical 
compartments. Following hysterectomy, prolapse of the vaginal apex with or 
without prolapse of the anterior and/or posterior vaginal wall is referred to as vault 
prolapse [2, 3].
2. Classification of pelvic organ prolapse
Pelvic organ support is maintained by complex interactions between the vagina, 
levator ani muscle, and pelvic floor connective tissue. A system of three integrated 
levels of vaginal support has been described by De Lancey [1].
• Level 1: The cardinal uterosacral ligament complex.
• Level 2: Midvaginal supports—pubocervical and rectovaginal fascia.
• Level 3: Urogenital diaphragm and the perineal body.
The prolapse is usually described according to the area of the vagina in which it 
occurs. Assumptions are often made about which organ is behind the vaginal wall 
that is prolapsing.
Anatomical classification according to vaginal wall:
• Anterior: cystocele (bladder most common) and urethrocele (urethra).
• Middle: vault of the uterus (after hysterectomy).
• Posterior: rectocele (rectum) and enterocele (small bowel, omentum).
2.1 Shaw’s classification
• Anterior wall
 ○ Upper 2/3 cystocele
 ○ Lower 1/3 urethrocele
• Posterior wall
 ○ Upper 1/3 enterocele
 ○ Middle 1/3 rectocele
 ○ Lower 1/3 deficient perineum
• Uterine prolapse
 ○ Grade 0: Normal position
 ○ Grade 1: Descent into vagina not reaching the introitus
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 ○ Grade 2: Descent up to the introitus
 ○ Grade 3: Descent outside the introitus
 ○ Grade 4: Procidentia [2]
• Uterovaginal prolapse usually occurs in nulliparous prolapse due to congenital 
weakness of cervical ligaments.
• Vaginouterine prolapse usually occurs in cases of prolapse resulting from 
obstetrical trauma.
3. Pelvic organ prolapse quantification system (POP-Q )
Pelvic organ prolapse quantification system refers to an objective, site-
specific system for describing, quantifying, and staging pelvic support in women 
(Figure 1). It provides a standardized tool for documenting, comparing, and 
communicating clinical findings with proven interobserver and intraobserver reli-
ability. The POP-Q system gained the attention of the specialists all over the world, 
being approved by the International Continence Society (ICS), the American 
Urogynecologic Society (AUGS), and the Society of Gynecologic Surgeons for the 
description of female pelvic organ prolapse. It is the most common system used 
by gynecologists and urogynecologists, although other systems have been devised 
(Figures 2–9) [4].
The POP-Q may be an easier classification system to use in routine clinical 
practice. It was developed by the International Urogynecological Association to 
provide a less cumbersome exam tool [4]. The POP-Q stages (Table 1) prolapse 
Figure 1. 
POP-Q points. Aa, anterior vaginal wall 3 cm proximal to the urethral meatus (−3 cm to +3 cm); Ba,most 
distal position of the remaining upper anterior vaginal wall (−3 cm to +tvl); C, most distal edge of 
cervix or vaginal cuff scar; D, posterior fornix (n/a if posthysterectomy); Ap, posterior vaginal wall 3 cm 
proximal to the hymen (−3 cm to +3 cm); Bp, most distal position of the remaining upper posterior vaginal 
wall (−3 cm to + tvl); genital hiatus (gh), measured from the middle of external urethral meatus to the 
posterior midline hymen; perineal body (pb), measured from the posterior margin of gh to the middle 
of anal opening; total vaginal length (tvl), depth of the vagina when point D or C is reduced to normal 
position.
Lower Urinary Tract Dysfunction - From Evidence to Clinical Practice
12
Presently, the pelvis is divided into anterior, posterior, and middle or apical 
compartments. Following hysterectomy, prolapse of the vaginal apex with or 
without prolapse of the anterior and/or posterior vaginal wall is referred to as vault 
prolapse [2, 3].
2. Classification of pelvic organ prolapse
Pelvic organ support is maintained by complex interactions between the vagina, 
levator ani muscle, and pelvic floor connective tissue. A system of three integrated 
levels of vaginal support has been described by De Lancey [1].
• Level 1: The cardinal uterosacral ligament complex.
• Level 2: Midvaginal supports—pubocervical and rectovaginal fascia.
• Level 3: Urogenital diaphragm and the perineal body.
The prolapse is usually described according to the area of the vagina in which it 
occurs. Assumptions are often made about which organ is behind the vaginal wall 
that is prolapsing.
Anatomical classification according to vaginal wall:
• Anterior: cystocele (bladder most common) and urethrocele (urethra).
• Middle: vault of the uterus (after hysterectomy).
• Posterior: rectocele (rectum) and enterocele (small bowel, omentum).
2.1 Shaw’s classification
• Anterior wall
 ○ Upper 2/3 cystocele
 ○ Lower 1/3 urethrocele
• Posterior wall
 ○ Upper 1/3 enterocele
 ○ Middle 1/3 rectocele
 ○ Lower 1/3 deficient perineum
• Uterine prolapse
 ○ Grade 0: Normal position
 ○ Grade 1: Descent into vagina not reaching the introitus
13
Pelvic Organ Prolapse: Examination and Assessment
DOI: http://dx.doi.org/10.5772/intechopen.91357
 ○ Grade 2: Descent up to the introitus
 ○ Grade 3: Descent outside the introitus
 ○ Grade 4: Procidentia [2]
• Uterovaginal prolapse usually occurs in nulliparous prolapse due to congenital 
weakness of cervical ligaments.
• Vaginouterine prolapse usually occurs in cases of prolapse resulting from 
obstetrical trauma.
3. Pelvic organ prolapse quantification system (POP-Q )
Pelvic organ prolapse quantification system refers to an objective, site-
specific system for describing, quantifying, and staging pelvic support in women 
(Figure 1). It provides a standardized tool for documenting, comparing, and 
communicating clinical findings with proven interobserver and intraobserver reli-
ability. The POP-Q system gained the attention of the specialists all over the world, 
being approved by the International Continence Society (ICS), the American 
Urogynecologic Society (AUGS), and the Society of Gynecologic Surgeons for the 
description of female pelvic organ prolapse. It is the most common system used 
by gynecologists and urogynecologists, although other systems have been devised 
(Figures 2–9) [4].
The POP-Q may be an easier classification system to use in routine clinical 
practice. It was developed by the International Urogynecological Association to 
provide a less cumbersome exam tool [4]. The POP-Q stages (Table 1) prolapse 
Figure 1. 
POP-Q points. Aa, anterior vaginal wall 3 cm proximal to the urethral meatus (−3 cm to +3 cm); Ba,most 
distal position of the remaining upper anterior vaginal wall (−3 cm to +tvl); C, most distal edge of 
cervix or vaginal cuff scar; D, posterior fornix (n/a if posthysterectomy); Ap, posterior vaginal wall 3 cm 
proximal to the hymen (−3 cm to +3 cm); Bp, most distal position of the remaining upper posterior vaginal 
wall (−3 cm to + tvl); genital hiatus (gh), measured from the middle of external urethral meatus to the 
posterior midline hymen; perineal body (pb), measured from the posterior margin of gh to the middle 
of anal opening; total vaginal length (tvl), depth of the vagina when point D or C is reduced to normal 
position.
Lower Urinary Tract Dysfunction - From Evidence to Clinical Practice
14
Figure 3. 
Point Ba being measured by graded spatula.
Figure 2. 
Point Aa being measured by graded spatula.
15






Lower Urinary Tract Dysfunction - From Evidence to Clinical Practice
14
Figure 3. 
Point Ba being measured by graded spatula.
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Point Aa being measured by graded spatula.
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for the anterior and posterior vaginal walls, the apex/cuff of the vagina and the 
cervix. For women posthysterectomy, there are three stages; for women with an 
intact uterus, there are four. The exam is carried out similarly to the standard 
POP-Q exam, with a half speculum placed in the vagina to visualize the vaginal 
walls and cervix.
A disadvantage of POP-Q is that all points and measures are taken in the mid-
line; as a consequence, the POP-Q does not reflect asymmetries and cannot be used 
to describe, for example, paravaginal defects. One has also to keep in mind that the 
POP-Q depends on the cooperation of the patient and to the strength of her cough 
or Valsalva maneuver; it is therefore unreasonable to assume that in an individual 
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4. History
Most patients with pelvic organ prolapse are asymptomatic. Seeing or feeling 
a bulge of tissue that protrudes to or past the vaginal opening is the most specific 
symptom.
4.1 Bulge in the vagina
During a well-woman examination, she should be asked regarding any obvious 
bulge seen or felt in vagina. The report of a bulge has an 81% positive predictive 
value and a 76% negative predictive value for pelvic organ prolapse.
Patient may complain of an increase in bulging and discomfort with progression 
of day [1]. Extensive standing, lifting, coughing, and physical exertion may increase 
patient awareness of discomfort in the pelvis, vagina, abdomen, and low back. 
Pelvic organ prolapse may progress with increasing body mass index. Weight loss 
does not reverse the prolapse.
4.2 Vaginal discharge
Vaginal discharge may be present in patients with complete uterine prolapse 
(i.e., procidentia) who have a decubitus ulcer of the cervix or vagina.
4.3 Urinary symptoms
Patients may have difficulty urinating—stress incontinence affects 40% of 
patients with pelvic organ prolapse; therefore, they should be asked about fre-
quency, urgency, and sensation of incomplete emptying of the bladder, because 
they may not volunteer such information. Urinary outlet obstruction may occur 
because of the pressure on the urethra in anterior vaginal prolapse and sometimes 
in large posterior vaginal prolapse. Screening is advocated for urinary tract infec-
tion, postvoid residual urine volume, and the presence or absence of bladder 
sensation.
Pelvic organ prolapse quantification system
Stage Description
0 No prolapse
I >1 cm above the hymen
II ≤1 cm proximal or distal to the plane of the hymen
III >1 cm below the plane of the hymen, but protrudes no farther than 2 cm less than the total 
vaginal length
IV Eversion of the lower genital tract is complete
POP-Q staging criteria.
Stage 0: Aa, Ap, Ba, Bp = −3 cm and C or D ≤ − (tvl − 2) cm.
Stage l: Stage 0 criteria not met and leading edge < −1 cm.
Stage ll: Leading edge ≥ −1 cm but ≤ +1 cm.
Stage lll: Leading edge > +1 cm but < + (tvl − 2) cm.
Stage lV: Leading edge ≥ + (tvl −2) cm [3, 4].
Table 1. 
Evaluation/staging of pelvic organ prolapse.
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Symptoms may not correlate with the location or severity of the prolapsed 
compartment.
4.4 Bowel symptoms
Patients with posterior vaginal prolapse sometimes use manual pressure on the 
perineum or posterior vagina to help with defecation. These maneuvers are called 
“splinting.”
4.5 Back pain
Though patients of prolapse attribute back and pelvic pain to their prolapse, 
very little evidence is available to show that this disorder causes pain, so other 
causes of pain should be ruled out.
4.6 Sexual discomfort
Sexual activity, body image, and quality of life may be affected [3].
5. Examination
5.1 General physical examination
Assessment will include weight, body mass index, and blood pressure, as well as 
assessment of any varicose veins or hypermobile joints, since these can be markers 
of a tendency to connective tissue laxity which predisposes to POP and, impor-
tantly, to recurrence after surgical repair [2].
5.2 Abdominal examination
On examination of the abdomen, inspect for incisions of previous surgery 
(which may be associated with intra-abdominal adhesions affecting subsequent 
surgical approaches), and exclude masses or ascites. The presence of umbilical or 
other hernia can again indicate underlying connective tissue weakness and may 
require concomitant surgical correction [2, 3].
5.3 Local examination
On inspection of the vulva, note the presence of any atrophy and whether there 
is any ulceration of prolapsed tissues that may require local estrogen therapy before 
surgery. Wide genital hiatus with visible vaginal walls or midline asymmetry on 
Valsalva shows levator ani damage.
For stress urinary incontinence, the patient needs to be examined with full 
bladder and asked to cough or strain, and leakage of urine confirms positive stress 
provocation test.
On examination in lithotomy position, if there is visible vaginal bulge, look for 
vaginal wall rugosities which predict an intact fascial layer in the midline and a 
probable lateral defect, or if absent, it suggests a midline defect with only the skin 
and attenuated connective tissue present.
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bladder and asked to cough or strain, and leakage of urine confirms positive stress 
provocation test.
On examination in lithotomy position, if there is visible vaginal bulge, look for 
vaginal wall rugosities which predict an intact fascial layer in the midline and a 
probable lateral defect, or if absent, it suggests a midline defect with only the skin 
and attenuated connective tissue present.
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6. Examination in various positions
6.1 Standing position
In some mild cases of vaginal wall and uterine prolapse, examination of the 
patient in standing position is the only way to explore it.
6.2 Dorsal position
Mostly for demonstration of uterine prolapse. Either the uterus will be obviously 
protruded or protrude when the patient is asked to strain.
6.3 Sims’ position
In this position, the aim is to demonstrate the different types of vaginal wall 
prolapse. The patient is asked to lie on her left side at the edge of the table. The left 
leg is extended, while the right leg is flexed. Afterward, a sterile Sims’ speculum 
is inserted into the vagina gently first to expose the anterior vaginal wall. Then it 
is pulled backward gradually to expose the posterior vaginal wall. Cystocele and 
rectocele are usually diagnosed by this examination.
7. Per speculum examination
Examination with a Cusco’s bivalve speculum allows assessment of the cervix 
(including a Pap smear, if appropriate), but not of prolapse. The use of a Sims’ 
speculum is required to carefully assess the anterior and posterior compartments 
and to assess the supports of the cervix or the vault if there has been a previous 
hysterectomy. If prolapse is visible at the vaginal introitus or on Valsalva maneuver, 
a systematic examination should be performed. With the patient in a supine posi-
tion, a suitable sized vaginal speculum is introduced in the vagina to view the cervix 
or vaginal cuff, and the extent to which the cervix or the vaginal vault follows 
the speculum through and out of the vagina is noted, and the speculum is slowly 
removed while performing Valsalva maneuver.
To examine the anterior vaginal wall, the posterior vaginal wall is retracted with 
the fixed blade, and the extent of any anterior vaginal prolapse during the Valsalva 
maneuver is noted and vice versa to examine posterior vaginal wall. Any resulting 
prolapse is noted.
Decubitus ulcers are inspected and palpated. It is common to require sponge 
holding forceps to aid in support of the vaginal walls, as this can obscure the 
view.
8. Per vaginal and rectovaginal examination
Bimanual examination is performed to check the uterine size and mobility, as 
well as to exclude unsuspected adnexal pathology, such as ovarian tumors. This also 
allows an assessment of vaginal muscle tone. Rectal examination may distinguish 
rectocele from enterocele. Make sure you ask the woman to direct your attention 
to any other findings that she has noted, that you have not discovered, or that she 
wants to draw your attention to.
Bonney’s stress test is performed following reduction of prolapsed. If test 
is positive, incontinence surgery should be performed at the time of prolapse 
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surgery. Testing for integrity of anal sphincter should be assessed for resting tone 
and voluntary squeeze and sensation around the vulva with the bulbocavernous 
reflex. (Stroking lateral to clitoris contraction of bilateral bulbocavernous muscle 
is observed.) The anocutaneous reflex (anal wink sign) is triggered by stroking 
the skin immediately surrounding the anus and observing a reflexive contraction 
of the external anal sphincter; this reflex should be elicited bilaterally. Absence of 
these reflexes is not always abnormal, and hyperreflexia or asymmetry may in fact 
be more suggestive of a neurologic etiology. Crude sensory testing is advocated for 
evidence of pudendal neuropathy [4, 5].
Grading pelvic floor muscle strength:
1. No discernible contraction.
2. Barely palpable, flickering contraction, not visible on inspection of the 
 perineum.
3. Weak, distinctly palpable contraction, felt as slight pressure on the examining 
finger.
4. Moderate muscle strength, distinct pressure on the examining finger, palpable 
upward and forward movement, visible on the perineal surface.
5. Good muscle strength, elevation possible against slight resistance, circu-
lar pressure can be felt around the examining finger. During simultaneous 
examination by the index and middle finger, these are pressed against each 
other.
6. Very strong muscle strength, contraction possible against vigorous resis-
tance, with suction-type effect on the examining finger. During simultaneous 
 examination by the index and middle finger, these are pressed against each 
other despite resistance.
Digital examination makes it possible to distinguish between the left and 
right side of the levator ani. It is capable of quantifying strength, strength 
endurance, fast contraction, and fast contraction endurance for clinical pur-
poses [2].
9. Quantifying and documenting the findings
A full description of the examination is recorded, including the following:
• Type of examination table, speculum, and retractors
• Patient position
• Bladder and rectal fullness
It is important to note and document any episodes of urinary, fecal, or flatal 
incontinence that occur during the examination. The findings of the examination 
should be recorded using a quantitative and reproducible method for recording 
POP such as the POP-Q , Baden-Walker, or Shaw systems [4, 5].
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10. Further evaluation
Further studies depend on the symptoms, stage of prolapse, and treatment plan. 
If needed for definitive treatment planning, urodynamic studies can help in iden-
tifying those patients with lower urinary tract symptoms (urinary incontinence) 
who are most likely to get benefit from surgery or may require stress incontinence 
surgery. Patients with defecatory symptoms and/or fecal incontinence may need 
anal manometry and endoanal ultrasonography [5].
11. Conclusion
Taking a thorough history and performing a careful physical examination of 
women who are referred help in the assessment of prolapse. Examination should 
be carried out with dignity and care, using some basic tools that aid in the accurate 
evaluation of anatomical and functional defects. A standardized assessment system 
has been used to document findings which should explain everything in under-
standable terms.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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Abstract
Lower urinary tract dysfunction (LUTD) is common in both men and women, 
and the incidence and prevalence increases as people age. Commonly observed 
symptoms of LUTD include nocturia, urgency, urinary incontinence and frequency 
of voiding. Recognizing the key role accurate monitoring and evaluation of LUTD 
play in the day-to-day assessment of the condition, this chapter will explore the 
diagnostic capabilities of imaging modalities including MRI, ultrasound and 
fluoroscopy in assessing bladder wall thickness (BWT), detrusor wall thickness 
(DWT) and estimation of bladder weight both in real-time and static positions, and 
finally analyze their suitability as surrogates for bladder outlet obstruction (BOO) 
or detrusor overactivity (DO).
Keywords: lower urinary tract dysfunction, bladder, MRI, ultrasound, PET
1. Introduction
The lower urinary tract (LUT), consisting of the urinary bladder and urethra, 
functions to store and expel urine in a controlled and coordinated manner [1, 2]. 
This key function is dependent upon neural circuits located in the central and 
peripheral nervous system (CNS) (brain, peripheral ganglia, spinal cord and 
brain) [1], thus distinguishing LUT from other visceral structures such as cardio-
vascular system and gastrointestinal tract, that are able to sustain a certain level of 
activity even after elimination of extrinsic neural input [3]. Considering the fact 
that control over urine storage and voiding is somehow complex and also depen-
dent on neurological elements widely distributed in anatomical terms, the function 
of LUT can be affected by a myriad of neurological diseases and disorders of the 
peripheral organs [4].
Lower urinary tract dysfunctions (LUTD) may thus result from lesions affect-
ing the brain, suprasacral spinal cord and sacral spinal cord or peripheral nerve 
[5]. Lesions affecting the suprasacral or spinal pathways affect the storage phase, 
leading to reduced bladder capacity and detrusor overactivity, which is character-
ized by varying degrees of urinary frequency, urgency, incontinence and nocturia, 
while lesions of the sacral spinal cord pathways result in voiding dysfunction, 
associated with non-relaxing sphincter and/or absent or poorly sustained detrusor 
contractions [6]. As a result, functional disorders such as bladder outlet obstruction 
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secondary to prostatic enlargement, overactive bladder and urinary incontinence 
are common, as are prostate and bladder carcinoma [7].
Clinical assessment of LUDT may include tests such as post-void residual 
volume measurement, renal ultrasound, uroflowmetry, urethrocystoscopy, neu-
rophysiology and urodynamics depending on the indication [6]. Furthermore, 
urodynamic tests including filling cystometry and pressure flow study are consid-
ered as the gold standard methods for diagnosing detrusor overactivity (DO) and 
bladder outlet obstruction (BOO) respectively. The key issue with the urodynamic 
techniques is that, they are invasive and hence are associated with potential patient 
morbidity [8]. Therefore, there have been efforts over the years toward developing 
non-invasive techniques such as ultrasound, magnetic resonance imaging (MRI), 
fluoroscopy and near-infrared spectroscopy, with the potential of serving as suit-
able surrogates for diagnosing BOO and DO. Recognizing the key role these imaging 
modalities play in accurate monitoring and evaluation of LUTD, this chapter set out 
to explore their diagnostic potential in LUTD and finally examine their suitability 
as surrogates for the urodynamic tests.
2. The lower urinary tract
The lower urinary tract (LUT) consists of urinary bladder and urethra, and also 
includes the prostate in males. These organs are actively involved in the involuntary 
storage of urine formed in the upper urinary tract and the voluntary expulsion of 
urine at a suitable place and time [7]. The effectiveness of these functions depend 
on the activity of striated and smooth muscles in the bladder, urethra and external 
urethral sphincter, which is in turn controlled by neural circuits in the spinal cord, 
peripheral ganglia and brain [4]. Owning to the differences in sexual function and 
pelvic anatomy, there are considerable differences in the anatomy of LUT in males 
and females.
The bladder is a hollow organ located within the pelvis. Its wall consists of five 
layers from inside out, and the muscle of the bladder, the detrusor, is composed of 
smooth muscle fibers [9]. The wall thickness of the bladder decreases from 2 cm to 
2 mm during expansion. The principal function of the bladder is that of a reservoir, 
storing urine at lower pressures, even with large filling volumes. The normal blad-
der holds 200–500 ml urine, and for imaging assessment, a full bladder is preferred 
for visualization. Due to the visco-elastic properties of the bladder wall and the 
inhibition of the filling phase detrusor contractions, the bladder is compliant and 
the pressure inside usually remain low [10]. In the clinical assessment of images of 
the LUT, it is important to note the close relation between the anterior vaginal wall 
and the urethra in women and between seminal vesicles and prostate and posterior 
urethra and the bladder base in men [11].
2.1 Lower urinary tract dysfunction (LUTD)
The primary physiological functions of the LUT are the storage of urine (at 
relatively low pressure) and its voiding (expulsion) at appropriate time. LUT 
dysfunction is a common problem, and the prevalence increases with ageing. The 
term “dysfunction” indicates an abnormality in the physiology of the lower uri-
nary tract, including urinary sphincter, associated nervous system, bladder neck 
and detrusor muscle. This may result in failure to store urine, failure to empty or a 
combination of both [12]. Lower urinary tract symptoms can thus be divided into 
storage phase symptoms, voiding phase symptoms and postmicturition symp-
toms. These symptoms can be caused by various types of bladder dysfunctions 
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such as overactive bladder, underactive bladder, urinary tract infections and 
neurogenic disorders [13]. Storage symptoms include increased nocturia, daytime 
frequency, urgency and incontinence. Voiding symptoms include splitting or 
spraying, slow stream, intermittency, hesitancy, straining and terminal dribble. 
Post micturition symptoms include a feeling of incomplete emptying and post 
micturition dribble [14].
2.1.1 Bladder outlet obstruction (BOO)
Voiding as intended by nature should result in complete emptying of the blad-
der. This depends on a coordinated contraction of the detrusor smooth muscle with 
a simultaneous lowering of bladder outlet resistance. Distortion, compression or 
occlusion of the outlet of the bladder obstructs urine flow during expulsion, with 
attendant characteristic symptoms of dribbling, poor stream, incomplete emptying 
and hesitancy. Bladder outlet obstruction (BOO) is an indication of the existence 
of abnormal tissue which modifies the configuration of the bladder outlet through 
distortion, compression or occlusion, thus impeding the urine flow at the time 
of expulsion. Accompanying urine symptoms include slow stream, intermittent 
stream, hesitancy, straining to void, terminal dribble, post-micturition dribble and 
feeling of incomplete emptying [15].
These LUT symptoms are caused by a variety of different pathologies. The 
commonest processes responsible for BOO in men are benign prostatic enlarge-
ment (BPE) or urethral stricture disease [15]. For lesser degrees of obstruction, 
the symptomatic consequences may be slight, owing to compensatory responses, 
such as enhanced bladder contractility. However, a potential feature of BPE is 
the progression of obstruction with ageing, which leads to evident expulsion and 
post-micturition LUT symptoms. Also, the emergence of LUT symptoms point to 
relative inadequacy in the expulsive capacity of the bladder, which may be a con-
sequence of detrusor underactivity. Detrusor underactivity is characterized by a 
contraction of reduced duration and/or strength, thus resulting in failure to achieve 
complete bladder emptying within regular time span and/or prolonged bladder 
emptying. The variables of detrusor contraction strength, contraction duration 
and outlet obstruction severity leads to varied clinical features of BOO. The basis 
of obstruction in females may be bladder neck distortion, urethral compression or 
luminal occlusion and functional issues [16]. However, in women, due to difficulty 
in assessing bladder contractility, there is difficulty in arriving at decisions on issues 
regarding diagnosis of BOO [15]. Diagnosis of BOO can be made based on invasive 
urodynamic study, such as videourodynamic study or pressure flow study. Also, a 
noninvasive method to diagnose BOO is needed for more accurate treatment [17].
2.1.2 Overactive bladder (OAB) and detrusor overactivity (DO)
According to the International Continence Society (ICS), overactive bladder 
(OAB) is defined as a complex of urgency, usually with increased daytime fre-
quency and nocturia, with (OAB wet) or without (OAB dry) urinary incontinence. 
Urgency is the key symptom of OAB, and it is a sudden compelling desire to pass 
urine, which is difficult to defer [18]. In diagnosing OAB, it is assumed that con-
flicting issues such as, urinary tract infections are excluded. OAB might be because 
of increased bladder sensation or detrusor overactivity (DO). Confusion usually 
exists between these two disease states because patients usually cannot differentiate 
the sensation of urgency from the urge to void [19].
DO is an urodynamic observation characterized by involuntary detrusor con-
tractions during the filling phase that may be provoked or spontaneous. The ICS 
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2.1.2 Overactive bladder (OAB) and detrusor overactivity (DO)
According to the International Continence Society (ICS), overactive bladder 
(OAB) is defined as a complex of urgency, usually with increased daytime fre-
quency and nocturia, with (OAB wet) or without (OAB dry) urinary incontinence. 
Urgency is the key symptom of OAB, and it is a sudden compelling desire to pass 
urine, which is difficult to defer [18]. In diagnosing OAB, it is assumed that con-
flicting issues such as, urinary tract infections are excluded. OAB might be because 
of increased bladder sensation or detrusor overactivity (DO). Confusion usually 
exists between these two disease states because patients usually cannot differentiate 
the sensation of urgency from the urge to void [19].
DO is an urodynamic observation characterized by involuntary detrusor con-
tractions during the filling phase that may be provoked or spontaneous. The ICS 
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2002 report categorizes DO into two types: (1) terminal, which is a single invol-
untary detrusor contraction that often results in complete bladder emptying; and 
(2) phasic, which may or may not lead to urinary incontinence. Therefore, OAB is 
a symptom-based diagnosis, while DO is an urodynamic diagnosis. A research on 
OAB and DOO showed that 64% of patients with OAB symptoms had DO on uro-
dynamic investigation, while 30% of the patients with DO did not have AOB [18].
3. Imaging modalities used for the clinical assessment of LUTD
The lower urinary tract (LUT) requires coordination of the prostate, bladder, 
pelvic floor, urethra, and specific spinal cord and brain areas. Different imaging 
modalities can be utilized to visualize these structures and are employed to study its 
pathophysiology and diagnose voiding dysfunction. Although the bladder and ure-
thra are anatomically distinct structures, they are functionally closely interrelated. 
Therefore, imaging of the bladder is often needed to confirm clinical examination.
Imaging modalities including ultrasound (US), voiding cystourethrogram 
X-ray (VCUG), magnetic resonance imaging (MRI), computed tomography (CT), 
positron emission tomography (PET) and functional magnetic resonance imaging 
(fMRI) are used to visualize the distinctive structures of the LUT. US is the com-
monly used technique in daily practice, to evaluate LUTD. The utilization of MRI 
for voiding dysfunction however remains limited, but several clinical studies have 
already shown its potential in the benign prostatic hyperplasia (BPH) and diagnosis 
of stress urinary incontinence. Also, PET and fMRI of the brain have made it pos-
sible to study supraspinal control of the LUT, in the light of LUT being subjected to 
a complex neural control mechanism.
Urodynamic tests have over the years been considered the gold standard method 
for diagnosing common conditions of the lower urinary tract such detrusor over-
activity (DO) and bladder outlet obstruction (BOO). However, with increasing 
concern about their “invasiveness” and associated potential patient morbidity, there 
has been a search towards non-invasive techniques such as ultrasound, computed 
tomography (CT), PET, magnetic resonance imaging (MRI), with the potential of 
becoming the mainstay diagnostic tools for LUTD. Furthermore, clinical assess-
ment of the urethral symptoms is challenging and often requires further evaluation 
with imaging.
3.1 Ultrasonography
Ultrasonography (US) has over the years emerged as the most widely used imag-
ing technique for the study of the LUT. In the past, US was identified as a technique 
of approach and guidance for the evaluation of LUT, but it is now recognized 
worldwide as the investigation of choice allowing precise diagnosis of many patho-
logical conditions of the LUT, usually obviating the need for further radiological 
examinations. For instance, Transabdominal US is a cheap and easy modality to 
evaluate structural abnormalities of the bladder, stone disease of the bladder, post-
void residual urine (PVR) or vesico-ureteral junction, neoplasms and inflammatory 
disorders [20].
The US, although simple to use, safe and acceptable by majority of patients, 
still remains real-time operator dependent, and in the light of new applications, 
requires experienced and skilled operator in whose hands often becomes the only 
exam needed to be able to direct the next phase of the diagnostic algorithm. Recent 
advances in US, incorporating a high resolution multi frequency transducers allows 
a meticulous study of the kidneys, its size, location and parenchymal structure, 
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including a thorough assessment of the urinary bladder, perivesical space as well 
as pelvicalyceal and ureteral dilatation [21]. The use of US requires when possible 
a full bladder which is not distended to the extent that the individual has pain. 
This is necessary because, it is only a well-distended bladder that allows true mass 
abnormalities to be seen, or else, apparent focal wall diverticula or masses can be 
stimulated by invaginations of the deflated bladder, usually obscuring true bladder 
lesions such as calculi by the non-distended bladder folds [22].
In the assessment of LUT using US, patients are normally examined in the 
supine position but sometimes is required when there is the need to differenti-
ate mobile intravesical abnormalities such as foreign bodies or stones from fixed 
lesions. The use of a 3.5–5-MHz curved array is normally acceptable for most US 
examinations of the LUT, however, with regards to anterior bladder wall, higher 
frequency linear probes are sometimes required for better resolution [22].
3.1.1 Ultrasonographic methods in the assessment of LUTD
Ultrasonography has proven to be essential in the evaluation of patients with 
lower urinary tract dysfunction (LUTD). This is based on the premise that LUTD 
may result in an alteration of the anatomic structures of the lower urinary tract 
(LUT) and vice versa [23]. In routine practice, US is mostly used to accurately 
measure the post-void residual urine (PVR) which indicates how completely an 
individual empties his bladder. Individuals with bladder outlet obstruction (BOO) 
and/or detrusor underactivity are commonly associated with elevated PVR [24]. 
The ultrasound measurement of bladder wall thickness (BWT) has also been linked 
to the diagnosis of overactive bladder (OAB) and BOO, with several studies report-
ing that increases in BWT can be a valuable biomarker for detrusor overactivity 
(DO) in subjects with an OAB syndrome [25, 26]. This is based on the assumption 
that increased BWT in BOO or OAB is secondary to hypertrophy of the detrusor 
wall, which is associated with increased isometric detrusor contraction against 
a competent urethral sphincter. These contractions lead to a rise in intravesical 
pressure, giving the individual a very strong desire to void [27]. Furthermore, 
it is generally accepted that an increase in mean BWT is unique to DO, with a 
study recording a statistically significant correlation between DO and BWT [27]. 
Detrusor wall thickness (DWT) might be a more accurate measure for BOO. A 
DWT >2 mm has been reported in 94% of men with signs of BOO on urodynamics 
[28]. In addition, measurement of DWT or BWT with US can used to examine the 
response to surgical or medical treatment of BOO. For instance, reduced BWT is 
detected after treatment with α-1 receptor blockers and transvesical prostatectomy 
[29, 30]. The ultrasonographic sections of the urinary bladder are defined from 
outside-in as bladder hyperechoic (adventitia), hypoechoic (detrusor muscle) and 
hyperechoic (bladder mucosa) [31, 32]. DWT measures only the middle layer, while 
the measurement of BWT involves all the three layers. The only issue with BWT 
measurement is that, it is volume dependent, and bladder wall thickness decrease 
with increasing filling volume. Hence, there is the need to measure bladder weight 
which should remain constant at different bladder volumes. Thus, with the aid 
of US, bladder weight is calculated from the thickness of the bladder wall and the 
intravesical volume assuming a spherical bladder (see Figure 1).
The benefit of utilizing US to monitor the deformation in the detrusor muscle 
have been shown by a recent study [33]. This provides insight into the detrusor 
muscle’s dynamic and structural properties related to bladder pressure. In the study, 
it was demonstrated that US could be used to estimate strain in the detrusor muscle, 
which was positively correlated with the detrusor pressure. This suggests a possibil-
ity of using US in a real time manner to monitor detrusor muscle activity. Also, this 
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measure the post-void residual urine (PVR) which indicates how completely an 
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and/or detrusor underactivity are commonly associated with elevated PVR [24]. 
The ultrasound measurement of bladder wall thickness (BWT) has also been linked 
to the diagnosis of overactive bladder (OAB) and BOO, with several studies report-
ing that increases in BWT can be a valuable biomarker for detrusor overactivity 
(DO) in subjects with an OAB syndrome [25, 26]. This is based on the assumption 
that increased BWT in BOO or OAB is secondary to hypertrophy of the detrusor 
wall, which is associated with increased isometric detrusor contraction against 
a competent urethral sphincter. These contractions lead to a rise in intravesical 
pressure, giving the individual a very strong desire to void [27]. Furthermore, 
it is generally accepted that an increase in mean BWT is unique to DO, with a 
study recording a statistically significant correlation between DO and BWT [27]. 
Detrusor wall thickness (DWT) might be a more accurate measure for BOO. A 
DWT >2 mm has been reported in 94% of men with signs of BOO on urodynamics 
[28]. In addition, measurement of DWT or BWT with US can used to examine the 
response to surgical or medical treatment of BOO. For instance, reduced BWT is 
detected after treatment with α-1 receptor blockers and transvesical prostatectomy 
[29, 30]. The ultrasonographic sections of the urinary bladder are defined from 
outside-in as bladder hyperechoic (adventitia), hypoechoic (detrusor muscle) and 
hyperechoic (bladder mucosa) [31, 32]. DWT measures only the middle layer, while 
the measurement of BWT involves all the three layers. The only issue with BWT 
measurement is that, it is volume dependent, and bladder wall thickness decrease 
with increasing filling volume. Hence, there is the need to measure bladder weight 
which should remain constant at different bladder volumes. Thus, with the aid 
of US, bladder weight is calculated from the thickness of the bladder wall and the 
intravesical volume assuming a spherical bladder (see Figure 1).
The benefit of utilizing US to monitor the deformation in the detrusor muscle 
have been shown by a recent study [33]. This provides insight into the detrusor 
muscle’s dynamic and structural properties related to bladder pressure. In the study, 
it was demonstrated that US could be used to estimate strain in the detrusor muscle, 
which was positively correlated with the detrusor pressure. This suggests a possibil-
ity of using US in a real time manner to monitor detrusor muscle activity. Also, this 
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finding is important because, it is an indication that US imaging could be used as a 
non-invasive modality option to replace the pressure flow studies which remain the 
standard diagnostic urodynamic tests for lower urinary tract symptoms (LUTS).
With recent advances in US imaging of the urethra, imaging of different struc-
tural abnormalities such as urethral neoplasms and urethral diverticulae are now 
possible. The typical symptoms of urethral diverticula are dyspareunia, urethral 
pain and post-voiding dribbling [34]. In addition, the multiplanar US allows imag-
ing of the size, location, content, and configuration of the diverticulum. Also, in 
the case of surgical planning, US allows the diverticulum neck can to be evaluated, 
together with the presence of calculi in sac [20].
3.1.2 Recent innovations in the field of ultrasonography
The recent years have seen an evolution in the field of ultrasonography, with 
the introduction of applications which have great importance in the assessment of 
LUT. These new applications include harmonic imaging, motion-mode, transperi-
neal US and 3D and 4D ultrasound.
Figure 1. 
(A) An ultrasound image of the urinary bladder (transverse scan) showing normal bladder wall thickness 
(BWT) (a, arrow) in a middle-aged woman with irritative lower urinary tract symptoms (LUTS) and 
normal filling cystometry (FCM); (B) ultrasound image (longitudinal scan) showing increased BWT (b, 
arrow) in a middle-aged man with irritative LUTS and detrusor overactivity [26].
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Harmonic imaging (HI) is based on the harmonic response generated by the 
tissue or, when used by the contrast medium, rather than on the reflection of the 
fundamental frequency of the ultrasound beam. This provides a better defini-
tion of the profiles, particularly of the fluid structure systems, such as reduces 
artifacts; improves the representation of the contrast medium; and dilated col-
lectors. Thus, HI removes low frequency sonic artifact which is usually the result 
of reverberation artifact and help better define the bladder wall. Motion-mode 
(M-mode) assists in the assessment of movement, and is therefore valuable in 
providing documentation and semiquantitative evaluation of ureteral peristalsis. 
Transperineal US, incorporating high-frequency linear probes allows ideal visu-
alization of the vagina, urethra and surrounding structures. 3D and 4D US offer 
a multiaxial illustration of the entire kidney and bladder, thus improving renal 
parenchymal volume calculation, mostly in hydronephrosis or irregularly shaped 
kidneys. This is possible because, the dilated collecting system can be deducted 
from the overall kidney volume. Also, the potential of creating rendered views will 
allow the comprehensive demonstration of complex pathology [21, 35].
3.2 Voiding cystourethrogram X-ray (VCUG) of LUTD
VCUG uses a small amount of radiation to make images of an individual’s uri-
nary system, and it enables the assessment of the bladder’s size and shape and also 
looks for abnormalities, such as a blockage along the path of the urine [36]. Images 
from VCUG can also show whether the urine is moving in the right direction. The 
normal flow of urine is from the kidneys down to the bladder through the ureters. 
However, in a condition called vesicoureteral (VU) reflux, urine flows backward 
from the bladder to one or both ureters and sometimes to the kidneys, and it some-
times occurs only at the voiding stage [37]. VU reflux can be detected by VCUG, 
which also includes taking X-ray images while the bladder is being emptied. This 
makes VCUG appropriate for diagnosing VU that only occurs while voiding [38].
During VCUG, a patient’s bladder is filled with contrast material, followed by an 
X-ray machine used to send beams of radiation through the abdomen and pelvis, 
and images are recorded on special film or a computer. These images help physicians 
see problems in parts of the urinary system, including the bladder, urethra (the tube 
connecting the bladder with the outside of the body), and the ureters (the tubes 
connecting the kidneys to the bladder) (LUT), aiding in diagnosing LUTDS [39].
3.3 Magnetic resonance imaging in the assessment of LUTD
Technological advancement in imaging modalities, allowing cross-sectional 
imaging of the LUT is essential for further functional and/or morphological evalu-
ation. Primary disorders for MRI of the LUT are bladder tumors and congenital 
abnormalities, and in addition, MRI is usually employed as a secondary imaging 
modality, particularly for assessing voiding dysfunction in pediatric urology [40]. 
MRI can also be used in conjunction with US for imaging of the size, content 
and position of the urethral diverticulae (see Figure 2). With regards to urethral 
neoplasms, MRI can reveal different characteristics of the different types of the 
neoplasms (see Figure 2). These neoplasms of the urethra appear as more heteroge-
neous lobulated, deeply infiltrating or exophytic lesions [20]. Urethral hypermobil-
ity can also be identified on both MR imaging and US, and it has been linked with 
stress urinary incontinence in women [42].
Currently, MRI is the only imaging modality that provides outstanding func-
tional imaging and anatomical information without the use of ionizing radiation. 
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MR imaging, in the light of rapid technological changes is now faster with less 
movement artifact, and therefore improved image quality and resolution. It allows 
an overall evaluation of the renal parenchyma, excretory cavity, surrounding 
tissue, together with the main vessels. The dynamic contrast enhancement of MRI 
is comparable to renal scintigraphy, and thus ensures a higher contrast spatial and 
temporal resolution. As a result of this inherently superior contrast resolution, MRI 
of the pelvis provides much better anatomical visualization than CT. Furthermore, 
heavy T2-weighted MRI is well suited for imaging of the urinary bladder, since the 
organ is filled with fluid, thus improving bladder visualization. With the advent of 
diffusion weighted MRI, in which imaging and MRI signals are weighted toward 
the diffusion characteristics of water, evaluation of LUT neoplasms, particularly 
bladder cancer has been done [21].
The evident advantages of MRI include the lack of both nephrotoxic contrast 
media and ionizing radiation required for CT, thus making it particularly suitable 
for imaging during renal failure and pregnancy. As a result, indications for MRI 
have been increasing rapidly over the years, and it is currently used as the standard 
imaging modality for staging pelvic cancers. In fact, it is better than CT for the 
anatomical depiction of the bladder wall [22].
3.4 Computed tomography in the assessment of LUTD
The combination of contrast studies and US scan have revolutionized imaging 
of LUT, pinpointing many of the clinical problems originating in the bladder. CT 
has become a vital complementary tool in the investigation of several disorders, 
and crucial for staging cancers. Thus, CT imaging is often employed in the staging 
of bladder cancer, however, its utility in the evaluation of LUTD remains limited. 
CT is the standard imaging modality for the study of adult urology, with or without 
contrast medium for the detection of stones [22]. Key advantages of CT are in 
providing detailed demonstration of overall bladder and pelvic anatomy.
Considering the fact that CT examination is highly radiant, its diagnostic 
potential cannot be transferred carelessly to children, since they have a higher radio 
Figure 2. 
A woman undergoing MRI evaluation of possible urethral diverticulum. Patient had previously undergone 
hysterectomy. Midline sagittal T2-weighted TSE image (6000/116, flip angle, 180°) obtained at rest shows 
no significant prolapse. Solid line represents pubococcygeal line, above which all pelvic organs are located. 
B = bladder, dotted line = urethra, R = rectum. Adapted from Bennett et al. [41].
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sensitivity, smaller structures, lesser representation of adipose tissue, different 
tissue composition and different diseases, contrary to that of adults. Also, CT is not 
suitable for imaging of the urethra, penis and prostate, which are better assessed 
with MRI. That is, CT has limitations when applied to the urinary tract beyond the 
bladder.
Nevertheless, recent technological advancement in CT, incorporating multi-
slice scanning with the possibility of isotropic imaging have further enhanced the 
precision of CT. In isotropic imaging, the block (or voxel) of imaging is acquired 
as a perfect cube, and is thus as dimensionally accurate as possible. Therefore, the 
3D reconstruction of the contrast-filled bladder is rendered precisely, and virtual 
cystoscopy is possible. Thus, CT urography is being touted as one-stop imaging of 
the entire urinary tract, with the potential to replace conventional contrast studies 
and ultrasound, but this however requires further technical developments.
3.5  Positron emission tomography and functional MRI in the assessment of 
LUTD
Positron emission tomography (PET) and functional magnetic resonance 
imaging (fMRI) are powerful non-invasive tools utilized in the study of the supra-
spinal control of the LUT directly through imaging of the brain. fMRI measures 
the changing proportion of deoxygenated and oxygenated hemoglobin in activated 
brain centers, while PET needs the injection of a radioactive isotope that will accu-
mulate in a metabolically active brain region [20]. fMRI has a superb spatial and 
temporal resolution but needs multiple runs of the same event to increase signal-to-
noise ratio, while PET is very sensitive for small changes in neural activity but not 
able to detect rapid changes in brain metabolism [42, 43].
Near infrared spectroscopy (NIRS) is occasionally utilized in the study of 
supraspinal control of the bladder. NIRS takes advantage of the varying concentra-
tions of hemoglobin in the cerebral cortex, but its key disadvantage is the very 
limited resolution for deeper brain structures since it can only accurately measure to 
a depth of 1 cm beneath the skull [44].
In recent years, these different brain imaging techniques have been widely 
spread and optimized, providing a vast amount of literature about nearly every 
human cortical function. Unfortunately, the number of studies that have looked 
into brain control of bladder function is until now still relatively small, but 
nevertheless these studies have provided us with valuable new insights into LUT 
pathophysiology.
3.6  Imaging modalities as surrogates to urodynamic tests for the clinical 
assessment of BOO and DO
Lower urinary tract symptoms alone are usually not sufficient in diagnosing 
common complications of the LUT such as BOO, DO and BPE. Hence, in most 
cases, other investigations are required.
Uroflowmetry, though cheaper and easy to perform in clinical setting, is limited 
by its lack of specificity and inability to differentiate between BOO and detrusor 
underactivity. In much the same way, pressure-flow studies which serve as gold 
standard for diagnosing BOO are able to provide key information on the presence of 
obstruction as well as detrusor contractility. But this come at a cost, as urodynamic 
tests are invasive and require specialist equipment and training to perform tests and 
interpreted results, coupled with associated potential patient morbidity.
Therefore, the search for non-invasive diagnostic tests as potential replace-
ment for these urodynamic tests, especially for the diagnosis of BOO, has been 
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MR imaging, in the light of rapid technological changes is now faster with less 
movement artifact, and therefore improved image quality and resolution. It allows 
an overall evaluation of the renal parenchyma, excretory cavity, surrounding 
tissue, together with the main vessels. The dynamic contrast enhancement of MRI 
is comparable to renal scintigraphy, and thus ensures a higher contrast spatial and 
temporal resolution. As a result of this inherently superior contrast resolution, MRI 
of the pelvis provides much better anatomical visualization than CT. Furthermore, 
heavy T2-weighted MRI is well suited for imaging of the urinary bladder, since the 
organ is filled with fluid, thus improving bladder visualization. With the advent of 
diffusion weighted MRI, in which imaging and MRI signals are weighted toward 
the diffusion characteristics of water, evaluation of LUT neoplasms, particularly 
bladder cancer has been done [21].
The evident advantages of MRI include the lack of both nephrotoxic contrast 
media and ionizing radiation required for CT, thus making it particularly suitable 
for imaging during renal failure and pregnancy. As a result, indications for MRI 
have been increasing rapidly over the years, and it is currently used as the standard 
imaging modality for staging pelvic cancers. In fact, it is better than CT for the 
anatomical depiction of the bladder wall [22].
3.4 Computed tomography in the assessment of LUTD
The combination of contrast studies and US scan have revolutionized imaging 
of LUT, pinpointing many of the clinical problems originating in the bladder. CT 
has become a vital complementary tool in the investigation of several disorders, 
and crucial for staging cancers. Thus, CT imaging is often employed in the staging 
of bladder cancer, however, its utility in the evaluation of LUTD remains limited. 
CT is the standard imaging modality for the study of adult urology, with or without 
contrast medium for the detection of stones [22]. Key advantages of CT are in 
providing detailed demonstration of overall bladder and pelvic anatomy.
Considering the fact that CT examination is highly radiant, its diagnostic 
potential cannot be transferred carelessly to children, since they have a higher radio 
Figure 2. 
A woman undergoing MRI evaluation of possible urethral diverticulum. Patient had previously undergone 
hysterectomy. Midline sagittal T2-weighted TSE image (6000/116, flip angle, 180°) obtained at rest shows 
no significant prolapse. Solid line represents pubococcygeal line, above which all pelvic organs are located. 
B = bladder, dotted line = urethra, R = rectum. Adapted from Bennett et al. [41].
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sensitivity, smaller structures, lesser representation of adipose tissue, different 
tissue composition and different diseases, contrary to that of adults. Also, CT is not 
suitable for imaging of the urethra, penis and prostate, which are better assessed 
with MRI. That is, CT has limitations when applied to the urinary tract beyond the 
bladder.
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as a perfect cube, and is thus as dimensionally accurate as possible. Therefore, the 
3D reconstruction of the contrast-filled bladder is rendered precisely, and virtual 
cystoscopy is possible. Thus, CT urography is being touted as one-stop imaging of 
the entire urinary tract, with the potential to replace conventional contrast studies 
and ultrasound, but this however requires further technical developments.
3.5  Positron emission tomography and functional MRI in the assessment of 
LUTD
Positron emission tomography (PET) and functional magnetic resonance 
imaging (fMRI) are powerful non-invasive tools utilized in the study of the supra-
spinal control of the LUT directly through imaging of the brain. fMRI measures 
the changing proportion of deoxygenated and oxygenated hemoglobin in activated 
brain centers, while PET needs the injection of a radioactive isotope that will accu-
mulate in a metabolically active brain region [20]. fMRI has a superb spatial and 
temporal resolution but needs multiple runs of the same event to increase signal-to-
noise ratio, while PET is very sensitive for small changes in neural activity but not 
able to detect rapid changes in brain metabolism [42, 43].
Near infrared spectroscopy (NIRS) is occasionally utilized in the study of 
supraspinal control of the bladder. NIRS takes advantage of the varying concentra-
tions of hemoglobin in the cerebral cortex, but its key disadvantage is the very 
limited resolution for deeper brain structures since it can only accurately measure to 
a depth of 1 cm beneath the skull [44].
In recent years, these different brain imaging techniques have been widely 
spread and optimized, providing a vast amount of literature about nearly every 
human cortical function. Unfortunately, the number of studies that have looked 
into brain control of bladder function is until now still relatively small, but 
nevertheless these studies have provided us with valuable new insights into LUT 
pathophysiology.
3.6  Imaging modalities as surrogates to urodynamic tests for the clinical 
assessment of BOO and DO
Lower urinary tract symptoms alone are usually not sufficient in diagnosing 
common complications of the LUT such as BOO, DO and BPE. Hence, in most 
cases, other investigations are required.
Uroflowmetry, though cheaper and easy to perform in clinical setting, is limited 
by its lack of specificity and inability to differentiate between BOO and detrusor 
underactivity. In much the same way, pressure-flow studies which serve as gold 
standard for diagnosing BOO are able to provide key information on the presence of 
obstruction as well as detrusor contractility. But this come at a cost, as urodynamic 
tests are invasive and require specialist equipment and training to perform tests and 
interpreted results, coupled with associated potential patient morbidity.
Therefore, the search for non-invasive diagnostic tests as potential replace-
ment for these urodynamic tests, especially for the diagnosis of BOO, has been 
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ongoing for many years. As such, parameters such as PVR, free uroflowmetry and 
quantification of prostate volume has been investigated. However, over the past two 
decades, the interest has been on BWT, DWT and bladder wall weight, owing to the 
rationale that BOO and DO are associated with an increase in bladder wall thick-
ness and detrusor hypertrophy. These parameters (BWT, DWT) has been shown by 
several studies to be diagnostic of BOO and DO. Ultrasonography has thus emerged 
as the easiest and non-invasive option capable of measuring BWT, DWT and blad-
der wall weight, thus potentially obviating the need to resort to cumbersome and 
invasive urodynamic tests to diagnose BOO and DO (see Figure 1).
4. Conclusion
Imaging techniques can contribute prominently to our current understanding 
of lower urinary tract dysfunction. A variety of imaging modalities is available to 
visualize the urethra, bladder, prostate and pelvic floor. These techniques can be used 
to enhance our current knowledge of LUT pathophysiology and confirm clinical diag-
nosis, as an alternative diagnostic method to replace invasive urodynamic studies.
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Stress Urinary Incontinence: A 
Proteomics Overview
Goran Mitulović, Thomas Mohr and Marianne Koch
Abstract
Proteomics research offers one strategy to elucidate the etiology of stress urinary 
incontinence (SUI) by identification of a significant and sufficient number of 
proteins, which provides the ability to avoid a preselection of candidate proteins for 
a possible early detection of the SUI. SUI represents both a psychological as well as 
an economic burden, and prevalence rates are expected to increase in the future, 
due to increasing of life expectancy. The classical epidemiology of SUI is well 
understood, with many environmental and lifestyle risk factors identified, includ-
ing age, obesity, parity, vaginal delivery, and family history. Despite this, much of 
the etiology of SUI remains unclear, and it is difficult to predict which women are 
at risk. This chapter shows some results based on proteomic analysis of the urine 
proteome, which might give the answer to the question on pathways activated in 
SUI. Besides proteins originating from the blood, urine contains proteins secreted 
from the inner wall of the bladder and the urethra, and these proteins might explain 
the processes involved in genesis of SUI.
Keywords: stress urinary incontinence, urinary proteome, proteomics
1. Introduction
Stress urinary incontinence (SUI) is a disorder observed with the female popula-
tion with widely varying prevalence, which is estimated to be 15–80%. The condi-
tion represents both a psychological and an economic burden, and it is expected 
that prevalence rates shall increase in the future, mainly due to increasing of life 
expectancy.
While the classical epidemiology of SUI is understood quite well, many envi-
ronmental and lifestyle risk factors leading to the condition have been identified. 
Among others, these are age, obesity, parity, vaginal delivery, and family history of 
SUI. Despite this much of the etiology of SUI remains unclear, and it is difficult to 
predict which women are at risk.
Proteomic research offers one strategy to elucidate the etiology of SUI by 
identification of a significant and sufficient number of proteins, which provides the 
ability to avoid a preselection of candidate proteins. Many different serum, urine, 
and/or tissue protein markers have been investigated in the context of SUI. Almost 
all studies have targeted specific proteins as putative biomarkers, but with typically 
negative results. Prior studies have investigated a role for serum C-reactive protein, 
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1. Introduction
Stress urinary incontinence (SUI) is a disorder observed with the female popula-
tion with widely varying prevalence, which is estimated to be 15–80%. The condi-
tion represents both a psychological and an economic burden, and it is expected 
that prevalence rates shall increase in the future, mainly due to increasing of life 
expectancy.
While the classical epidemiology of SUI is understood quite well, many envi-
ronmental and lifestyle risk factors leading to the condition have been identified. 
Among others, these are age, obesity, parity, vaginal delivery, and family history of 
SUI. Despite this much of the etiology of SUI remains unclear, and it is difficult to 
predict which women are at risk.
Proteomic research offers one strategy to elucidate the etiology of SUI by 
identification of a significant and sufficient number of proteins, which provides the 
ability to avoid a preselection of candidate proteins. Many different serum, urine, 
and/or tissue protein markers have been investigated in the context of SUI. Almost 
all studies have targeted specific proteins as putative biomarkers, but with typically 
negative results. Prior studies have investigated a role for serum C-reactive protein, 
serum relaxin, and serum estradiol, without finding significant associations with 
symptoms.
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2. Materials and methods
2.1 Samples
In order to generate valid data and exclude possible false-positive and false-
negative samples being analyzed, urinary and serum samples from patients affected 
by stress incontinence cases and a proven history of symptoms of SUI for at least 
3 months were obtained. This included a specific history of complaint of involun-
tary leakage on effort or exertion or on sneezing or coughing, a positive provocation 
stress test, which was defined as an observed transurethral loss of urine simultane-
ous with a cough or Valsalva maneuver at a bladder volume of minimum 300 ml. 
Furthermore, negative urine dipstick testing was necessary; all patients were older 
than 18 years and capable of independent toileting and having at least one previ-
ous vaginal delivery. In accordance with rules of the Medical University of Vienna, 
written informed consent was obtained from all participants. We excluded patients 
who had previous treatment for SUI (either surgical or pharmacological), a his-
tory of overactive bladder symptoms, and/or urinary incontinence other than SUI 
(tested using the ICIQ-UI Short Form questionnaire) [1]. In addition, a history of 
neurological disorders potentially affecting the urinary tract system, such as mul-
tiple sclerosis, Parkinson’s disease, pelvic organ prolapse stage ≥ II (International 
Continence Society classification), clinically significant bladder outlet obstruction, 
and/or post-void residual volume > 100 ml, was also exclusion criteria. A series of 
other criteria were also observed, as described in Koch et al. [2]: the history of acute 
urinary retention or history of repeated catheterizations; history of bladder cancer 
or previous operation on the urinary tract; acute or recurrent urinary tract infection 
and/or hematuria; history of urinary tract stones, renal insufficiency, and hepatic 
disease; history of alcohol and/or drug abuse; pregnancy or lactation; and finally 
any patient with a serious medical condition.
Participants in the control group met identical criteria, but with no symptom-
atic SUI (ICIQ-short form score equal to 0) and negative cough stress test. Urine 
samples were obtained once only without requirement for a specific time of day. 
Participants were given a sterile urine cup (maximum 50 ml) and asked to deliver 
the first-void urine. In addition we retrieved blood samples from peripheral veins 
of all participants to determine their creatinine, transaminase, and bilirubin status. 
Urine samples were stored in the refrigerator at 4°C for a maximum of 1 hour before 
they were taken to the Clinical Institute of Laboratory Medicine (Proteomics Core 
Facility) for immediate processing.
2.2 Proteomics sample preparation
Trypsin for protein digestion was purchased from Promega Inc. (Vienna, 
Austria). Solvents for high-performance liquid chromatography (HPLC)—metha-
nol (MeOH), acetonitrile (AcN), 2,2,2-trifluoroethanol (TFE), formic acid (FA), 
heptafluorobutyric acid (HFBA), iodoacetamide (IAA), triethyl bicarbonate 
(TEAB), and dithiothreitol—were purchased from Sigma-Aldrich (Vienna, 
Austria).
Protein precipitation from urine was performed according to the internally 
modified Wessel-Fluege method for protein precipitation, and all solvents were 
kept at −20°C. All working steps were performed on ice and centrifugation in a 
cooled centrifuge at +4°C. A sample volume of 2 ml of each urine sample was mixed 
with 6 ml methanol and 2 ml dichloromethane in a 50 ml Falcon tube, and samples 
were vigorously vortexed. After adding 6 ml of water to each sample, solutions were 
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vortexed another time. Samples were subsequently stored at −20°C for a minimum 
of 20 minutes for enhancement of protein precipitation. Phase separation was 
carried out by subsequent centrifugation for 5 minutes at 4500 rounds per minute 
(rpm). The upper layer of the solution was then carefully discarded while keeping 
the interphase and lower layer, and additional 6 ml of methanol were added prior to 
vigorous vortexing. Final centrifugation was performed for 5 minutes. The resulting 
supernatant was carefully removed, and the remaining protein pellet was dried on 
air. The dried protein pellet was later dissolved in 200 μl of 50 mM triethylammo-
nium bicarbonate (TEAB) at pH 8.5. In cases where the protein pellet could not be 
properly dissolved in 200 μl of 50 mM TEAB, additional 50–1000 μl 50 mM TEAB 
were added, and the sample was sonicated by using the ultrasonic cell disruptor 
(Ultrasonic Cell Disruptor, Branson 5200, Dietzenbach, Germany).
Blood samples were prepared as described by Koch et al. [3]. Briefly, samples 
were immediately centrifuged to separate serum from blood cells and then frozen in 
separate vials at −20°C until further processing and an in-solution enzymatic diges-
tion of all proteins extracted from both urinary and serum samples were achieved 
by applying a combination of Glu-C and trypsin (Promega, Vienna, Austria). This 
combination was selected in order to achieve improved sequence coverage for pro-
teins. All steps for sample preparation were performed using previously published 
protocols [4–6].
2.3 Chromatographic separation and detection
Peptide separation was achieved using nano-high-performance liquid chroma-
tography on a nano-RSLC Ultimate 3000 system (ThermoFisher Scientific, Vienna, 
Austria) using the PepMap C18 column (75 μm ID × 50 cm length, 3 μm ID, 100 Å 
pore size, ThermoFisher Scientific, Vienna, Austria). The separation column was 
mounted in a column oven and operated at 60°C. Prior to the separation on the 
nano-separation column, peptides were loaded onto a trap column (300 μm ID × 
5 mm length, PepMap 300 Å pore size, ThermoFisher Scientific, Vienna, Austria). 
The analysis of biological samples bears the risk of carry-over and contamination 
of subsequent runs in cases where injected samples contained high amounts of 
peptides. Therefore, separation system was flushed between sample injections using 
the method developed earlier and described by Mitulovic et al. [7]. Optimization of 
loading conditions have been described in a number of other publications; however, 
we have used the conditions described in a paper by Schöbinger et al. where loading 
mobile phase was cooled to 3°C in order to enable improved peptide trapping on the 
trap column, which was operated at 60°C.
Details on separation gradient formation and mobile phases used are described 
in publications by Koch et al. [2, 3].
Mass spectrometric detection of digested peptides was performed using the 
maXis Impact time-of-flight (qToF) MS (Bruker, Bremen, Germany) equipped with 
the Captive Spray nano-electrospray source and operated at 1.6 kV; source tem-
perature was set to 180°C for effective desolvatization of the analytes introduced 
from LC. Peptide masses were scanned in the range of m/z 300–m/z 2000, and 20 
most intense signals were selected for MS/MS fragmentation. Fragmentation was 
performed by using collision-induced dissociation with nitrogen in the CID cell. 
Single-charged ions were excluded from MS/MS fragmentation, and those car-
rying charges of +2 to +4 were fragmented. In order to ensure fragmentation of a 
maximum number of ions, already fragmented masses were excluded from further 
fragmentation for 60 seconds but were allowed if the following MS/MS intensity 
was three times higher as compared to the previous MS/MS peak intensity. All 
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were added, and the sample was sonicated by using the ultrasonic cell disruptor 
(Ultrasonic Cell Disruptor, Branson 5200, Dietzenbach, Germany).
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The analysis of biological samples bears the risk of carry-over and contamination 
of subsequent runs in cases where injected samples contained high amounts of 
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we have used the conditions described in a paper by Schöbinger et al. where loading 
mobile phase was cooled to 3°C in order to enable improved peptide trapping on the 
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Details on separation gradient formation and mobile phases used are described 
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Mass spectrometric detection of digested peptides was performed using the 
maXis Impact time-of-flight (qToF) MS (Bruker, Bremen, Germany) equipped with 
the Captive Spray nano-electrospray source and operated at 1.6 kV; source tem-
perature was set to 180°C for effective desolvatization of the analytes introduced 
from LC. Peptide masses were scanned in the range of m/z 300–m/z 2000, and 20 
most intense signals were selected for MS/MS fragmentation. Fragmentation was 
performed by using collision-induced dissociation with nitrogen in the CID cell. 
Single-charged ions were excluded from MS/MS fragmentation, and those car-
rying charges of +2 to +4 were fragmented. In order to ensure fragmentation of a 
maximum number of ions, already fragmented masses were excluded from further 
fragmentation for 60 seconds but were allowed if the following MS/MS intensity 
was three times higher as compared to the previous MS/MS peak intensity. All 
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measurements were performed in triplicate to provide corrections for technical 
variability of chromatographic separation and the ionization.
2.4 Data analysis
In order to identify proteins in analyzed sample, database search of mass 
spectrometric data was performed using the Human Swiss-Prot Database in its 
actual version at the time of analysis. Details of data search are described by Koch 
et al. [3]. Briefly, all searches were performed using Mascot v. 2.51 (http://www.
matrixscience.com/). For the database search, trypsin and Glu-C were selected as 
enzymes with carbamidomethyl on Cys as fixed modification and oxidation on Met, 
phosphorylation on Ser, Thr, and Tyr as variable modifications.
Protein abundance was estimated by using peptide counts normalized to counts 
per million (cpm). Log2-fold change was estimated based on variance stabilized 
average log2 cpm values using the package edgeR. Resulting p values were corrected 
for multiple testing according to Burden et al. [8].
3. Results
Only proteins identified with at least two detected and identified peptides were 
selected for further analysis.
3.1 Proteins identified in urinary samples
The total number of identified individual proteins in the case group was 1459 
and 2148 in the control group. The median number of identified proteins per urine 
sample was 377 (range 1167) in the case group and 417 (range 1197) in the control 
group.
Only 6 of the 828 proteins showed a significant difference in abundance in urine 
samples. This difference between SUI and controls was observed with a q-value 
<0.25. Out of these six identifications, three known proteins showed a higher 
abundance in SUI samples compared to controls: plasma serine protease inhibitor 
(logFC 1.11), leucine-rich alpha-2-glycoprotein (logFC 3.91), and lysosomal alpha-
glucosidase (logFC 1.24). From three uncharacterized proteins, one protein (gene 
symbol: PPIA) also showed higher abundance in SUI samples (logFC 1.96), whereas 
the other two uncharacterized proteins (gene symbol, UMOD; gene symbol, 
KIAA0586) presented a lower abundance in SUI samples than controls (logFC-4.87; 
logFC-1.99, respectively). Table 1 shows the proteins identified in urinary samples 
with significant difference between the control and the case group.
Protein Gene symbol LogFC q-value
Plasma serine protease inhibitor SERPINA5 1.111 0.029
Leucine-rich alpha-2-glycoprotein LRG1 3.909 0.019
Lysosomal alpha-glycosidase GAA 1.237 0.062
Uromodulin UMOD −4.867 0.002
Peptidyl-prolyl cis-trans isomerase A PPIA 1.962 0.227
TALPID3 (KIAA0586) TALPID3 (KIAA0586) −1.992 0.227
Table 1. 
Proteins identified with a significantly different abundance in urine of patients with stress urinary 
incontinence (SUI) compared to control samples.
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4. Discussion
Current study is not the first one describing the urinary proteome [9–13]. 
However, this study was the first one to address specific clinical problem of 
SUI. The methodology used for both sample preparation and sample analysis was 
kept as simple as possible so that it can be easily reproduced in any proteomic 
laboratory without adaptations of existing hardware.
Figure 1 shows the typical chromatogram for separation of tryptic peptides 
from a patient’s urinary sample. The large number of peaks in the chromatogram 
indicates the presence of a large number of peptides. Database search revealed that 
in almost all cases of urinary proteomic analysis, the major proteins being identi-
fied are serum albumin and uromodulin. This is physiologically normal and com-
mon, although a common knowledge implies that no proteins or, at least, very low 
number of proteins shall be present in the urine.
4.1 Proteins identified
Uromodulin, being the major urinary protein, was a major hit following serum 
albumin.
The study identified six different, putative, probably SUI-specific urinary 
proteins for the first time.
The abundance of all these proteins was found to be higher in SUI samples, and 
these are plasma serine protease inhibitor (SERPINA5), leucine-rich alpha-2-glyco-
protein (LRG1), and lysosomal alpha-glucosidase (GAA).
The results showing the enrichment of mentioned proteins based on KEGG 
pathway analysis are shown in Figure 2.
SERPINA5 is usually present in urine in very low concentrations and serves, 
among other functions, as a pro-inflammatory factor, which might be an explana-
tion for it overexpression in samples of patients with SUI [1, 14–20]. Furthermore, 
SERPINA5 was recently mentioned in a number of publications addressing diverse 
medical conditions, including pediatric leukemia, breast cancer, HIV infection, and 
hepatocellular carcinoma, which have identified a role played by SERPINA5 during 
disease development [21–24].
Figure 1. 
UV Chromatogram trace at 210 nm showing the separation of tryptic peptides from urinary sample.
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measurements were performed in triplicate to provide corrections for technical 
variability of chromatographic separation and the ionization.
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matrixscience.com/). For the database search, trypsin and Glu-C were selected as 
enzymes with carbamidomethyl on Cys as fixed modification and oxidation on Met, 
phosphorylation on Ser, Thr, and Tyr as variable modifications.
Protein abundance was estimated by using peptide counts normalized to counts 
per million (cpm). Log2-fold change was estimated based on variance stabilized 
average log2 cpm values using the package edgeR. Resulting p values were corrected 
for multiple testing according to Burden et al. [8].
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sample was 377 (range 1167) in the case group and 417 (range 1197) in the control 
group.
Only 6 of the 828 proteins showed a significant difference in abundance in urine 
samples. This difference between SUI and controls was observed with a q-value 
<0.25. Out of these six identifications, three known proteins showed a higher 
abundance in SUI samples compared to controls: plasma serine protease inhibitor 
(logFC 1.11), leucine-rich alpha-2-glycoprotein (logFC 3.91), and lysosomal alpha-
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logFC-1.99, respectively). Table 1 shows the proteins identified in urinary samples 
with significant difference between the control and the case group.
Protein Gene symbol LogFC q-value
Plasma serine protease inhibitor SERPINA5 1.111 0.029
Leucine-rich alpha-2-glycoprotein LRG1 3.909 0.019
Lysosomal alpha-glycosidase GAA 1.237 0.062
Uromodulin UMOD −4.867 0.002
Peptidyl-prolyl cis-trans isomerase A PPIA 1.962 0.227
TALPID3 (KIAA0586) TALPID3 (KIAA0586) −1.992 0.227
Table 1. 
Proteins identified with a significantly different abundance in urine of patients with stress urinary 
incontinence (SUI) compared to control samples.
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Another protein, the leucine-rich alpha-2-glycoprotein, was also found to be 
increased in samples of SUI patients. This protein is secreted and normally present 
in plasma; however, it was also described to be involved in nonspecific inflamma-
tory and cancer processes [25–28]. It has recently been described in the context of 
ulcerative colitis activity, pediatric, invasive bladder cancer, biliary tract cancer, 
lung cancer, pancreatic cancer, heart failure, neutrophilic granulocyte differentia-
tion, and autoimmune diseases [29, 30].
Lysosomal alpha-glucosidase, another protein with increased expression in SUI 
samples, is essential for the degradation of glycogen to glucose in lysosomes, and it 
is present in, basically, all cells. Mutations in the respective gene result in Pompe dis-
ease, a severe and devastating glycogen storage disease caused by a deficiency in acid 
α-glucosidase. This condition is characterized by the lack of lysosomal alpha-glucosi-
dase, which leads to intralysosomal accumulation of glycogen, the final consequence 
of which is the failure of the heart and skeletal muscles. The Pompe disease is being 
treated by enzyme replacement therapy. However, this is not sufficient, although 
it helps preventing assisted patients’ ventilation and ensuring a ventilation-free 
survival. GAA is an enzyme that is essential for lysosomal glycogen hydrolysis, and 
the protein has also been identified as a potential biomarker for gut wall integrity in 
infants with necrotizing enterocolitis, an inflammatory process involving the intes-
tinal tissue [31]. GAA has not been described as a factor for SUI, but the involvement 
of GAA in pathologies of smooth muscle [32] suggests that this protein might have an 
important role for the proper function of the bladder. Niedworok et al. [33] suggested 
that GAA might be involved in bladder cancer as an endogenous inhibitor of bladder 
cancer cell proliferation. The authors concluded that GAA is upregulated in response 
to antiproliferative tyrosine kinase inhibitors. That would mean that high biglycan 
expression is associated with favorable prognosis for patients with bladder cancer.
Alsaikhan et al. [34] investigated the partial bladder obstruction and the 
expression, among other factors, of GAA. Authors describe that small leucine-rich 
proteoglycans, required for collagen fibrillogenesis showed a significant reduction, 
which was consistent with a pro-fibrotic environment and deregulated collagen 
assembly. Although this study did not address the matter of incontinence, it showed 
that leucine-rich proteoglycans have an important role to play for the regulation of 
bladder function.
A similar observation was made by Appunni et al. [35, 36] for the role of 
leucine-rich proteoglycans and the bladder cancer. Leucine-rich proteoglycans are 
not only required in the matrix for structural framework, but they also show to be 
effective in controlling various physiological functions. Among these functions are 
also the cell cycle regulation and the leucine-rich proteoglycans which perform the 
role of the guardians of the cellular matrix.
Figure 2. 
KEGG pathway for the set of proteins with affected expression in SUI samples.
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Upon database search and quantitation, peptidyl-prolyl cis-trans isomerase 
A (PPIA) was found to be overexpressed. This protein has been described to be 
involved in inflammatory processes and immunomodulation and induction of 
interleukin-6 release from macrophages. Recent publications have discussed an 
involvement in type 2 diabetes mellitus, vascular disease, and gastric adenocarci-
noma [31].
Two of the identified uncharacterized proteins, which are encoded by associated 
with the genes UMOD and KIAA0586, showed lower expression in SUI samples.
UMOD encodes for the protein uromodulin, which is, among other functions, 
involved in the prevention of urinary tract infection, water/electrolyte balance, 
and kidney innate immunity. Uromodulin is usually highly abundant in the urine of 
healthy humans, and, as mentioned previously, it is the most abundant protein in 
normal urine [37]. Interestingly, uromodulin is another glycoprotein identified to 
have different expression patterns in SUI samples as compared to control samples. 
UMOD is a GPI-anchored glycoprotein produced by the kidney but not derived 
from the blood. The function of these proteins is still not well understood, but it is 
taught to be linked to the water/electrolyte balance and kidney innate immunity. 
Hypertension in pregnancy was associated with a decrease in the uromodulin’s 
excretion rate [38], and the results of SUI samples also revealed that the level of 
uromodulin was decreased. Furthermore, UMOD can be used as a predictive factor 
for preeclampsia [39]. UMOD has been described to prevent the binding of the 
IgG light chain to their putative receptors [40]. Da Silva et al. described the role of 
UMOD as an allergen epitope [41] for activation of the allergy-associated T cells in 
mouse. There is no description of causality in humans; however, the lower expres-
sion of this protein in samples of SUI patients might be of importance considering 
the function of the smooth muscle of the urinary bladder.
KIAA0586 encodes for the protein TALPID3, which is required for ciliogen-
esis and sonic hedgehog/SHH signaling [42–48]. Fleming et al. [49] described 
the possible involvement of TALPID3 in kidney damage in patients with Joubert 
syndrome. Interestingly, all patients enrolled in this study and having a mutation 
on KIAA05866 gene, which encodes for TALPID3, showed to have significantly 
better chances of preserving the kidneys, which are, otherwise, affected by the 
Joubert syndrome. It is still unclear why this protein was identified with a decreased 
abundancy in samples of SUI patients.
Another protein that was ubiquitous in all samples was keratin. Keratin is com-
monly identified during proteomics analysis, and it often serves as a quality control 
of the analysis, if not present in high amounts. However, more often, keratin is 
considered being a contaminant and something that shall be kept out of the sample 
by any means.
Therefore, requirements were taken to exclude any possible contamination 
with keratin, but it was still identified in large amount in all samples. Besides being 
considered a contaminant for proteomics experiments, keratin is an important part 
of the urinary proteome which seems to be present in all collected samples.
As for now, no biomarkers have yet been identified for SUI, and it is rather 
improbable that a single protein will be a marker. A more probable scenario is that a 
group of proteins with a significantly different abundance in SUI patients compared 
to controls will be defined as putative markers.
The best chance to identify these proteins will be by investigating the known 
functions, tissue specificities, and interactions of the specific proteins identified in 
samples of SUI patients. It is also important to gain a detailed insight into potential 
mechanisms of the pathophysiology and etiology of SUI, which seem to depend 
on many factors and might be a complex process depending on more physiological 
processes taking place in the urinary bladder. Proteins, which were identified with 
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UMOD encodes for the protein uromodulin, which is, among other functions, 
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and kidney innate immunity. Uromodulin is usually highly abundant in the urine of 
healthy humans, and, as mentioned previously, it is the most abundant protein in 
normal urine [37]. Interestingly, uromodulin is another glycoprotein identified to 
have different expression patterns in SUI samples as compared to control samples. 
UMOD is a GPI-anchored glycoprotein produced by the kidney but not derived 
from the blood. The function of these proteins is still not well understood, but it is 
taught to be linked to the water/electrolyte balance and kidney innate immunity. 
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excretion rate [38], and the results of SUI samples also revealed that the level of 
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sion of this protein in samples of SUI patients might be of importance considering 
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better chances of preserving the kidneys, which are, otherwise, affected by the 
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abundancy in samples of SUI patients.
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of the analysis, if not present in high amounts. However, more often, keratin is 
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on many factors and might be a complex process depending on more physiological 
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significantly higher abundance in SUI samples, have been described earlier as active 
participants in inflammatory processes and cancer development. On the other 
hand, proteins that were identified and quantified with a significantly lower abun-
dance usually seem to have a protective effect in the urinary tract system although 
we cannot be explained at the current time.
5. Conclusion
It is important to stress out that one of the most important factors for a success-
ful analysis is the selection of samples to be analyzed. It is very important to include 
urine samples retrieved from a population with very strict inclusion and exclusion 
criteria in order to avoid confounding factors. Urine samples must be processed 
according to a standardized protocol within a short time frame after collection.
Although a thorough map of the human proteome has been described, and made 
available to researchers [50], this map is still not complete and it is prone to errors 
and biases. Therefore, the incomplete “humane proteome mapping” is an additional 
challenge despite efforts of the research community to identify and characterize all 
human proteins.
By investigating the urinary proteome at one time point only, no conclusion can 
be made on whether the significantly differently expressed proteins are a conse-
quence of the pathological process or whether they themselves are directly involved 
in causal processes.
Therefore, due to the characteristics of the identified proteins, it can be said 
that inflammatory processes may be involved in the etiology of SUI. However, the 
relevance of these findings regarding the pathogenesis of SUI needs to be broadly 
investigated, and the results described need to be replicated in a different popula-
tion and at different time points.
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Advances in Treatment of 
Nocturnal Enuresis in Children
Bingying Zhou, Jianxin Lu, Peiqi Shi and Yifang An
Abstract
Nocturnal enuresis is a condition with complex etiology affecting plenty of 
children and families. Even though multifarious clinical trials and studies have been 
designed and completed, some inconclusive results on nocturnal enuresis confuse 
clinicians. This article aims to provide useful information for clinicians by summa-
rizing the existing evidence on nocturnal enuresis and discussing the effectiveness 
and safety of different treatments. Nocturnal enuresis mainly results from the 
disorders related to central nervous system, which may cause nocturnal polyuria, 
nighttime bladder capacity decline, arousal disorder, and various accompanying 
diseases. We discussed the efficacy and safety of different treatments for mono-
symptomatic nocturnal enuresis, including standard therapies, simple behavioral 
interventions, complex behavioral interventions, alarm therapy, desmopressin and 
other drugs, biofeedback therapy, electrical stimulation, acupuncture, Chinese 
herbal medicine, massage, and so on. Alarm is still the most effective single therapy 
with lower relapse rate. Desmopressin has efficacy mainly in children with noctur-
nal polyuria. Children with detrusor overactivity or decreasing functional bladder 
capacity can choose anticholinergics. Additionally, tricyclic drugs, biofeedback 
therapy, electrical stimulation, acupuncture, massage, and so on are therapeutic 
options for children with nocturnal enuresis.
Keywords: nocturnal enuresis, alarm, desmopressin, behavioral interventions, 
acupuncture
1. Introduction
Nocturnal enuresis (NE) is a common disease that pediatricians often encounter. 
It is defined as an intermittent involuntary micturition during sleep in children 
over 5 years of age with at least two episodes per week and duration of more than 3 
months [1]. Basically, NE is divided into non-monosymptomatic nocturnal enuresis 
(NMNE) and monosymptomatic nocturnal enuresis (MNE) according to whether 
there are daytime lower urinary tract symptoms. On the other hand, it is also 
classified into primary nocturnal enuresis (PNE) and secondary nocturnal enuresis 
(SNE) according to whether or not the duration of dry days is less than 6 months 
[1]. Secondary NE requires clinicians to identify and evaluate the diseases which 
NE is secondary to and treat them first. In PNE, NMNE usually means that children 
have more complex bladder dysfunction or other potential pathology and need to be 
referred to a specialist for further diagnosis and treatment. Although some children 
with MNE can be self-healing and the prevalence gradually decrease with age [2], 
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1. Introduction
Nocturnal enuresis (NE) is a common disease that pediatricians often encounter. 
It is defined as an intermittent involuntary micturition during sleep in children 
over 5 years of age with at least two episodes per week and duration of more than 3 
months [1]. Basically, NE is divided into non-monosymptomatic nocturnal enuresis 
(NMNE) and monosymptomatic nocturnal enuresis (MNE) according to whether 
there are daytime lower urinary tract symptoms. On the other hand, it is also 
classified into primary nocturnal enuresis (PNE) and secondary nocturnal enuresis 
(SNE) according to whether or not the duration of dry days is less than 6 months 
[1]. Secondary NE requires clinicians to identify and evaluate the diseases which 
NE is secondary to and treat them first. In PNE, NMNE usually means that children 
have more complex bladder dysfunction or other potential pathology and need to be 
referred to a specialist for further diagnosis and treatment. Although some children 
with MNE can be self-healing and the prevalence gradually decrease with age [2], 
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most treatments for NE cannot achieve high cure rates and may cause high relapse 
rates. This may result from the complexity and uncertainty of the etiology of NE 
and the use of inappropriate treatment.
2. Epidemiology
According to Jain et al.’s review, the prevalence of MNE varies from 3.8 to 
18.9% in different countries [2]. The risk factors related to NE reported in differ-
ent studies include constipation, positive family history, obstructive respiratory 
disorder, deep sleep, corporal punishment at school, urinary tract infection, etc. 
[3–6]. However, the effect of each factor on NE varies from study to study, and no 
universal conclusion is drawn. The results from different studies may be contra-
dictory. For example, a few researches reported that the prevalence of NE was sig-
nificantly higher in boys than the one in girls [3, 7], while other studies draw the 
opposite conclusion that girls’ prevalence is higher [8]. The potential reasons for 
the contradiction of results in different studies performed in different countries 
may be related to the difference in diagnostic criteria followed by each survey, 
sample size, sampling method, questionnaire design, and cultural background in 
different regions. According to Wen’s survey about NE in Chinese children, the 
overall prevalence was 4.07%, which is much lower than counterparts in other 
countries [9]. In it, Dr. Wen reported that Chinese parents would wake their 
children to void once they found children’s dysphoria due to the fullness of the 
bladder. Besides, he also found that Chinese parents were more likely to withdraw 
the diaper for their children as early as possible, which is believed to be helpful for 
the children to build normal urination habits. Similar to the mechanism of alarm 
therapy, these actions may have a positive effect to promote the establishment 
of reflex between bladder filling feeling and urination. It is important to analyze 
epidemiological data, which may help us to understand the importance of the 
children and their parents’ behavior and other complex physiological, pathologi-
cal, and social psychological elements involved in the prevalence of NE.
3. Clinical diagnosis and treatment algorithm
There are a few diagnosis and treatment algorithms of NE proposed by the 
International Children’s Continence Society (ICCS), the International Continence 
Society (ICS), and some other literatures with similarities and differences. In this 
part, the algorithm of the ICCS’s practical consensus guideline is introduced and 
modified.
NE has many possible causes: genetic factors, renal physiological factors, defi-
ciency of antidiuretic hormone (ADH, vasopressin) leading to nocturnal polyuria, 
bladder dysfunction, arousal disorder, maturation delay, circadian rhythm disorder, 
etc. Moreover, many associated diseases such as obstructive sleep-disordered 
breathing, constipation, fecal incontinence, attention deficit disorder (ADD) and 
attention deficit hyperactivity disorder (ADHD), obesity, psychological problems, 
etc. can also be seen in children with NE. These associated diseases should be 
identified in the clinical evaluation and be treated first. For children without those 
conditions, the increase in nocturnal urine production and nighttime bladder 
capacity reduction are the two main prototypes. To provide an outline in the diag-
nosis and management of NE, we build an algorithm after summarizing available 
guidelines. Figure 1 is the clinical diagnosis and treatment algorithm adapted from 
the guideline of Walle et al [10]:
55
Advances in Treatment of Nocturnal Enuresis in Children
DOI: http://dx.doi.org/10.5772/intechopen.89106
1. Clinical management tool is a medical history and symptoms collection form 
(see [10]).
2. Voiding diary (bladder diary) is not necessary.
3. After MNE is diagnosed, the 2012 guideline recommends directly the alarm 
and desmopressin treatment options. John Michael’s review in 2014 recom-
mends 6 weeks of urotherapy first and then evaluating the child to decide 
whether to take alarm or desmopressin [11].
4. EBC: expected bladder capacity, calculated as {30 + (age in years × 30)} in 
milliliters.
5. MVV: maximum voided volume, the largest urine volume of 24 h (see part 
bladder diary for details).
Figure 1. 
Nocturnal enuresis algorithm (modified from Walle, 2012).
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According to the 2006 ICCS’s standardized terminology of lower urinary tract 
(LUT) function, urotherapy is defined as a nonsurgical and nonpharmacological 
treatment for LUT dysfunction [1]. It includes standard therapy which means the 
therapy is noninterventional and has specific interventions.
4.1.1 Standard therapy
The standard therapy usually has these components as below:
1. Health education. Health education refers to providing parents basic informa-
tion about normal LUT function and the causes, risk factors, different treat-
ments, and their implementation of MNE [1]. The clinicians should emphasize 
that the condition is common and can be healed by itself and that parents 
should have a positive attitude instead of thinking enuresis as a shame because 
this helps children to establish their motivation for active participation and 
reduce damage to their self-esteem, which is the key to treatment [12].
2. Lifestyle advice. Develop healthy drinking and eating habits: avoid foods or bever-
ages that have a diuretic effect, such as theophylline or caffeine; eat early in the 
evening, with less oil and less salt; and no more water or food and fruit rich in fluid 
at least 2 h before going to bed. These all avoid excessive nighttime fluids in body 
which may lead to overmuch urine production during the night. However, for 
children with MNE, fluid restriction may have a risk of reducing bladder capacity 
resulting in a decrease in the ratio of bladder capacity to nocturnal urine output, 
and so nocturnal enuresis increases [13]. Therefore, adequate fluid intake during 
the day is important, especially during the morning and early afternoon hours 
[14]. It is also good for cultivating the child’s feeling of bladder fullness. Moreover, 
a research indicates that holding exercises can increase the maximum voided 
volume of children with MNE, so it is better not to be active after dinner [15].
3. Developing regular voiding and bowel habits. As the ICCS recommended, 
children should develop a good habit of regular urination during the day and 
schedule to urinate before going to bed and in the early morning after wak-
ing up. The daily routine of micturition should be comprised of once in the 
morning, at least twice during school hours, and once each after school, at 
dinner, and before going to bed, with totally less than seven urinations dur-
ing daytime [14]. Besides, parents should instruct the child to use a comfort-
able voiding posture to relax the pelvic floor muscles—and that means sitting 
on the toilet safely with the bottom and feet supported. Constipation is a 
common concomitant disease in children with NE, especially with NMNE. It 
is recommended to eat more foods rich in dietary fiber and develop regular 
bowel movements every day, best after breakfast. Based on current evidence, 
medication can be used to soften children’s stools if necessary [14].
4. Voiding diary or bladder diary (VD or BD). According to the 2012 ICCS’s practi-
cal consensus guidelines for MNE’s management [10], BD is recommended to 
assess the children’s voiding habit, especially for the families in which parents 
are unclear about children’s voiding history. The most important function of 
BD is to evaluate the bladder capacity of children through daytime diary and 
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to assess the presence of nocturnal polyuria (NP) through nighttime diary. It 
is also helpful to distinguish NMNE through finding out daytime polyuria, 
stress urinary incontinence, urgency urinary incontinence, etc. A daytime diary 
should include at least fluid intake time, urination time, fluid intake volume, 
urination volume, and the occurrence of urinary incontinence and exclude the 
first urination after getting up in the morning. The recording time should be at 
least 3–4 consecutive days. Children attending school can choose to record two 
consecutive weekends [10]. In daytime diary, the most important thing that 
requires clinicians’ attention is the largest urinated volume which can indicate 
the child’s bladder capacity. It can be determined if the bladder capacity is 
reduced or increased when the maximum voided volume is <65% or >130% 
expected bladder capacity (EBC’s calculation formula is shown in Figure 1). 
The nighttime diary should include at least urination time (if the child gets up to 
the toilet), urination volume, diaper weight overnight, first urination volume 
after getting up in the morning, dry night or not (there is any enuresis or not), 
and whether there is bowel movement that day. The recording time should be at 
least seven consecutive nights [10]. What the nighttime diary can tell the clini-
cians is the child’s amount of urine produced at night by adding first urination 
after getting up in the morning, the nighttime diaper weight, and nocturnal 
urination volume to the toilet. If the total nighttime urine output exceeds 130% 
EBC, it is determined as nighttime polyuria (NP). Through analyzing indi-
vidual BD, children with MNE can be classified into one of the four subtypes 
as shown in Figure 1. Then the corresponding treatment could be determined. 
In addition, by calculating a child’s body surface area, we can find whether the 
24-h urine volume >2 L/m2, which means the child has polyuria; by observing a 
child’s water taking, we can know if the child has polydipsia which is considered 
as a predictor of diabetes or kidney disease. It is worth noting that children with 
these conditions are not suitable to take desmopressin.
4.1.2 Specific interventions
Specific interventions comprise behavioral modification and nonbehavioral 
strategies including pelvic muscle floor training, biofeedback, electrical stimula-
tion, etc. [1]. And the behavioral interventions can also be divided into simple 
and complex strategies based on whether it is a single action or they are composite 
interventions [16] (Table 1).
Simple behavioral Interventions Reward systems




Complex behavioral interventions Dry bed training (DBT)
Full-spectrum home training (FSHT)
Arousal therapy
1Lifting and waking therapy includes lifting with or without password and waking randomly or to a certain time.
2Bladder training includes retention control training, pelvic floor muscle training, sphincter control exercises, and 
stream interruption exercises.
Table 1. 
Categories of behavioral interventions.
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4.1.2.1 Simple behavioral interventions
Most of the simple behavioral interventions were initially presented in some 
early literatures, because the effects of first-line treatment on NE had not yet been 
determined at the time. They are often used in clinical treatment, but the efficacy 
is controversial since it lacks high-quality evidence. A systematic review about the 
efficacy and safety of simple behavioral interventions for NE has been published in 
the Cochrane Library. Unfortunately, only limited evidence is available. For most 
interventions only a single clinical trial was included, and therefore the data cannot 
be combined for meta-analysis except for the comparison between bladder training 
and alarm [16]. Furthermore, some other important limitations about the clinical 
trials were discussed in this review: for children with NE included in the trials, 
MNE and NMNE were not further distinguished; most trials had methodological 
deficiencies, and more than half of the trials reporting continuous outcomes did 
not report SDs; the trials’ sample size was small, risk of bias was high, and the 
confidence interval was too wide; since there is a lack of long-term follow-up after 
the end of treatment, no data were available to assess the long-term efficacy of the 
interventions [16]. The following is a summary of this review’s conclusion which 
needs to be cautiously referenced.
In the simple behavioral interventions referring to reward systems, lifting or 
waking the children, bladder training, and fluid restriction (cleanliness training was 
not reviewed), though all of them were more effective statistically than the control 
group, none of them had a better effect than others at the end of the treatment. 
When compared with alarm or different drugs, they were usually less effective 
except for bladder training which has no significant difference with drugs [16]. In 
terms of safety, adverse events were not reported in the included trials.
Bladder training is a behavioral therapy aiming to increase bladder capac-
ity and strengthen the control of bladder in children. According to the review, 
bladder training seemed to be superior to the nonactive movements group in 
gaining less mean wet nights at the end of the treatment. However, there was 
no difference in the number of children who did not achieve 14 dry nights [16]. 
Another prospective trial further revealed that the basic bladder training’s effects 
mostly were pronounced after the third month of treatment for the MNE children 
who did not receive any previous treatment. Therefore, for children who are not 
strongly willing to accept behavioral interventions, early administration of alarm 
or desmopressin is necessary [17]. But it seems to have good efficacy in children 
with NMNE [18].
Lifting without password is a controversial intervention because it allows the 
children to urinate while asleep, but it is useless to reduce the occurrence of noctur-
nal enuresis [19]. Being consistent with the conclusions of this review, a study also 
showed that the lifting without password group had a significantly higher propor-
tion in the number of dry children than the control group and was even superior 
to lifting with password group and rewards group. In terms of long-term effect, 
both lifting groups had more dry children than the two other groups during 3 years 
follow-up [20].
4.1.2.2 Complex behavioral interventions
Dry bed training (DBT) is the oldest complex behavioral interventions with 
a multicomponent package of nighttime waking schedule, cleanliness training, 
reinforcement techniques, and other interventions. It has different versions and a 
few adapted versions with some components removed [21]. Full-spectrum home 
training (FSHT) is a combination with alarm, cleanliness training, and retention 
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control training in the daytime. To maximize the effect, the FSHT needs to be 
overlearned (giving extra fluids at bedtime after successfully  becoming dry). 
Specific implementation steps of DBT and FSHT have been described by Brown 
and Glazener [22, 23]. In a Cochrane review of NE, complex behavioral inter-
ventions were compared with control, alarm, and other complex behavioral 
interventions. Moreover, complex behavioral interventions removing alarm 
were compared with control, alarm, and complex behavioral interventions 
supplemented by alarm. The conclusions were that DBT or FSHT was better 
than control in efficacy and relapse rate and marginally superior to alarm alone. 
Either complex behavioral interventions removing alarm or control intervention 
was inferior to alarm alone or complex behavioral interventions supplemented 
by alarm. There is no evidence for the comparison between complex behavioral 
interventions removing alarm and control. Additionally, adverse events were not 
described by the trials [23]. Unfortunately, the included studies in the systematic 
review have some limitations including small scale, small quantity, and poor 
quality. Besides, it has to be mentioned that the interventions are heavy burdens 
on families.
Alarm and reward system are the components of arousal therapy/training, 
which was reported to have a high efficacy and low relapse rate in an early literature 
[24]. However, they have not been recommended by the guideline [10] because 
there is not enough clinical evidence, which is similar to FSHT [25].
4.1.2.3 Nonbehavioral interventions
Biofeedback therapy and electrical stimulation therapy were originally used to 
treat voiding dysfunction, and now they have been tried to treat refractory MNE or 
PNE with a reported good efficacy. Dr. Hoekx and his colleagues prospectively evalu-
ated the effect of bladder biofeedback in 21 boys and 3 girls (mean age 10.4 years). 
After treatment 17/24 patients showed good response that means they achieved totally 
dry. During the 60-month follow-up, 4 patients were lost, 15 were dry at night, and 
4 continued bed-wetting. The proportion of children with small bladder capacity in 
responders is much less than the one in non-responders [26]. In a randomized clinical 
trial published in 2015, 54 children with PNE were included and randomly divided 
into interferential (IF) electrical stimulation group and control group. A responding 
rate was reported as 55.5 and 22% in the IF and control group at the 1-year follow-up 
(P = 0.01), respectively. In terms of the mean number of dry nights per week and 
the mean improvement score, the IF group was superior compared to control group. 
Additionally, no adverse events were reported [27]. In another trial, children with 
refractory MNE were randomly assigned to intra-anal biofeedback with behavioral 
therapy, electrical stimulation with behavioral therapy, and pelvic floor muscle train-
ing groups. The trial stated a total efficacy of three groups in the outcomes and that 
intra-anal ES group was superior to BF training group. But in these three outcomes, 
the method to assess nighttime bladder capacity with morning first urine volume is 
not accurate [28]. In short, there is no adequate clinical evidence to determine the 
therapeutic effectiveness of these NE treatments (Table 2).
Nonbehavioral interventions Biofeedback (BF)1
Electrical stimulation (ES)
1Including bladder biofeedback and intra-anal biofeedback
Table 2. 
Categories of nonbehavioral interventions.
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Table 2. 
Categories of nonbehavioral interventions.
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4.2 Alarm
Alarm therapy, also known as enuretic alarm devices (EADs) or enuresis alarm 
treatment (EA), is a kind of therapy with sufficient evidence which shows a higher 
response rate and a superior long-time success than the control or other therapies. 
Although its relapse rate is still a little high, the addition of overlearning and dry 
bed training or avoiding penalties can reduce the rate by nearly half [29]. In terms 
of different types of alarms, there was no enough evidence to draw conclusions, 
neither did the comparison between alarm and other behavioral therapies [29]. Two 
other Cochrane reviews revealed that alarm had better effects than simple behav-
ioral interventions, but not when compared with complex behavioral therapies 
[16, 23]. Some researchers believed the effect of alarm might be weakened if only 
the parents were waked by the alarm instead of the children. A result from Tsuji’s 
study showed whether the parents or children themselves are waked by the alarm 
or the effectiveness of alarm is equal [30]. Apos E. et al.’s study published in 2018 
stated excellent effects of alarm therapy for MNE, NMNE, PNE, and SNE children 
using alarm therapy and especially for NMNE children [31]. The ICCS guideline 
also recommended that the alarm should be considered as the therapeutic option 
for every child. Furthermore, those children who have motivated parents should be 
given a priority [14].
It has to be mentioned that alarm does not have an immediate effect. Normally, it 
often needs to take a period of time to achieve the expected efficacy. The appropriate 
course recommended by the ICCS is 2–3 months until children achieve 14 consecu-
tive dry nights or the effect is not good [14]. Similarly, the ICS’s recommendation is 
to evaluate the efficacy of alarm after at least 6–8 weeks [12]. It also states that the 
efficacy will increase with treatment duration; however, the ideal course of alarm has 
not been introduced [12]. In one study, a total of 455 children with PMNE were ran-
domly divided into three groups and received 3, 4, and 5 months of uninterrupted 
alarm treatment, respectively. The results showed that children with 16–20 weeks’ 
treatment had better curative effect [32]. Unfortunately, this study did not observe 
the effect with a longer follow-up. So we cannot conclude if the longer treatment can 
further increase the effect of alarm. In another study, NE children who were inef-
fective after 3 months’ alarm treatment were randomized into two groups to receive 
a repeat alarm treatment for ≥3 months without interval and with an interval of 
more than 6 months, separately. The success rate in the latter group was significantly 
higher than the former, which means repeat alarm therapy with at least one interval 
may reawaken children’s response [33]. Despite the small sample size, this study may 
provide new ideas for children who have no response to alarm treatment.
The possible mechanism of alarm therapy may be a gradual establishment of 
a conditioned reflex between bladder filling and waking. Evidence showed that 
it could increase the prepulse inhibition (PPI), similar to the effect of desamino-
arginine vasopressin (dDAVP), which suggested that the alarm could also promote 
the maturation of the reflex control of NE [34]. In addition, a study reported that 
children’s daytime functional bladder capacity increased markedly after treatment 
with alarm [35]. Therefore, the efficacy of alarm on children with NE may be 
achieved through multiple effects.
4.3 Desmopressin
Desmopressin is an arginine vasopressin analog that enhances the reabsorption 
of water by the distal convoluted tubules and collecting ducts of the kidney and 
inhibits the secretion of aldosterone. Schulz-Juergensen et al.’s study published 
in 2007 showed that 1-desamino-8-d-arginine vasopressin (dDAVP) could make 
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PMNE children’s PPI upregulate to the age-related normal level. The authors offered 
a different explanation about dDAVP that it not only had a role in the kidney but 
also acted as a central neurotransmitter which has a positive effect on the delayed 
maturation of NE children’s micturition reflex [36]. According to the results of 
this study, desmopressin has the ability to cure a substantial group of children with 
NE in theory. However, it is more complicated in practice with problems of how to 
choose the potential suitable children for desmopressin therapy. Moreover, what is 
the appropriate dose and course of treatment are also big issues. To assess the effect 
of desmopressin, a number of studies have been performed. Evidence showed that 
it could significantly reduce bed-wetting by 1–2 nights per week during the treat-
ment, but there is no difference in wet nights per week compared with the placebo 
group. Additionally, when comparing with alarm therapy, lower effectiveness and 
higher subsequent relapse rate were reported in the desmopressin group according 
to a Cochrane review [37].
In general, children with nocturnal polyuria are suitable for desmopressin 
therapy. Basically, we can identify this subtype of MNE using the bladder diary. 
However, there is an evidence showing that children with NE may not present 
continuous nocturnal polyuria. Nocturnal urine production increases significantly 
on wet nights than the dry nights. Children without abnormal increase in nocturnal 
urine production do not respond to desmopressin [38]. This study revealed the 
polyuria characteristics for a subgroup of NE children and confirmed the efficacy 
of desmopressin for these children. Furthermore, some other studies also showed 
that desmopressin was not effective in children with low functional bladder capac-
ity [39] and those with abnormal bladder volume and wall thickness (BVWT) [40], 
indicating that desmopressin’s clinical use should carefully identify children with 
potential bladder dysfunction.
Referring to appropriate dose of desmopressin, there is an insufficient evidence 
to determine whether higher dose is more effective or not [37]. The recommended 
safe dose is 0.2–0.4 mg for tablets and 120–240 μg for melt formulation [14]. There 
is no enough evidence to state what is the appropriate course of treatment. Because 
of high relapse rate after treatment, it is advised to gradually reduce the drug 
dose instead of stopping it directly at the time of getting a complete response. For 
long-term safety, desmopressin is proven to be safe enough to use for several years. 
Water intoxication with hyponatremia is only a severe adverse event that needs to 
be concerned. Fluid restriction of 200 ml or less for the whole night is advised with 
desmopressin treatment [14]. Moreover, nasal spray reports more hyponatremia 
than oral formulations [41].
4.4 Pharmacotherapy (other than desmopressin)
Anticholinergic drugs are widely used for the management of NE since they 
can bind to choline receptors and produce antagonistic activity against acetylcho-
line and consequently relieve detrusor overactivity. They can be classified into M 
and N receptor blockers according to their selectivity for different receptors. M 
receptor blockers, also called as antimuscarinics, are more commonly used to treat 
NE. Generally, M receptors consist of five different subtypes, including M1, M2, 
M3, M4, and M5. Of those, M2 and M3 subtypes are mainly distributed in the blad-
der wall, and M3 has an upregulated expression in patients with overactive bladder. 
Therefore, the therapeutic mechanism of antimuscarinics is to inhibit  
the bladder M receptor, relax the detrusor, and consequently expand the bladder 
capacity. The mechanism determines that antimuscarinic drugs should be mainly 
used in treatment of NE children who are suffering from latent bladder smooth 
muscle spasm, detrusor overactivity, or decreased functional bladder capacity. 
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This kind of children usually has daytime symptoms of lower urinary tract and 
is classified as NMNE. However, some children diagnosed as MNE are also suit-
able for anticholinergic drug therapy because they have only nighttime detrusor 
overactivity or mild urinary tract symptoms during daytime. For children who do 
not respond to alarm or desmopressin therapy, anticholinergic agents are usually a 
kind of therapeutic option. The clinical application of anticholinergic drugs should 
focus on how to identify the children with indications through bladder diary and 
other diagnostic techniques. Studies to evaluate the efficacy of anticholinergic drugs 
and their combination with alarm or desmopressin on these children should be 
conducted as well.
Differing from anticholinergic drugs, the mechanism of tricyclic drugs in the 
treatment of NE is still unclear. The possible mechanism includes inhibiting rapid 
eye movement sleep to promote sleep arousal and stimulating antidiuretic hormone 
secretion. A Cochrane review showed that tricyclic drugs could reduce about one 
wet night per week, but most children relapsed after treatment which is similar to 
desmopressin and inferior to alarm [42]. In addition, most tricyclic drugs may cause 
serious side effects such as cardiotoxicity, so they are only used for the treatment 
of refractory or therapy-resistant NE. An exception is reboxetine. Neveus and his 
colleagues attempted to treat children with therapy-resistant NE using reboxetine, 
and they found that 59% of the patients reached a full response after 4 weeks of 
treatment. Moreover, during treatment, no significant cardiac toxicity was reported 
[43]. Lundmark et al. used reboxetine to treat therapy-resistant NE children 
and also achieved good results without significant cardiac adverse events [44]. 
Therefore, reboxetine may be a good therapeutic option instead of imipramine, but 
its effectiveness and safety need more clinical studies to prove.
4.5 Complementary and alternative approaches
Although a large amount of evidence has shown the effectiveness of conven-
tional treatment including alarm and pharmacotherapy on NE [31, 45], these 
approaches cannot meet all the needs of the children and their parents. It is 
reported that as high as 30% of families discontinue the treatment of alarm on their 
own reason [46]. On the other hand, the side effects related to medications bother 
both children and their family members. Therefore, a number of parents are more 
likely to seek help from complementary and alternative medicine for their children. 
Being outside of conventional medicine, complementary and alternative medicine 
includes a series of medical approaches, such as acupuncture, herbal therapy, and 
massage. Recently, an increasing evidence has shown the efficacy of complemen-
tary and alternative medicine on management of NE.
4.5.1 Acupuncture
Acupuncture, as a component of traditional Chinese medicine, has been used to 
manage a number of chronic diseases. Even though acupuncture originates in China, 
its efficacy on various urological diseases has been recognized in industrial world 
[47]. A number of studies have demonstrated the effectiveness of acupuncture in 
treatment of NE. In a single-arm trial, Bjorkstrom et al. [48] showed that an 8-week 
treatment with 20 sessions of acupuncture decreased the episodes of NE and the sleep 
arousal threshold significantly in 65 and 50% of children, respectively, at the follow-
up of 6 months. Another study further revealed that acupuncture might increase 
the nocturnal bladder capacity significantly in responders [49]. To assess the effect 
of acupuncture on NE, several systematic reviews were conducted. As presented in 
a part of Cochrane systematic review [50], Glazener et al. showed that acupuncture 
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might result in a more significant improvement for children with NE than sham inter-
vention. Moreover, acupuncture seemed to have a lower failure rate than combination 
therapy with meclofenoxate, oryzanol, and thiamine. Six years later, the updated 
Cochrane systematic review [50] demonstrated the same result. Another systematic 
review showed that acupuncture in conjunction with other treatment could reduce 
the number of NE more significantly than other treatment alone [51]. It needs to be 
mentioned that some methodological limitations have to be taken into consideration 
when we analyze the evidence. These systematic reviews included the nonrandom-
ized and quasi-randomized studies besides randomized controlled trials, which 
may weaken the level of evidence. To provide the high quality of evidence, a recent 
published systematic review excluded nonrandomized and quasi-randomized trials 
and showed that acupuncture might be more effective in management of NE than 
sham procedure or drug treatment [52]. However, some studies with the intervention 
of acupoint injection were included in the systematic review, which may make the 
results controversial. As is known, acupuncture only provides physical effect, while 
both physical and chemical effects are involved in acupoint injection.
To further provide evidence, we designed and conducted a systematic review. 
After performing a comprehensive search of medical literature, including Cochrane 
Central Register of Controlled Trials, MEDLINE, EMBASE, CBM, ClinicalTrials.gov, 
and the World Health Organization International Clinical Trials Registry Platform, 
on February 22, 2019, a total of 238 randomized controlled trials were reviewed, and  
10 of them with 953 randomized participants (441 in acupuncture group and 412 in 
control group) were included. We found that compared with the other treatment, 
acupuncture resulted in significantly higher complete response rate [OR = 2.41, 
95%CI (1.41, 4.93) P = 0.002], so did the significance when compared with conven-
tional drug, sham procedure, and herbal therapy, respectively. Moreover, although 
acupuncture did not reduce the average number of NE in comparison with other 
treatment, a significant decrease was found when compared to the sham interven-
tion [MD = −1.49, 95%CI (−2.26, −0.72) P = 0.0002]. In terms of adverse events, 
there was no significant difference between acupuncture and other treatment 
[OR = 0.62, 95%CI (0.04, 8.72) P = 0.72]. Based on our results, acupuncture may 
have a better effect in management of NE, when compared to conventional drug, 
sham procedure, and herbal therapy, respectively.
The potential mechanism of acupuncture’s effectiveness in managing NE might 
be the regulation on bladder function and secretion of antidiuretic hormone. A 
study assessed the effect of acupuncture on urodynamic parameters in children 
with NE and found acupuncture could suppress the detrusor overactivity [53]. On 
the other hand, an animal experiment showed that acupuncture could downregu-
late the concentration of arginine vasopressin in the hypothalamic paraventricular 
nucleus and upregulate the concentration of arginine vasopressin in the hypotha-
lamic supraoptic nucleus, periaqueductal gray, caudate nucleus, and nucleus raphe 
magnus [54], which may cause an antidiuretic effect.
4.5.2 Herbal therapy
Herbal therapy is an important component of traditional medicine. About 
3500 years ago, Papyrus Ebers described that cypress, juniper berries, and 
beer might be used to treat NE, which is the earliest record for the treatment 
of NE. Although there is lack of enough evidence, some herbs, such as St John’s 
wort (Hypericum perforatum), infusions of horsetail, or corn silk (Zea mays), are 
considered to be helpful to regulate bladder function [55]. Hosein et al. performed 
a double-blind randomized controlled trial to evaluate the effectiveness of chamo-
mile oil in treating NE, in which 80 patients were allocated to receive chamomile 
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oil or placebo. After 2 weeks treatment, the patients’ mean wet night frequency in 
chamomile oil group decreased from 8.2 to 5.6 nights/2 weeks, while no signifi-
cant difference was found in placebo group [56]. We hope more clinical trials can 
provide more evidence for the efficacy of herbal therapy in future.
4.5.3 Massage and chiropractic
Both massage and chiropractic are a kind of manipulative therapy acting 
on the body with appropriate pressure. The former focuses on the relaxation 
of muscle, while the latter centers on the regulation of spinal articulations. 
They can be the therapeutic options for NE since their effectiveness has been 
reported. An early study attempted to treat five children with NE using mas-
sage which pressed the acupoint located in the creases between the first and the 
second and the third phalanx of the 5th finger. After an average of 20 sessions of 
therapy, two children achieved complete recovery, and one got partial recovery 
[57]. In another study, Yuksek et al. performed an efficacy comparison of mas-
sage with oxybutynin. After 6 months treatment, 83.3% of patients in massage 
group experienced a significant improvement, which is better than 58.3% in 
oxybutynin group [58].
In a case series study, 171 children with NE were treated by chiropractic. After 
2 weeks treatment, the median episodes of NE decreased from 7.0 per week at 
baseline to 5.6 per week and further dropped to 4.0 per week at the end of treat-
ment [59]. Another finding of the study is that the more severe symptoms children 
had, the less benefit they got from the treatment, which means those with mild to 
moderate NE might be suitable for chiropractic. Reed et al. designed and conducted 
a 10-week controlled clinical trial, in which children with NE received chiropractic 
or sham intervention. After the treatment, a significant reduction was observed in 
children’s mean wet night frequency (from 9.1 to 6.7 nights/2 weeks) in chiropractic 
group. By contrast, the counterpart in sham intervention group did not change 
markedly (12.1 vs 12.2 nights/2 weeks) [60]. Van Poecke and his colleague found 
that the resolution rate within 1 year in children who received chiropractic was 
about 66.6% after analyzing the data of 33 patient records [61].
5. New about diagnostic and treatment
Enuretic bladder capacity is a big issue discussed in some recent research. 
Researchers are more likely to use the reduction in maximum voiding volume 
(MVV) on bladder diary to determine the decreased nocturnal bladder capacity 
(NBC). However, it might be unreasonable because a study found the enuretic 
bladder capacity of enuresis children was significantly less than their daytime 
functional bladder capacity (FBC), while healthy children’s NBC was the same as 
FBC [62]. Kim et al.’s study also showed that the proportion of NE children with 
small NBC and small MVV was quite different. The accuracy using decreased 
MVV to identify small NBC is only medium to low [63]. Another study per-
formed by Borg et al. measured the difference in diaper weight between the early 
part and the later part of the night, as the enuretic bladder capacity, in MNE chil-
dren with normal MVV, and found that 82% of children had less bladder capacity 
than MVV during enuresis, even less than 65% of expected bladder capacity 
[64]. These studies indicate that although small MVV can be used to determine 
the reduction of FBC, it cannot assess accurately NBC or enuretic bladder capac-
ity. If pediatricians manage MNE children with normal MVV with desmopressin 
following the ICCS guidelines, these children may still experience nocturnal 
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enuresis due to a mismatch between bladder capacity and urine volume at night. 
Therefore, a new method for assessing NBC and enuretic bladder capacity needs 
to be explored.
Barroso et al. assessed the efficacy of a new device, which is the combina-
tion of alarm and electrical stimulation to the pelvic floor muscles, for NE. This 
device presented an advantage that helps children to achieve no wet beds dur-
ing the period of treatment. On the one hand, pelvic floor muscle contraction 
induced by electrical stimulus may cause an increased urethral closure pressure, 
which allows children to keep dry during nighttime. On the other hand, alarm 
would also be triggered by the humidity sensor, and children would be waked to 
void [65]. This device needs more trials to determine its effectiveness and safety. 
Additionally, there was an intelligent autonomous alarm using ultrasound and 
smartphone ML techniques raised in 2019. It could monitor the bladder and trig-
ger before the voiding desire. It also has the advantage to achieve totally dry bed 
during treatment [66].
6. Conclusions
Standard therapy should be applied to every child when he first visits the clinic. 
Then clinicians follow the diagnosis algorithm to distinguish MNE from NMNE and 
determine which subtype the child is. According to the ICCS’s guideline [10], MNE 
children with normal nocturnal urine volume (normal or reduced MVV) should 
choose the alarm therapy. It is believed as the most effective single-therapy with the 
lower recurrence rate and has efficacy for most types of MNE, even NMNE. The 
addition of overlearning can reduce the relapse rate of alarm. Therefore, it is neces-
sary to perform overlearning after the success of the alarm treatment. Complex 
behavioral therapies supplemented by alarm are more effective than alarm and can 
reduce the recurrence rate. It can be advised to families with better motivation and 
seeking for better efficacy. Desmopressin should be used for the treatment of MNE 
children with polyuria (normal or reduced MVV). To avoid relapse, the drug can be 
taken for a long time and then gradually reduced.
The guideline recommended small MVV and NP children to use combination 
therapy of alarm and desmopressin [10]. The addition of alarm can increase the 
long-term efficacy of desmopressin [37]. However, combination therapy seems 
not to reduce the number of children who do not achieve 14 consecutive dry nights 
compared with alarm alone [29], indicating that patients who do not have full 
response to these two therapies may be mostly overlapped.
For refractory NE, clinicians should reassess children’s potential physiological 
malformations and neurogenic bladder diseases using MRI, urodynamics, cystos-
copy, urography, etc. if necessary. After first-line treatment failure, children with 
detrusor overactivity or decreasing functional bladder capacity can choose anti-
cholinergic drugs. Other children can choose tricyclic drugs, biofeedback therapy, 
electrical stimulation interventions, acupuncture, massage and so on, or a combina-
tion of first-line therapy and second-line therapy.
In summary, after meticulous diagnosis and assessment and appropriate treat-
ment with sufficient evidence, most MNE children can get a great relief or even cure.
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oil or placebo. After 2 weeks treatment, the patients’ mean wet night frequency in 
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cant difference was found in placebo group [56]. We hope more clinical trials can 
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sage which pressed the acupoint located in the creases between the first and the 
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baseline to 5.6 per week and further dropped to 4.0 per week at the end of treat-
ment [59]. Another finding of the study is that the more severe symptoms children 
had, the less benefit they got from the treatment, which means those with mild to 
moderate NE might be suitable for chiropractic. Reed et al. designed and conducted 
a 10-week controlled clinical trial, in which children with NE received chiropractic 
or sham intervention. After the treatment, a significant reduction was observed in 
children’s mean wet night frequency (from 9.1 to 6.7 nights/2 weeks) in chiropractic 
group. By contrast, the counterpart in sham intervention group did not change 
markedly (12.1 vs 12.2 nights/2 weeks) [60]. Van Poecke and his colleague found 
that the resolution rate within 1 year in children who received chiropractic was 
about 66.6% after analyzing the data of 33 patient records [61].
5. New about diagnostic and treatment
Enuretic bladder capacity is a big issue discussed in some recent research. 
Researchers are more likely to use the reduction in maximum voiding volume 
(MVV) on bladder diary to determine the decreased nocturnal bladder capacity 
(NBC). However, it might be unreasonable because a study found the enuretic 
bladder capacity of enuresis children was significantly less than their daytime 
functional bladder capacity (FBC), while healthy children’s NBC was the same as 
FBC [62]. Kim et al.’s study also showed that the proportion of NE children with 
small NBC and small MVV was quite different. The accuracy using decreased 
MVV to identify small NBC is only medium to low [63]. Another study per-
formed by Borg et al. measured the difference in diaper weight between the early 
part and the later part of the night, as the enuretic bladder capacity, in MNE chil-
dren with normal MVV, and found that 82% of children had less bladder capacity 
than MVV during enuresis, even less than 65% of expected bladder capacity 
[64]. These studies indicate that although small MVV can be used to determine 
the reduction of FBC, it cannot assess accurately NBC or enuretic bladder capac-
ity. If pediatricians manage MNE children with normal MVV with desmopressin 
following the ICCS guidelines, these children may still experience nocturnal 
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enuresis due to a mismatch between bladder capacity and urine volume at night. 
Therefore, a new method for assessing NBC and enuretic bladder capacity needs 
to be explored.
Barroso et al. assessed the efficacy of a new device, which is the combina-
tion of alarm and electrical stimulation to the pelvic floor muscles, for NE. This 
device presented an advantage that helps children to achieve no wet beds dur-
ing the period of treatment. On the one hand, pelvic floor muscle contraction 
induced by electrical stimulus may cause an increased urethral closure pressure, 
which allows children to keep dry during nighttime. On the other hand, alarm 
would also be triggered by the humidity sensor, and children would be waked to 
void [65]. This device needs more trials to determine its effectiveness and safety. 
Additionally, there was an intelligent autonomous alarm using ultrasound and 
smartphone ML techniques raised in 2019. It could monitor the bladder and trig-
ger before the voiding desire. It also has the advantage to achieve totally dry bed 
during treatment [66].
6. Conclusions
Standard therapy should be applied to every child when he first visits the clinic. 
Then clinicians follow the diagnosis algorithm to distinguish MNE from NMNE and 
determine which subtype the child is. According to the ICCS’s guideline [10], MNE 
children with normal nocturnal urine volume (normal or reduced MVV) should 
choose the alarm therapy. It is believed as the most effective single-therapy with the 
lower recurrence rate and has efficacy for most types of MNE, even NMNE. The 
addition of overlearning can reduce the relapse rate of alarm. Therefore, it is neces-
sary to perform overlearning after the success of the alarm treatment. Complex 
behavioral therapies supplemented by alarm are more effective than alarm and can 
reduce the recurrence rate. It can be advised to families with better motivation and 
seeking for better efficacy. Desmopressin should be used for the treatment of MNE 
children with polyuria (normal or reduced MVV). To avoid relapse, the drug can be 
taken for a long time and then gradually reduced.
The guideline recommended small MVV and NP children to use combination 
therapy of alarm and desmopressin [10]. The addition of alarm can increase the 
long-term efficacy of desmopressin [37]. However, combination therapy seems 
not to reduce the number of children who do not achieve 14 consecutive dry nights 
compared with alarm alone [29], indicating that patients who do not have full 
response to these two therapies may be mostly overlapped.
For refractory NE, clinicians should reassess children’s potential physiological 
malformations and neurogenic bladder diseases using MRI, urodynamics, cystos-
copy, urography, etc. if necessary. After first-line treatment failure, children with 
detrusor overactivity or decreasing functional bladder capacity can choose anti-
cholinergic drugs. Other children can choose tricyclic drugs, biofeedback therapy, 
electrical stimulation interventions, acupuncture, massage and so on, or a combina-
tion of first-line therapy and second-line therapy.
In summary, after meticulous diagnosis and assessment and appropriate treat-
ment with sufficient evidence, most MNE children can get a great relief or even cure.
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and Innovations in Penile 
Urethroplasty
Francisco E. Martins, Pedro Simoes de Oliveira  
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Abstract
Penile urethral strictures are common and impact on quality of life and health-
care costs. Management of penile urethral strictures is complex and depends on 
the physical characteristics of the stricture. Contemporary studies show no dif-
ference between urethral dilation and internal urethrotomy in terms of long-term 
outcomes. Overall, long-term success rates range from 20 to 30%. However, their 
recurrence rate is greater for men with longer strictures, penile urethral strictures, 
multiple strictures, presence of infection, or history of prior procedures, which 
make them less cost-effective. Surgical urethroplasty is associated with higher 
long-term success rates, averaging from 85 to 90%, mostly in virgin or noncomplex 
cases. Historically, modern urethral reconstruction has evolved from 1950s with the 
revolutionary introduction of Johanson’s technique for staged urethral reconstruc-
tion. Since then, many techniques have been developed and employed for urethro-
plasty, depending on the location, length, and character of the stricture. Successful 
management of urethral strictures requires detailed knowledge of anatomy, patho-
physiology, proper patient selection, and reconstructive techniques.
Keywords: anterior urethra, urethral stricture, urethroplasty, penile
1. Introduction
Urethral strictures have been common since ancient times. Knowledge was 
gathered about the treatment of urethral stricture disease by ancient Egyptians and 
other civilizations more than two millennia ago. Nonetheless, little has changed 
until about 60 years ago. Since then, the management of urethral strictures, 
including the penile urethral segment, has been in continuous and rapid evolution. 
Although various reconstructive techniques are available for the treatment of penile 
urethral stricture, no single technique has been identified as the method of choice. 
An understanding of the penile urethral anatomy is important for the diagnosis and 
treatment of penile urethral stricture disease.
Urethral strictures, in general, are associated with significant impact on 
patients’ quality of life. Penile urethral strictures, in particular, due to their exposed 
anatomic location and their surgical treatment, may cause significant impact on 
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1. Introduction
Urethral strictures have been common since ancient times. Knowledge was 
gathered about the treatment of urethral stricture disease by ancient Egyptians and 
other civilizations more than two millennia ago. Nonetheless, little has changed 
until about 60 years ago. Since then, the management of urethral strictures, 
including the penile urethral segment, has been in continuous and rapid evolution. 
Although various reconstructive techniques are available for the treatment of penile 
urethral stricture, no single technique has been identified as the method of choice. 
An understanding of the penile urethral anatomy is important for the diagnosis and 
treatment of penile urethral stricture disease.
Urethral strictures, in general, are associated with significant impact on 
patients’ quality of life. Penile urethral strictures, in particular, due to their exposed 
anatomic location and their surgical treatment, may cause significant impact on 
patients’ sexual function and perception of (un)satisfactory penile cosmesis.
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The anatomical and physical characteristics of the penile urethra are associated 
with additional challenges when compared to other urethral locations, especially 
due to its unsuitability for anastomotic repair and its relatively thinner corpus 
spongiosum. The choice of penile urethroplasty technique is largely influenced 
by etiology, location, length of the stricture, as well as prior surgical treatments. 
There are a number of challenges and controversies in the surgical reconstruction 
of penile urethral strictures, such as the use of grafts vs. flaps, use of skin vs. oral 
mucosa graft (OMG) tissue for augmentation or substitution techniques, the most 
appropriate indications for a single or a staged (at times, multiple) reconstruction, 
and, lastly, the management of particularly complex cases such as panurethral 
stricture disease and hypospadias “cripples” to achieve the best possible outcome.
Although penile urethral strictures can be managed by any of the above-
mentioned procedures individually, they can also be more adequately treated by a 
combined approach. Among the various procedures available for treating urethral 
stricture, one-stage buccal mucosal graft urethroplasty is the current standard prac-
tice. The selection of technique for penile urethroplasty for an individual patient 
largely depends not only on the expertise of the surgeon but also upon the stricture’s 
etiology, pathological characteristics, and location. Therefore, contemporary recon-
structive urologists working in this field should be aware of, and permanently keep 
themselves updated on, the numerous surgical techniques required to deal with any 
condition of the urethra that might surface at the time of surgery.
This review provides a brief update of the options for the surgical reconstruction 
of different types and sites of penile urethral stricture as well as discussing current 
controversies, innovations, and possible future research in urethral reconstruction 
of the penile urethra.
2. Anatomical considerations
Classically, the anterior urethra is divided, at the level of the penoscrotal junc-
tion inferiorly and the suspensory ligament superiorly, into bulbar and penile 
segments, the penile part consisting of the external meatus, fossa navicularis, and 
the penile shaft urethra. The penile urethra extends from the distal margin of the 
bulbospongiosus (or penoscrotal junction) to the external meatus. The bulbar 
(proximal) segment is the shorter of the two and is located in the midline between 
both the penile crural and the cavernosal bodies. The penile urethra (distal segment 
of the anterior urethra), also called pendulous, lies in a dorsal groove between the 
two corpora cavernosa and extends from the penoscrotal junction to the tip of the 
glans penis. It is surrounded in its full length by the corpus spongiosum; it is mobile 
and stretches during penile erection; and its length varies according to the penile 
length. The caliber of the anterior urethral lumen is relatively uniform, widening 
distally to form the fossa navicularis, and narrowing again to end at the external 
meatus (Figure 1).
Histologically, the penile (distal anterior) urethra is surrounded by five tissue 
layers: urethral epithelium and lamina propria (urethral mucosa), corpus spon-
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75
Historical Perspective and Innovations in Penile Urethroplasty
DOI: http://dx.doi.org/10.5772/intechopen.85908
The anterior urethra obtains its blood supply from the first of three penile 
branches of the internal pudendal artery, which in turn is a branch of the internal 
iliac artery. The internal pudendal artery travels through the Alcock canal and gives 
the inferior rectal artery, posterior scrotal artery and perineal artery, and then ter-
minates as the common penile artery. Three branches arise from the common penile 
artery: the paired urethral or, most commonly, bulbourethral arteries that pierce the 
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that travel between the crura and beneath the pubic bone to run under the Buck’s 
fascia sending multiple circumflex branches to the corpus spongiosum and terminal 
branches to the glans penis, thus providing in a retrograde fashion a dual blood 
supply to the corpus spongiosum and urethra. It also sends cavernosal branches to 
contribute to the hemodynamics of the erection (Figure 2A and B). The venous 
Figure 1. 
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The anatomical and physical characteristics of the penile urethra are associated 
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drainage is through the emissary veins into the circumflex branches of the deep 
dorsal penile vein as well as through the urethral and bulbar veins into the internal 
pudendal vein. The anterior urethra is innervated by the urethrobulbar nerve, a 
branch of the perineal nerve derived from the pudendal nerve. The bulbocaver-
nosus nerve, which is a branch of the pudendal nerve, gives off two branches that 
penetrate the rhabdosphincter at the three and nine o’clock positions. The pudendal 
nerve, gathering fibers from the second, third and fourth sacral spinal nerve, is both 
motor to the urethral rhabdosphincter and sensory to the urethra and glans penis 
(Figure 3). The lymphatic drainage of the anterior urethra is via the superficial and 
deep inguinal nodes, whereas the lymphatic drainage of the more proximal (the 
bulbar, membranous, and prostatic) urethra can take three routes: to the external 
iliac nodes, to the obturator and internal iliac nodes, or to the presacral nodes [2].
Understanding the penile anatomy and, in particular, the penile skin arterial 
blood supply is an important resource for penile urethral surgical reconstruction. 
The penis is covered with an elastic layer of skin that has no subcuticular adipose 
tissue: the dartos fascia, a layer of loose areolar subcutaneous connective tissue in 
the penis and scrotum. It lies immediately beneath the penile skin, allowing the skin 
to move freely over the shaft of the penis and is contiguous with Colles fascia in the 
perineum. The dartos, also with no adipose tissue, slides freely over the underlying 
Buck’s fascia and is an extension of Scarpa’s fascia of the abdominal wall, carrying 
superficial nerves, lymphatics, and blood vessels, which make this fascia extremely 
useful in bringing blood supply and preventing fistulation in urethral reconstruc-
tion. Beneath the dartos fascia lies the Buck’s fascia, which surrounds the tunica 
albuginea of the two corpora cavernosa and the corpus spongiosum.
The development of fasciocutaneous penile skin island flaps, either as a vertical 
flap (as in Orandi flap) or as a circular transverse flap (as in McAninch/Quartey flap), 
takes advantage of the natural anatomical, relatively avascular cleavage planes between 
the skin and the dartos fascia and another between the dartos fascia and Buck’s fascia.
The blood supply to the penile skin and anterior scrotal wall comes from the 
external pudendal arteries, whereas the inferior and posterior aspect of the scrotum 
Figure 3. 
Schematic illustration of autonomic and somatic innervation of the penis and urethra (reproduced with 
permission from Dr. Enzo Palminteri).
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derives its blood supply from the posterior scrotal arteries, which are branches of 
the perineal artery, which in turn is a further branch of the internal pudendal artery 
(Figure 4). The superficial/superior branches of the external pudendal artery travel 
from medially and across the femoral triangle and within Scarpa’s fascia to enter the 
base of the penis. After giving off anterior scrotal branches, they arborize to form 
an arterial network within the dartos fascia. Also, at the base of the penis, branches 
from the axial penile artery form a subdermal plexus to supply the distal penile skin 
and prepuce. Because the communicating vessels between the subcutaneous and sub-
dermal arterial plexuses are minimal, a relatively avascular plane can be developed 
between the dartos and Buck’s fascia. This fascial plexus, that is considered axial, 
is the true blood supply to the penile island skin flaps used in urethroplasty and, 
therefore, they can be mobilized widely and transposed aggressively and reliably.
The venous drainage of the penis includes the superficial dorsal vein, the deep 
dorsal vein, and the crural veins. The superficial dorsal vein drains the skin of 
the penis and empties into the superficial external pudendal vein and then into 
the saphenous vein. The deep dorsal vein begins at the base of the glans and retro 
coronal area and then travels deep to the Buck’s fascia between the paired deep 
dorsal arteries. Along its course, it receives circumflex veins from the spongiosum 
until it passes under the pubic bone to join the periprostatic venous complex. The 
cavernosal veins drain into a subtunical venous plexus; then through emissary 
veins, they join the circumflex veins, which in turn empty into the crural vein and 
the periprostatic plexus or the internal pudendal veins. The lymphatic drainage of 
the penis is primarily to the superficial inguinal nodes.
A detailed understanding of the anatomy of the anterior urethra is a critical 
prerequisite for the accurate diagnosis and successful management of urethral 
strictures.
Figure 4. 
Schematic illustration of the superficial arterial supply and venous drainage of the penis and scrotum.
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3. Etiology
The etiology of contemporary urethral stricture disease involves a traumatic, 
iatrogenic, inflammatory, and idiopathic origin [3, 4]. Pathophysiology differs 
with age. The major causes of anterior urethral stricture in children are more 
likely to be trauma, mainly straddle injury, and complications from hypospadias 
surgery. Congenital and idiopathic strictures may also occur in children. In 
adult patients, most urethral strictures have an iatrogenic origin, mainly trau-
matic catheterization or transurethral manipulation or instrumentation. In the 
<10-year-old age group, strictures are mainly localized in the penile urethra, 
whereas in the >10-year-old age group, the bulbar urethra is the most common 
location [5].
In the past, inflammatory urethral strictures were predominantly associated 
with gonococcal urethritis, which has been effectively eradicated with penicillin-
based antimicrobial agents. However, the emergence of resistant strains of 
Neisseria gonorrhoeae may be responsible for resurgence in these cases. Lichen scle-
rosus (LS, also and erroneously known as balanitis xerotica obliterans) is another 
inflammatory and challenging cause of urethral stricture disease, which usually 
involves genital skin, often progressing to panurethral stricture disease, and is 
associated with comorbidities, such as diabetes and obesity, which may aggravate 
surgical treatment [6, 7].
Stricture etiology is of particular significance in the penile urethra, as they tend 
to be more diffuse in nature (averaging 6.1 cm), especially if associated with LS, 
and shorter in the bulbar urethra (averaging 3.1 cm). Urethral strictures can be 
classified by their most common urethral location. Strictures involving the external 
meatus and fossa navicularis are predominantly inflammatory and iatrogenic in 
origin in 33–47% [3]. In the series reported by Fenton et al., globally, the etiology of 
anterior urethral strictures was idiopathic in 34%, iatrogenic in 32%, inflammatory 
in 20%, and traumatic in 14% [3].
Iatrogenic strictures are typically associated with instrumentation, such as trans-
urethral resection, prolonged catheterization, and cystoscopy, totaling 90% of all 
penile strictures. Prior hypospadias repair and radical prostatectomy contributed to 
6.3 and 3.2%, respectively [3, 8]. Such strictures are mainly the result of an ischemic 
injury secondary to traumatic urethral manipulation or instrumentation, particularly 
when a large bore catheter or resectoscope is used. Therefore, whenever relatively 
prolonged catheterization is necessary, smaller caliber/Fr catheters are recom-
mended. For more extended periods of time, a suprapubic catheter is a better option.
Malignant strictures should be approached in a different clinical context and 
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4. Diagnostic evaluation
Clinical evaluation: the diagnosis of penile urethral strictures, like any other 
type of stricture, regardless of location, is based on a suggestive clinical history 
and physical examination. The main symptoms are related to obstructive void-
ing or urinary tract infection, or both. Some patients may less often present with 
urinary retention. Weak stream, incomplete bladder emptying, and a hyperactive 
bladder are usually the most prevalent complaints of patients with anterior urethral 
stricture [9]. If questioned carefully, most patients who present in chronic reten-
tion may state that their symptoms have been present for a long time, which they 
have tolerated fairly well and, therefore, have been neglected. In some occasions, 
the diagnosis is brought up to the urologist’s attention because of difficult urethral 
catheterization for any reason, often in the operating theater before an operation 
that requires routine urethral catheterization. In about 1.3%, renal failure is the 
initial presentation of a urethral stricture [9].
Any relevant past history of urethral instrumentation, hypospadias surgery, and 
genital trauma should be obtained. Obstructive voiding symptoms should be assessed 
with a validated questionnaire. Presence of risk factors and comorbidities that may 
provoke ischemia or impair wound healing should be probed for. These include 
obesity, diabetes mellitus, severe peripheral vascular disease, cigarette smoking, 
long-distance bicycle riding, horseback riding, and sexually transmitted infections.
Physical examination should include palpation of the penile shaft for nodules or 
dense urethral scarring or constriction. The urethral meatus should be examined 
for narrowing and the surrounding glans for signs of LS. The penis should be 
examined to assess whether the patient has been circumcised, or there is sufficient 
shaft skin to allow development of a penile skin flap. The bladder should be assessed 
for potential detrusor hypocontractility, distention, and presence of an abdominal 
scar from a previous suprapubic cystostomy.
Uroflowmetry: this test provides a quantitative estimate of the severity of 
obstruction. A flattened, “en plateau” voiding pattern along with elevated postvoid 
residual urine volume signals the degree of urethral narrowing and efficiency 
of voiding and bladder emptying (Figure 5). More formal urodynamic studies 
(pressure-flow studies) are rarely indicated or necessary, except for complex cases 
or when the anatomic location of obstruction is needed in presence of concomitant 
prostatic obstruction.
Radiographic contrast studies: contrast studies of the urethra are the cornerstone 
of the imaging diagnosis. The combination of dynamic retrograde urethrogram and 
voiding cystourethrogram allows accurate assessment of stricture length and loca-
tion (Figure 6). Dynamic retrograde urethrogram has been rated the gold standard 
of urethral stricture evaluation with a specificity and sensitivity of 90% [10].
Ultrasonography/sonourethrography: ultrasonography has a limited role in the 
evaluation of the male urethra. It may be useful to detect concomitant lesions such 
as calculus, trauma-induced soft tissue injury, or Peyronie’s plaques that may coexist 
with urethral stricture disease. Sonourethrography, introduced in the mid-1980s, 
was reported to be a more accurate tool for the diagnosis and characterization of 
strictures, particularly in the bulbar urethra [11]. In addition to providing accurate 
information of the urethral stricture characteristics, sonourethrography allows 
assessment of the health and integrity of the soft tissues surrounding the strictured 
urethra. This modality represents an adjunct to contrast-enhanced studies and can 
increase the accuracy of anterior stricture length and spongiofibrosis as well as the 
inner diameter of the urethral lumen and, thus, improve surgical planning [12].
Endoscopy: endoscopic evaluation of a urethral stricture has a limited role as it allows 
only the identification of the most distal portion of the urethra. It does not determine 
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the length of the stricture nor can it assess the proximal stricture extremity and the 
corresponding proximal urethra. However, it may help to determine the amount of 
distal urethral elasticity, or when the insertion of a guide-wire through the stricture is 
necessary or deemed safe, or in a rare case of suspicion of urethral carcinoma.
Figure 6. 
Retrograde urethrogram of long, irregular, “saw-toothed” penile urethral stricture typical of lichen sclerosus.
Figure 5. 
“En plateau” obstructive uroflow in a patient with anterior urethral stricture.
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5. Preoperative planning and intraoperative decision-making
Any appropriate treatment plan needs accurate identification of the stricture 
characteristics: location, length, depth, and thickness of fibrotic tissue (spongio-
fibrosis). It is critical that both the proximal and distal ends of a urethral stricture 
are completely and accurately assessed with endoscopy and bougienage during 
reconstruction as to not miss any diseased segment of the urethra. Both patient and 
urethral reconstructive surgeons must understand completely the goal(s) of treat-
ment before a decision is made. The decision to choose urethroplasty over another 
approach to a specific urethral stricture depends on patient expectations, goals, and 
comorbidities. In elderly or frail patients, an expectant or conservative manage-
ment is more likely to be offered. Therefore, treatment options and their individual 
potential outcomes in terms of cure, or simply palliation, and complications should 
be carefully discussed with the patients and their family. On the other hand, ure-
thral reconstructive surgeons need to keep themselves updated and abreast regard-
ing the vast array of treatment options and their precise and specific indications 
and, therefore, should be flexible enough to intraoperatively adapt and/or adopt a 
different strategy for a specific scenario, which was not anticipated preoperatively. 
Thus, it is only legitimate and ethical to embark on urethral reconstruction if one 
can master and offer the patient all necessary surgical options to treat his specific 
urethral problem. It is very important to bear in mind that the penile urethra is the 
most exposed segment of the male urethra, and any surgical procedure or technique 
should achieve not only a satisfactory functional outcome but also a cosmetic one.
6. Management options
The key techniques include mainly urethral dilatation, endoscopic urethrotomy, 
anastomotic repairs (rarely in the penile urethra), substitution repairs (ventral, dorsal, 
double-faced), free grafts of skin (full thickness and split thickness skin), oral 
mucosa, lingual mucosa, bladder mucosa, retroauricular skin (Wolf ’s graft), and 
skin flap repairs (circumferential, longitudinal and variants) from penile and (less 
commonly) scrotal skin, as well as the use of adjunctive maneuvers such as the use 
of advancement flaps for additional blood supply or defect coverage (Table 1).
Urethral dilatation: several methods for urethral dilatation exist: dilatation 
with a balloon, filiform and followers, urethral sounds (metallic or nonmetallic), 
or self-catheter dilatation. Urethral dilatation is carried out by gradual progres-
sive stretching of the urethral lumen to a maximal diameter of 24 Fr. However, 
if performed aggressively, it will lead to further urethral trauma and scarring. It 
should be regarded as a palliative procedure and rarely as a curative one. It is mainly 
indicated in very select cases of strictures of the external meatus and fossa navicu-
laris. It should be avoided in patients with LS as it often worsens the inflammatory 
process. Repeat dilatation should be avoided as it does not treat the underlying 
dense spongiofibrosis associated with more complex strictures.
Internal urethrotomy: also called direct vision internal urethrotomy (DVIU), it 
was first described by Sachse [13]. It consists of a cold-knife incision of the scar tissue 
allowing its release and healing of the underlying tissue by secondary epithelialization 
around a urethral catheter and thereby increasing the diameter of the urethral lumen. 
Apparently, only superficial strictures benefit from this treatment option when the 
incision is carried out through all thickness of the scar. Its success depends mostly on 
stricture length and degree of spongiofibrosis [14, 15]. It is best indicated for short 
strictures (<1.5 cm in length). Heyns et al. have suggested that if the stricture has not 
recurred within the first 3 months after a single DVIU (or dilatation), the stricture-free 
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recurred within the first 3 months after a single DVIU (or dilatation), the stricture-free 
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rate is 50–60% for up to 4 years of follow-up evaluation [16]. Recurrence rates vary in 
the penile and bulbar urethra: 84 and 58%, respectively [17]. Like dilatation, repeat 
urethrotomy is known to be associated with worse outcomes [15–18]. The failure rates 
of these minimally invasive strategies are poor and well documented, ranging from 
9% after 1–3 years of follow-up [18]. At ≥4 years, the chance of stricture-free status is 
nearly 0% [19]. Open urethral reconstruction should be considered in case of recur-
rence after these minimally invasive attempts, unless the patient prefers intermittent 
self-catheterization as a chronic treatment plan. Nonetheless, despite the limitation of 
these minimally invasive procedures, they may become more useful if new generations 
of currently experimental modalities for scar modulation prove successful [20].
Laser urethrotomy: it utilizes several types of lasers, including CO2, argon, 
potassium titanyl phosphate (KTP), neodymium-doped yttrium aluminum garnet 
(Nd:YAG), holmium, and excimer lasers. They use different technologies and dif-
ferent depths of tissue penetration.
A meta-analysis of outcomes and complications of laser versus cold-knife ure-
throtomy compared unfavorably regarding laser: 12 versus 6.5%, respectively [21]. 
Laser urethrotomy may look appealing for the anterior urethra but with no definitive 
benefit over cold-knife urethrotomy.
Grafts: excision and primary reanastomosis, onlay grafting, and the use of flaps 
have been used for anterior urethral reconstruction. However, anastomotic ure-
throplasty rarely has a place in the penile shaft urethra due to the high risk of penile 
chordee or curvature, which impacts on erectile function and cosmesis. In the penile 
urethra, graft urethroplasty is traditionally used as it does not cause urethral ten-
sion. Several types of tissue can be used as onlay/inlay grafts: skin (full-thickness or 
split-thickness grafts), bladder mucosa, oral mucosa (buccal, labial, or lingual), and 
rectal mucosa. Historically, preputial skin grafts were the mainstay of grafting mate-
rial until oral mucosa became popularized in the early 1990s [22, 23]. The crucial 
factor for grafting success is that the local tissue must have a healthy blood supply for 
normal graft taking. Single-stage graft urethroplasty uses the rich blood supply of 
spongiosal tissue ventrally or dorsally to support the graft, with overall success rates 
approaching 75–90% in the penile urethra, depending on stricture length [24, 25]. 
Little is found in the literature regarding both bladder epithelial grafts and rectal 
mucosal grafts, mainly due to lack of data about the process of take of these grafts.
Oral mucosal graft is currently the graft of choice, owing to their short harvest 
time, easy harvest technique, and the physical characteristics including resistance, 
durability, immunogenic properties, excellent vascularity, hairlessness, low oral 
morbidity, concealed donor site and high success rates [24, 25]. For these reasons, 
over the past 20 years, oral mucosal grafts have shown better handling character-
istics and long-term stricture-free outcomes, and have replaced both penile skin 
grafts and flaps. However, patients with long and complex urethral abnormalities 
or with contraindications to oral mucosal graft use, such as those with leukoplakia, 
systemic skin disease of the oral cavity or history of chronic tobacco chewing may 
still necessitate split or full thickness skin grafts.
One controversy in anterior urethral grafting is related to dorsal or ventral place-
ment of the graft on the urethra. Some urethral surgeons favor dorsal placement 
in both bulbar and urethral strictures, whereas others opt for ventral placement 
[26–31]. Although several studies have demonstrated comparable success rates for 
dorsal and ventral onlay grafting, the author of this chapter favors the use of dorsal 
placement of the graft in the penile urethra because the spongiosal vascularity in 
the ventral urethra is thinner and the graft support is less reliable when compared to 
the dorsal urethral surface.
Flaps: detailed knowledge of the blood supply to the penile skin and corpus spon-
giosum is mandatory for successful tissue harvest and transfer (see Section 2). Rather 
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than rely on the recipient site for survival, flaps depend on their native blood supply 
containing pedicle for transfer. Flaps can be classified by their blood supply, harvest 
technique or their method of transfer. Several types of flaps have been used in urethral 
reconstruction: penile skin, hairless scrotal skin, gracilis muscle, and the forearm or 
upper arm as free flaps or (microvascular free-transfer flaps). Popularized in the past, 
scrotal skin flaps are random rotational flaps that can be used for urethral and genital 
reconstruction [32–36]. However, their use for urethral reconstruction was associated 
with unacceptable long-term complications. They were predominantly used for repair 
of complex bulbar urethral strictures as these flaps were difficult to reach the penile 
urethra because of their short pedicle. They are practically abandoned.
Various penile skin flaps have been described, which can be raised ventrally or dor-
sally on the penile shaft and taken longitudinally or circumferentially [37–39]. These 
flaps are fasciocutaneous in nature and are based on dartos fascia pedicle. The ventral, 
longitudinal flap, as described by Orandi, is best suited for penile shaft urethral stric-
tures that do not reach the base of the penis or any part proximal to the penoscrotal 
angle because hair-bearing skin will inevitably be involved in the reconstruction. On 
the contrary, the transverse, circumferential preputial/distal penile skin flaps are long 
enough to bridge defects of the entire penile urethra and most of the bulbar urethra 
for example in panurethral defects. Ideally, flaps should be hairless, adapted to a 
moist environment, with a reliable vascular pedicle, mobile, and cosmetic. In general, 
anterior urethral reconstruction with the use of flaps has become less prevalent due to 
the increased popularity of oral mucosa grafts. A rise in prevalence of genital and ure-
thral LS has also contributed to the near abdication of the use of flaps. Nonetheless, 
island skin flaps still find an important indication in reoperative cases with extensive 
spongiofibrosis and ischemic urethral mucosal plates where chances of graft take are 
minimal. These circumstances occur after irradiation, severe trauma, or infection.
One-stage vs. two (multiple)-stage reconstruction: in the past, most penile 
urethral strictures were repaired through a staged approach [40–43]. However, 
because of advancements with pediatric hypospadias surgery, adult noncomplicated 
penile urethral strictures are now more commonly repaired with single-stage proce-
dures. In 1995, Bracka described a two-stage urethral reconstruction, which enables 
a versatile approach to surgical reconstruction of previously failed, complex penile 
urethral strictures, especially hypospadias cripples [42]. The Johanson marsupial-
ization was developed and subsequently reserved for penile urethral strictures [43].
Repairs in adults who failed hypospadias repair in childhood pose a particular 
reconstructive challenge because of dense scarring, tissue inelasticity, inflamma-
tion, impaired blood supply, and penile and urethral shortening from previous, 
often multiple, operations [44–47]. Penile urethroplasty should be performed in 
a single stage, whenever feasible, to avoid discomfort and disability to the patient 
from a multistage repair. Most strictures associated with trauma, infection, or 
instrumentation, where the penile skin, dartos fascia and spongiosum are not 
significantly damaged, can be approached through a single-stage procedure. On the 
other hand, presence of local infection or inflammation associated with a specific 
underlying disease process obliterated urethral segments with dense surrounding 
fibrosis, and a history of prior interventions, especially prior flap or hypospadias 
repairs, are contraindications for single-stage repairs and, therefore, should not be 
advised. The two-stage reconstruction involves surgical opening of the stricture, 
augmentation, or substitution (more commonly with use of oral mucosa graft-
ing) of the diseased urethral segment and creation of temporary urethrostomy 
for drainage (first stage), followed between 4 and 6 months later by neourethral 
tubularization (second stage). Therefore, it should be confined to situations where 
it is inappropriate to maintain the axial integrity of the urethral plate and a full 
circumference urethral reconstruction is mandatory.
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7. Urethral reconstruction by stricture location
In order to facilitate description and discussion of the various surgical proce-
dures used for adult penile urethral reconstruction, we will group them according to 
stricture location in the urethra: (1) external meatus and fossa navicularis and (2) 
penile shaft urethra. Furthermore, a separate section will be devoted to procedures 
used for previously failed repairs or reoperative procedures (Table 2).
7.1 External meatus and fossa navicularis
Strictures involving exclusively the external meatus may be treated with dilatation 
if the stricture is not obliterative or the scarred tissue is minimal, the urethral lumen 
is still patent and elastic. It is considered palliative and should be attempted only once. 
Strictures associated with LS rarely respond to conservative options, such as dilata-
tion, urethrotomy, and meatotomy.
Meatotomy/meatoplasty: either ventral or dorsal, meatotomy can be used for 
select meatal strictures. A ventral or dorsal midline incision is performed sharply, and 
the resultant mucosal edges are everted and reapproximated to the glans using 4–0 or 
5–0 absorbable sutures. The dorsal side should be avoided, which can bleed profusely 
by cutting into the highly vascularized spongiosal tissue of the glans. The ventral 
approach usually leaves the patient with a slight degree of hypospadias that is usually 
well tolerated. The goal is to create a patent 22–24 F urethral lumen, particularly in 
cases of LS. Adjuvant topical therapy may be helpful. Meatal strictures that need 
meatoplasty usually require concomitant reconstruction of the fossa navicularis.
In 2004, Malone described a technique to relieve stenosis of the external urinary 
meatus resulting from LS [48]. The procedure is rapid and easy to perform on an 
outpatient basis, providing good cosmesis and functional voiding without spray-
ing. The meatotomy is carried out dorsally avoiding a hypospadiac meatus. If the 
stricture extends into the fossa navicularis, oral mucosa graft reconstruction is 
performed. The final result is a slit-shaped with good caliber meatus at the tip of the 
glans. The procedure has been successfully reproduced by others [49].
Longitudinal skin flap techniques: initially reported in the early 1960s, it is 
based on the Y-V principle and used for short strictures of the meatus and fossa 
navicularis [50, 51]. Good outcomes can be achieved with these techniques, espe-
cially in patients with strictures resulting from instrumentation such as a large bore 
catheter or transurethral resection and those that are not associated with LS. The 
use of genital skin in LS patients has a high failure rate.
Several variants have been reported. Cohney in 1963 described a penile flap 
procedure based on a circumferential elevated random penile skin flap. The distal 
urethra is well open, but the patient is left with a less appealing cosmetic result 
and a retrusive meatus (Figure 7A and B). Blandy-Tresidder in 1967 developed a 
flap procedure based on dartos fascia vascularity. It also provides good functional 
outcomes, but only modest improvement of the cosmetic final appearance. The 
meatus is usually left at the coronal level (Figure 7C and D). The Brannen flap 
repair [52], a modification of Blandy’s procedure, was described in 1976 to try to 
create a better cosmetic appearance of the glans and distal penile segment [53]. 
However, some mechanical problems associated with the flap advancement make 
this procedure inefficient and, therefore, offer marginal improvement in terms of 
cosmesis (Figure 7E and F). Designed to create a cosmetically normal meatus and 
glans penis, De Sy in 1984 further modified the Blandy and Brannen techniques 
using an advancement midline skin island flap [54]. However, the proximal 
portion of the flap is de-epithelialized leaving a distal skin island on dartos fascia 
(Figure 7G and H). Again, the mechanics of the flap advancement is inefficient.
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A. Ext. meatus and fossa navicularis
• Meatotomy/meatoplasty
• Longitudinal skin flap techniques
 ○ Cohney [50]
 ○ Blandy-Tresidder [51]
 ○ Brannen [52]
 ○ De Sy [53]
• Transverse ventral/circumferential fasciocutaneous skin island flaps
 ○ Jordan [54]
 ○ McAninch [39]
• Graft techniques
 ○ Tubularized full-thickness skin graft (Devine, 1979)
 ○ Inner prepuce [41]
 ○ OMG [41]
• Combination of grafts and flaps [65]
• Endourethroplasty techniques
 ○ Nandé (1998)
 ○ Nikolavsky et al. [64]
• Staged techniques
 ○ Bracka [41]
 ○ Jordan (2009)
• Tubularized incised plate urethroplasty
 ○ Snodgrass [58]
B. Penile shaft urethra
• Flap reconstruction
 ○ Orandi flap [37]
 ○ Quartey flap [67]
 ○ Mcflinch flap (1993)
 ○ Turner-Warwick flap (1993)
• Graf reconstructions
 ○ Dorsal OMG onlay (Barbagli, 1996)
 ○ Dorsal OMG inlay by ventral urethrotomy [59]
 ○ Penile inversion and one-sided dorsolateral OMG graft tech [75]
• Staged reconstructions
 ○ Johanson’s techniques [40]
 ○ Mesh graft urethroplasty [77]
 ○ Staged OMG urethroplasty
• Tissue engineering/stem cell therapy
Table 2. 
Urethral reconstruction by stricture location.
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performed. The final result is a slit-shaped with good caliber meatus at the tip of the 
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and a retrusive meatus (Figure 7A and B). Blandy-Tresidder in 1967 developed a 
flap procedure based on dartos fascia vascularity. It also provides good functional 
outcomes, but only modest improvement of the cosmetic final appearance. The 
meatus is usually left at the coronal level (Figure 7C and D). The Brannen flap 
repair [52], a modification of Blandy’s procedure, was described in 1976 to try to 
create a better cosmetic appearance of the glans and distal penile segment [53]. 
However, some mechanical problems associated with the flap advancement make 
this procedure inefficient and, therefore, offer marginal improvement in terms of 
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glans penis, De Sy in 1984 further modified the Blandy and Brannen techniques 
using an advancement midline skin island flap [54]. However, the proximal 
portion of the flap is de-epithelialized leaving a distal skin island on dartos fascia 
(Figure 7G and H). Again, the mechanics of the flap advancement is inefficient.
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A. Ext. meatus and fossa navicularis
• Meatotomy/meatoplasty
• Longitudinal skin flap techniques
 ○ Cohney [50]
 ○ Blandy-Tresidder [51]
 ○ Brannen [52]
 ○ De Sy [53]
• Transverse ventral/circumferential fasciocutaneous skin island flaps
 ○ Jordan [54]
 ○ McAninch [39]
• Graft techniques
 ○ Tubularized full-thickness skin graft (Devine, 1979)
 ○ Inner prepuce [41]
 ○ OMG [41]
• Combination of grafts and flaps [65]
• Endourethroplasty techniques
 ○ Nandé (1998)
 ○ Nikolavsky et al. [64]
• Staged techniques
 ○ Bracka [41]
 ○ Jordan (2009)
• Tubularized incised plate urethroplasty
 ○ Snodgrass [58]
B. Penile shaft urethra
• Flap reconstruction
 ○ Orandi flap [37]
 ○ Quartey flap [67]
 ○ Mcflinch flap (1993)
 ○ Turner-Warwick flap (1993)
• Graf reconstructions
 ○ Dorsal OMG onlay (Barbagli, 1996)
 ○ Dorsal OMG inlay by ventral urethrotomy [59]
 ○ Penile inversion and one-sided dorsolateral OMG graft tech [75]
• Staged reconstructions
 ○ Johanson’s techniques [40]
 ○ Mesh graft urethroplasty [77]
 ○ Staged OMG urethroplasty
• Tissue engineering/stem cell therapy
Table 2. 
Urethral reconstruction by stricture location.
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Transverse ventral fasciocutaneous skin island flap: as initially described by 
Jordan, this is a broad-based penile skin island flap oriented transversally on the ven-
tral penile skin and elevated on a dartos fascia pedicle [55]. Minimal flap advance-
ment is required, and the cosmetic appearance is virtually normal (Figure 8). 
McAninch modified this technique avoiding any disruption of the ventral glanular 
Figure 7. 
Schematic illustration of several techniques for surgical reconstruction of strictures of the urethral meatus and 
fossa navicularis. (A, B) Cohney’s meatoplasty: an eccentric, transversely oriented, subcoronal flap is developed, 
and the urethrotomy is extended to normal urethra. The transverse flap is rotated into the urethrotomy defect. 
(C, D) Blandy’s meatoplasty: creation of a midline flap. Urethrotomy is extended till normal urethral lumen. 
The flap is advanced into the urethrotomy defect. (E, F) Brannen’s meatoplasty: a longer midline dartos-based 
flap is developed and is then widely advanced. (G, H) De Sy’s meatoplasty: a midline flap similar to Brannen’ 
technique is mobilized. The proximal portion of the flap is de-epithelialized leaving a distal skin island 
attached to a dartos pedicle. The de-epithelialized surface of the flap is anastomosed, and the ventral glans is 
reapproximated over the reconstruction (from Jordan and McCammon [96]).
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integrity, which he assumed to provide a superior cosmetic result. This would be of 
paramount importance to the patient, overshadowing the functional success of the 
reconstruction. In his technique, the glans is exposed in either a glans-cap or a glans-
wings fashion (Figure 9) [56, 57].
Graft techniques: penile skin grafts were first employed and preferred tissue 
for urethroplasty before the advent of oral mucosa. Devine described a procedure 
using a tubularized full-thickness skin graft to reconstruct the external meatus 
and fossa navicularis [58]. Bracka reported in 2008 that the inner prepuce can 
be used for postischemic or infectious scarring as it is thin, flexible, with a reli-
able take, adapted to a moist environment and with no potential for hair growth 
(Figure 10) [43]. If not available, then postauricular skin graft is an acceptable 
alternative if oral mucosa cannot be harvested. However, due to its physical and 
biological characteristics, abundance, easy harvesting with minimal impact on the 
concealed donor site, and low oral morbidity, oral mucosa has become the most 
popular material for substitution or augmentation in urethral stricture repair. Oral 
mucosa can be used in strictures related to LS. It can be used in a single or staged 
procedure. Single-stage procedures are appropriate if the urethral plate is salvage-
able. In 1994, Snodgrass described a technique for the correction of pediatric 
hypospadias, which involved incision of the urethral plate followed by tubulariza-
tion and secondary healing of the incised plate [59]. Although it produces good 
results in children, this procedure has not been associated with similar results in 
adults, often requiring inlay OMGs to increase the urethral lumen diameter [60]. 
Endourethroplasty techniques emerged in the early 1980s [61]. A few variants 
were reported later [62, 63]. However, due to inherent technical difficulties and 
complications of surgical reconstruction of distal penile and fossa navicularis 
strictures, these procedures have not become popular. Recently, Nikolavsky et al. 
has introduced a novel surgical technique for the reconstruction of distal urethral 
strictures using OMG through a transurethral approach with encouraging initial 
results (Figures 11 and 12) [64]. They designed this novel and elegant surgical 
concept in order to avoid the complications, technical difficulties, and limitations 
of the previous procedures used in this urethral area. The surgical procedure 
is applicable to the entire distal penile urethra, avoids an external ventral skin 
incision, preserves the glans penis, and employs oral mucosa for grafting, thus 
Figure 8. 
Schematic illustration of Jordan’s ventral transverse skin island flap procedure. (A–C) After urethrotomy is made 
till normal urethra, a ventral skin island flap is elevated above Buck’s fascia, and the lateral glans wings are exposed. 
The skin island is rotated, transposed, and inverted into the urethrotomy defect. The glans wings are sutured ventrally. 
Inset shows details of the rotation, transposition, and inversion of the flap (from Jordan and McCammon [96]).
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integrity, which he assumed to provide a superior cosmetic result. This would be of 
paramount importance to the patient, overshadowing the functional success of the 
reconstruction. In his technique, the glans is exposed in either a glans-cap or a glans-
wings fashion (Figure 9) [56, 57].
Graft techniques: penile skin grafts were first employed and preferred tissue 
for urethroplasty before the advent of oral mucosa. Devine described a procedure 
using a tubularized full-thickness skin graft to reconstruct the external meatus 
and fossa navicularis [58]. Bracka reported in 2008 that the inner prepuce can 
be used for postischemic or infectious scarring as it is thin, flexible, with a reli-
able take, adapted to a moist environment and with no potential for hair growth 
(Figure 10) [43]. If not available, then postauricular skin graft is an acceptable 
alternative if oral mucosa cannot be harvested. However, due to its physical and 
biological characteristics, abundance, easy harvesting with minimal impact on the 
concealed donor site, and low oral morbidity, oral mucosa has become the most 
popular material for substitution or augmentation in urethral stricture repair. Oral 
mucosa can be used in strictures related to LS. It can be used in a single or staged 
procedure. Single-stage procedures are appropriate if the urethral plate is salvage-
able. In 1994, Snodgrass described a technique for the correction of pediatric 
hypospadias, which involved incision of the urethral plate followed by tubulariza-
tion and secondary healing of the incised plate [59]. Although it produces good 
results in children, this procedure has not been associated with similar results in 
adults, often requiring inlay OMGs to increase the urethral lumen diameter [60]. 
Endourethroplasty techniques emerged in the early 1980s [61]. A few variants 
were reported later [62, 63]. However, due to inherent technical difficulties and 
complications of surgical reconstruction of distal penile and fossa navicularis 
strictures, these procedures have not become popular. Recently, Nikolavsky et al. 
has introduced a novel surgical technique for the reconstruction of distal urethral 
strictures using OMG through a transurethral approach with encouraging initial 
results (Figures 11 and 12) [64]. They designed this novel and elegant surgical 
concept in order to avoid the complications, technical difficulties, and limitations 
of the previous procedures used in this urethral area. The surgical procedure 
is applicable to the entire distal penile urethra, avoids an external ventral skin 
incision, preserves the glans penis, and employs oral mucosa for grafting, thus 
Figure 8. 
Schematic illustration of Jordan’s ventral transverse skin island flap procedure. (A–C) After urethrotomy is made 
till normal urethra, a ventral skin island flap is elevated above Buck’s fascia, and the lateral glans wings are exposed. 
The skin island is rotated, transposed, and inverted into the urethrotomy defect. The glans wings are sutured ventrally. 
Inset shows details of the rotation, transposition, and inversion of the flap (from Jordan and McCammon [96]).
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achieving both excellent functional and cosmetic results. This procedure is espe-
cially indicated for patients affected by LS-related distal strictures, where only oral 
mucosal grafts are advised.
Combined flap and graft technique: in 2011, Gelman and Sohn described a proce-
dure combining a dorsal onlay graft with a ventral onlay flap for a subset of patient 
with ischemic, obliterated distal strictures who had already failed urethral repair, or 
who had a history of hypospadias [65]. This procedure is particularly useful in stric-
tures associated with compromised urethral plates due to ischemia and dense scarring 
from previous repairs and when a two-stage procedure is not desired (Figure 13).
Staged techniques: these techniques are best suited for patients who have failed 
hypospadias repairs or the urethral plate is deficient or densely scarred, or if there 
is involvement of LS. These techniques may be considered more versatile than flap 
repairs and are preferred in patients with LS. The modern staged urethral recon-
struction described by Bracka in 1995 is a versatile approach to difficult anterior 
urethral reconstructions [41–43]. In Bracka’s procedure, the diseased urethra is 
excised entirely and the urethral plate is replaced by an OM onlay graft (Figure 10). 
Jordan later described a similar technique [66].
Figure 9. 
Fasciocutaneous distal penile flap urethroplasty as described by McAninch. (A–H) Urethral exposure followed 
by ventral longitudinal urethrotomy. The fossa navicularis is exposed with either a glans-cap or a glans-wings 
technique. A fasciocutaneous distal, transverse, ventral penile flap is developed. The urethral stricture can be 
corrected by either a ventral onlay or a neourethral tube. The glans wings or cap is sutured to cover the flap 
reconstruction (from Armenakas and McAninch [97]).
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Figure 10. 
Two-stage distal urethra reconstruction as described by Bracka. (a–b) Marsupialization of the urethra and 
placement of the oral mucosal graft after excision of the diseased urethral mucosa at the first stage. Aspect of 





Transurethral ventral buccal mucosa graft inlay urethroplasty for reconstruction of fossa navicularis and 
distal urethral meatus as described by Nikolavsky. (a-e) Transurethral ventral shallow resection of scar tissue. 
Placement of double-armed suture through buccal graft and through apex of urethrotomy (inside out). External 
apical suture tying, meatal BMG edge fixation, and additional inside-out quilting of the graft with double-
armed sutures (reproduced with permission from Springer Science + Business Media Dordrecht, Ref. [62]).
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7.2 Penile shaft urethra
For penile shaft urethral strictures, a stricturotomy and onlay or inlay patch 
graft, or alternatively a flap reconstruction, can be used for simple strictures. More 
complex cases may eventually require total excision of the strictured area and 
circumferential reconstruction with OM grafts or penile skin flap. In more complex 
situations, such as after previous failed repairs and compromised or obliterated 
urethras, a staged reconstruction is preferable. Penile urethral strictures are rarely 
cured by dilatation or DVIU. If either of these procedures fail once, the chance of a 
better outcome with a second attempt is almost nil, making urethroplasty the only 
Figure 12. 
Intraoperative demonstration of the procedure described in Figure 11 (reproduced with permission from 
Springer Science + Business Media Dordrecht, Ref. [62]).
Figure 13. 
Schematic illustration of single-stage, combined flap graft technique as described by Gelman. (A–C) Oral 
mucosal graft is placed and quilted dorsally followed by closure of the urethrotomy defect by a penile skin flap 
(from Gelman and Sohn, Ref. [63]).
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curative option. Anastomotic urethroplasty should be avoided in the penile urethra, 
even in short strictures, as ventral curvature usually occurs.
Patient advanced age and comorbidities may steer the urologist away from open 
surgery. In these circumstances, periodic urethral (self)-dilatation or definitive 
urethrostomy should be strongly considered.
Flap reconstructions: penile skin island flaps may be elevated in a longitudinal 
or transverse, circumferential fashion, and variants.
Orandi flap: the Orandi flap is a longitudinal, ventral, fasciocutaneous island 
penile flap that is appropriate for single-stage reconstruction of strictures 
of the penile shaft urethra [37]. Inclusion of the distal bulbar urethra in the 
reconstruction may be hampered by hair-bearing skin of the more proximal part 
of the flap. Careful planning of the flap is critical before skin incision to avoid 
jeopardizing the flap design and its blood supply. The flap must be handled 
meticulously with the use of atraumatic surgical tools and eventually loupe mag-
nification. It then must be mobilized gently to preserve its arterial and venous 
blood supply. The type and size of suture material is paramount to minimize 
tissue reaction.
With the penis on stretch, a longitudinal nonhair-bearing skin island is marked 
on the ventral aspect of the penis. The description of the surgical technique is out-
lined in Figure 14. The penis is snugly dressed to avoid hematoma. Drains are rarely 
required. Patients are kept on strict bed rest for 3–5 days to minimize swelling. 
Intravenous antibiotics are administered for at least 48 h, followed by oral antibiotic 
prophylaxis for one additional week. Erections should be avoided. The use of a 
suprapubic catheter for urinary drainage is not mandatory but preferable, which 
should be kept for 2 weeks. The urethral catheter is left plugged to act as a stent 
only. After 2–3 weeks, the urethral catheter is removed and the patient is sent home 
with the suprapubic tube occluded, allowing the patient to resume urethral voiding. 
The suprapubic tube is removed after a few days of normal urethral voiding. If a 
Figure 14. 
Orandi flap procedure. (A–C) Deep skin incision is made over the strictured urethra. Dotted line indicates skin 
incision. Dartos pedicled flap is created lateral to the superficial skin incision, which will cover the urethrotomy 
defect. The skin is closed in the midline (from Elliott and McAninch [98]).
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Figure 15. 
Quartey flap procedure. (A, B) Hockey stick skin island flap is fashioned. The length of the flap may be 
tailored as needed. After ventral longitudinal urethrotomy, the flap is anastomosed similar to the Orandi 
technique.
fistula develops, the urethral catheter is not reinserted and the suprapubic diversion 
is maintained for another week. If still persistent, then it should be repaired after 
4–6 months.
The Orandi flap is a reliable and relatively easy flap to harvest. It is a useful solu-
tion for a single-stage reconstruction of penile urethral strictures.
Quartey flap: in 1983, Quartey described a one-stage flap urethroplasty tech-
nique using a transverse distal penile or preputial island of skin as a flap, which 
is supplied axially by the superficial external pudendal vessels for penile urethral 
strictures with possible extended application to the entire penile and bulbar urethra 
and even difficult posterior urethral strictures [67, 68]. He described the possibility 
of this island of skin being used either as a patch or as a tube. In very long strictures, 
the complete circumference of the distal penile skin can be extended ventrally and 
proximally toward the base of the penis in the hairless area. This flap design granted 
it the term “hockey stick island flap” (Figure 15).
McAninch flap: in 1993, McAninch reported the initial circular fasciocutaneous 
penile skin flap for the reconstruction of extensive anterior urethral strictures [39]. 
This flap is a variant of the flap described by Quartey 10 years earlier with the differ-
ence that this fasciocutaneous flap uses Buck’s fascia as a paddle to carry the vascular 
pedicle to the distal flap skin. It can provide a hairless flap up to 15 cm in length, mak-
ing this flap, like Quartey’s flap, extremely versatile. It can be used in uncircumcised 
as well as circumcised men. The width of the flap varies from 2.0 to 2.5 cm, depend-
ing on the stricture characteristics. With the penis on traction, the distal incision is 
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carried down deeply beneath the pedicle just beneath Buck’s fascia, but superficial to 
the dorsal neurovascular bundle (dorsally), circumflex vessels (laterally), and urethra 
(ventrally). The proximal incision extends proximally to the base of the penis through 
a dissection plane beneath the skin and subdermal or dartos fascia (Figure 16). The 
flap and pedicle can be divided either ventrally or dorsally and rotated to cover the 
urethral area as an onlay flap. This flap also allows reconstruction of complex stric-
tures of various lengths in a single stage even in circumcised patients. The cosmetic 
and functional results are excellent in experienced hands.
Turner-Warwick flap: described by Turner-Warwick, this is a bilateral, longitudi-
nal, ventral-based pedicle skin flap supported by right and left ventrolateral branches 
of the external pudendal artery. Although it may be employed in penile urethral 
stricture repair, this flap is most useful in bulbar urethral reconstruction [69].
Graft reconstructions: historically, grafts have been used for reconstruction 
of anterior urethral strictures since the early 1960s [70]. Several different types of 
graft material have been used with favorable results since then, but in the modern 
era, oral mucosa has become the graft of choice for its excellent graft characteristics 
and ease and low morbidity of harvest.
Dorsal OMG onlay technique (Barbagli): ventral onlay grafts are usually discour-
aged on the corpus spongiosum if the penile urethra is thin, not allowing spongio-
plasty maneuvers to support the graft and optimize graft take. Therefore, a dorsal 
onlay approach is used in this urethral segment. The urethra can be exposed either 
through a circular, subcoronal incision followed by penile shaft degloving, or a 
ventral midline incision, the latter one being favored by the author of this chapter 
for its associated lower local morbidity. After identifying the obstruction of a soft 
20F Nelaton catheter or Bougie-a-Boule, the urethra is mobilized circumferentially 
off of the corpora cavernosa along the stricture length. The urethra is rotated 180° 
for preparation of the dorsal urethrotomy after placing marking stitches at both 
ends of the stricture. The graft is quilted to the corpora cavernosa, and the edges of 
the graft and urethrotomy are sewn together. Barbagli et al. have suggested the use 
of fibrin glue for one-stage penile graft urethroplasty. The authors reported that 
this new adjunct was safe and effective, with limited complications and satisfactory 
preliminary outcomes [71].
Dorsal OMG inlay through a ventral sagittal urethrotomy (Asopa): in 2001, Asopa 
described the technique of dorsal OMG inlay through a ventral sagittal urethrotomy 
approach as an alternative to the Barbagli technique for the repair of penile stric-
tures (Figure 17). The advantages are a simpler dissection, no mobilization of the 
urethra, and preservation of the urethral blood supply through circumflex and 
Figure 16. 
McAninch fasciocutaneous circular distal penile island flap. (A–D) Flap harvesting followed by ventral 
division of flap and pedicle, and then, it is rotated and anastomosed to the urethrotomy defect (from 
McAninch [99]).
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Figure 15. 
Quartey flap procedure. (A, B) Hockey stick skin island flap is fashioned. The length of the flap may be 
tailored as needed. After ventral longitudinal urethrotomy, the flap is anastomosed similar to the Orandi 
technique.
fistula develops, the urethral catheter is not reinserted and the suprapubic diversion 
is maintained for another week. If still persistent, then it should be repaired after 
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nique using a transverse distal penile or preputial island of skin as a flap, which 
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ence that this fasciocutaneous flap uses Buck’s fascia as a paddle to carry the vascular 
pedicle to the distal flap skin. It can provide a hairless flap up to 15 cm in length, mak-
ing this flap, like Quartey’s flap, extremely versatile. It can be used in uncircumcised 
as well as circumcised men. The width of the flap varies from 2.0 to 2.5 cm, depend-
ing on the stricture characteristics. With the penis on traction, the distal incision is 
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carried down deeply beneath the pedicle just beneath Buck’s fascia, but superficial to 
the dorsal neurovascular bundle (dorsally), circumflex vessels (laterally), and urethra 
(ventrally). The proximal incision extends proximally to the base of the penis through 
a dissection plane beneath the skin and subdermal or dartos fascia (Figure 16). The 
flap and pedicle can be divided either ventrally or dorsally and rotated to cover the 
urethral area as an onlay flap. This flap also allows reconstruction of complex stric-
tures of various lengths in a single stage even in circumcised patients. The cosmetic 
and functional results are excellent in experienced hands.
Turner-Warwick flap: described by Turner-Warwick, this is a bilateral, longitudi-
nal, ventral-based pedicle skin flap supported by right and left ventrolateral branches 
of the external pudendal artery. Although it may be employed in penile urethral 
stricture repair, this flap is most useful in bulbar urethral reconstruction [69].
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era, oral mucosa has become the graft of choice for its excellent graft characteristics 
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onlay approach is used in this urethral segment. The urethra can be exposed either 
through a circular, subcoronal incision followed by penile shaft degloving, or a 
ventral midline incision, the latter one being favored by the author of this chapter 
for its associated lower local morbidity. After identifying the obstruction of a soft 
20F Nelaton catheter or Bougie-a-Boule, the urethra is mobilized circumferentially 
off of the corpora cavernosa along the stricture length. The urethra is rotated 180° 
for preparation of the dorsal urethrotomy after placing marking stitches at both 
ends of the stricture. The graft is quilted to the corpora cavernosa, and the edges of 
the graft and urethrotomy are sewn together. Barbagli et al. have suggested the use 
of fibrin glue for one-stage penile graft urethroplasty. The authors reported that 
this new adjunct was safe and effective, with limited complications and satisfactory 
preliminary outcomes [71].
Dorsal OMG inlay through a ventral sagittal urethrotomy (Asopa): in 2001, Asopa 
described the technique of dorsal OMG inlay through a ventral sagittal urethrotomy 
approach as an alternative to the Barbagli technique for the repair of penile stric-
tures (Figure 17). The advantages are a simpler dissection, no mobilization of the 
urethra, and preservation of the urethral blood supply through circumflex and 
Figure 16. 
McAninch fasciocutaneous circular distal penile island flap. (A–D) Flap harvesting followed by ventral 
division of flap and pedicle, and then, it is rotated and anastomosed to the urethrotomy defect (from 
McAninch [99]).
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perforating vessels [72]. However, it involves an extra urethrotomy, which may 
potentially lead to additional urethral trauma. In the bulbar urethra, it can be used 
in combination with a second ventrally placed graft. Again, either a degloving 
or a ventral midline incision can be used. An alternative perineal approach for 
exclusive penile urethral strictures has been recently adapted from the Kulkarni 
perineal approach to panurethral stricture repair (Figure 18) [73, 74]. This perineal 
approach avoids the morbidity and less optimal cosmetic results of a penile incision 
and scar, allowing the performance of penile graft urethroplasty through either 
Barbagli’s dorsal onlay or Asopa’s dorsal inlay or Kulkarni’s one-sided dorsolateral 
approach with equivalent functional results.
Penile inversion and one-sided dorsolateral OMG graft technique (Kulkarni): 
Kulkarni first described the technique of perineal approach with penile inversion to 
expose the full length of anterior urethra for reconstruction of panurethral strictures 
with avoidance of a penile incision. In 2009, he reported and popularized a slight 
but important modification of his original technique, which involved a one-sided 
urethral dissection [75]. The preservation of the one-sided vascular supply to the 
urethra and its entire muscular and neurogenic support should represent a slight but 
significant step toward perfecting the surgical technique of urethral reconstruction 
using a minimally invasive approach. The preservation of the vascular blood supply 
(a) (b) (c)
Figure 18. 
Kulkarni’s one-sided dorsal onlay graft for anterior urethroplasty for long urethral strictures. (a-c) The penile 
shaft has been inverted into the perineum where the entire reconstruction is performed. This technique can be 
used to repair the entire length of the anterior urethra (reproduced with permission from Sanjay Kulkarni, MD).
Figure 17. 
(A-B) Asopa technique used in long penile urethral stricture approached through a ventral incision.
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to one side of the urethra along with its muscular and neural support had a signifi-
cant impact on functional outcomes. The whole operation is performed through the 
perineal approach only, making this a minimally invasive approach (Figure 18).
Staged reconstructions: staged urethroplasty is used for complicated stric-
tures with significant scar tissue involved, failed hypospadias repair, multiple 
prior urethroplasty failures, long obliterative strictures, presence of diverticulum 
or fistulation, and strictures caused by lichen sclerosus, where complete removal 
of the native diseased urethra may be necessary. In all these circumstances, there 
is absence of enough healthy tissue to allow a successful one-stage reconstruc-
tion. Staged reconstructions are based on the marsupialization of the strictured 
urethra and involve a planned repair strategy characterized by more than one 
operation and inherent free tissue transfer. Classically, the term “two-stage 
urethroplasty” is a misnomer as a significant number of these patients end up 
requiring more than two operations to produce the final result, that is, a pat-
ent tubularized urethra [76]. Alternatives to staged urethroplasty are definitive 
perineal urethrostomy, combined double face grafting, or other less common 
individualized procedures.
Johanson’s technique: in the first stage, the penis is placed on stretch and the 
distal end of the stricture is identified. A longitudinal penile skin incision is car-
ried out over the strictured area. The stricturotomy is extended proximally until 
normal urethra is exposed. The lateral edges of the urethra are sewn with the skin 
edges (Figure 19). Because voiding in a standing position is not possible without 
dribbling, soiling of the scrotum, and a forward stream, patients may be offered a 
temporary perineal urethrostomy, if necessary, which is closed at the second stage 
of the reconstruction. At the second stage, the urethral plate is tubularized and a 
dartos flap is developed to cover the suture line to avoid fistulation.
Mesh graft urethroplasty: this procedure was first described by Schreiter and 
Noll [77]. In the first stage, a longitudinal incision is made over the strictured 
urethra. The urethra is marsupialized preserving the native urethral plate. The 
split thickness graft (or foreskin) is harvested in the standard fashion with an 
Figure 19. 
Johanson’s two-stage procedure. (A–C) The anastomosis of the skin edges and the longitudinal urethrotomy 
is performed at the first stage. The urethrotomy is fashioned as a neourethral tube at the second stage. 
Modification with use of oral mucosal graft has been described.
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perforating vessels [72]. However, it involves an extra urethrotomy, which may 
potentially lead to additional urethral trauma. In the bulbar urethra, it can be used 
in combination with a second ventrally placed graft. Again, either a degloving 
or a ventral midline incision can be used. An alternative perineal approach for 
exclusive penile urethral strictures has been recently adapted from the Kulkarni 
perineal approach to panurethral stricture repair (Figure 18) [73, 74]. This perineal 
approach avoids the morbidity and less optimal cosmetic results of a penile incision 
and scar, allowing the performance of penile graft urethroplasty through either 
Barbagli’s dorsal onlay or Asopa’s dorsal inlay or Kulkarni’s one-sided dorsolateral 
approach with equivalent functional results.
Penile inversion and one-sided dorsolateral OMG graft technique (Kulkarni): 
Kulkarni first described the technique of perineal approach with penile inversion to 
expose the full length of anterior urethra for reconstruction of panurethral strictures 
with avoidance of a penile incision. In 2009, he reported and popularized a slight 
but important modification of his original technique, which involved a one-sided 
urethral dissection [75]. The preservation of the one-sided vascular supply to the 
urethra and its entire muscular and neurogenic support should represent a slight but 
significant step toward perfecting the surgical technique of urethral reconstruction 
using a minimally invasive approach. The preservation of the vascular blood supply 
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Figure 18. 
Kulkarni’s one-sided dorsal onlay graft for anterior urethroplasty for long urethral strictures. (a-c) The penile 
shaft has been inverted into the perineum where the entire reconstruction is performed. This technique can be 
used to repair the entire length of the anterior urethra (reproduced with permission from Sanjay Kulkarni, MD).
Figure 17. 
(A-B) Asopa technique used in long penile urethral stricture approached through a ventral incision.
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to one side of the urethra along with its muscular and neural support had a signifi-
cant impact on functional outcomes. The whole operation is performed through the 
perineal approach only, making this a minimally invasive approach (Figure 18).
Staged reconstructions: staged urethroplasty is used for complicated stric-
tures with significant scar tissue involved, failed hypospadias repair, multiple 
prior urethroplasty failures, long obliterative strictures, presence of diverticulum 
or fistulation, and strictures caused by lichen sclerosus, where complete removal 
of the native diseased urethra may be necessary. In all these circumstances, there 
is absence of enough healthy tissue to allow a successful one-stage reconstruc-
tion. Staged reconstructions are based on the marsupialization of the strictured 
urethra and involve a planned repair strategy characterized by more than one 
operation and inherent free tissue transfer. Classically, the term “two-stage 
urethroplasty” is a misnomer as a significant number of these patients end up 
requiring more than two operations to produce the final result, that is, a pat-
ent tubularized urethra [76]. Alternatives to staged urethroplasty are definitive 
perineal urethrostomy, combined double face grafting, or other less common 
individualized procedures.
Johanson’s technique: in the first stage, the penis is placed on stretch and the 
distal end of the stricture is identified. A longitudinal penile skin incision is car-
ried out over the strictured area. The stricturotomy is extended proximally until 
normal urethra is exposed. The lateral edges of the urethra are sewn with the skin 
edges (Figure 19). Because voiding in a standing position is not possible without 
dribbling, soiling of the scrotum, and a forward stream, patients may be offered a 
temporary perineal urethrostomy, if necessary, which is closed at the second stage 
of the reconstruction. At the second stage, the urethral plate is tubularized and a 
dartos flap is developed to cover the suture line to avoid fistulation.
Mesh graft urethroplasty: this procedure was first described by Schreiter and 
Noll [77]. In the first stage, a longitudinal incision is made over the strictured 
urethra. The urethra is marsupialized preserving the native urethral plate. The 
split thickness graft (or foreskin) is harvested in the standard fashion with an 
Figure 19. 
Johanson’s two-stage procedure. (A–C) The anastomosis of the skin edges and the longitudinal urethrotomy 
is performed at the first stage. The urethrotomy is fashioned as a neourethral tube at the second stage. 
Modification with use of oral mucosal graft has been described.
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electrical dermatome and is meshed with a mechanical skin mesher using a 1:15 
ratio sheet. The graft is placed on the wound ground lateral to the preserved ure-
thral plate (Figure 20). The graft is fixed by running 5–0 monofilament sutures. 
The second stage (urethral tubularization) is performed in a standard fashion. 
In a study by Carr et al., success was achieved in 80% at a median follow-up of 
38 months [78].
Staged oral mucosa graft urethroplasty: today, staged reconstructions using oral 
mucosal grafts has become a reliable and the most popular procedure to treat 
difficult anterior urethral strictures that are not amenable to single-stage graft or 
flap reconstructions. The indications are similar to the procedures described above. 
The surgical technique is generally similar (to variants) and based on the technique 
used for the Johanson and Schreiter’s operations, that is, urethral marsupialization 
in the first stage followed by urethral tubularization 4–6 months later, the OMG 
being placed at the first stage. At times, it may be necessary to use additional grafts 
at the time of tubularization to optimize the urethral plate. This is the procedure of 
choice for strictures associated with LS. Success rates are very good when compared 
to earlier techniques with an acceptable number of surgical revisions. Multistage 
urethroplasty should replace “two-stage” urethroplasty as the accepted terminology 
as it is not uncommon for patients to require more than two procedures to complete 
Figure 20. 
Mesh graft urethroplasty as described by Schreiter. Meshed skin graft has been placed on the wound ground and 
quilted to the host bed (first stage). The prepared urethral plate is tubularized approximately 6 months later 
(second stage).
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successful tubularization. This may lead to more realistic patient expectations as 
well. Although completion of the second stage may not always be necessary for 
functional improvement, cosmetic outcomes with restoration of a glanular meatus 
can be excellent and achieved in the majority of patients [79]. An algorithm of 
surgical reconstruction of strictures of the meatus, fossa navicularis, and penile 
urethral shaft is suggested (Figure 21).
Tissue engineering, stem cell, and future: the field of tissue engineering 
and scar modulation is an exciting area of research in reconstructive urology and 
is rapidly progressing. Much research has been devoted to the development of 
a tissue-engineered urethral graft. Currently used grafts, when long, can cause 
initial donor site morbidity or may be insufficient. Researchers have investigated 
cell-free and cell-seeded grafts as substitutes for human urethra. There are dif-
ferent approaches to developing these grafts with variable reported successes in 
studies conducted in animal and human models. Further research may improve 
the management of long and complex urethral strictures that usually require 
oral mucosa substitution of urethroplasty with tissue-engineered grafts. These 
grafts have become necessary because the use of oral mucosa may be limited by 
its availability. A combination of buccal (cheek), lingual (tongue), and labial 
(lip) mucosa may be utilized and necessary in some cases. Patients with reduced 
mouth opening or previous oral surgery may have less oral tissue for use. In addi-
tion, longer grafts carry a greater morbidity. The risk of donor site morbidity is 
increased in smokers, tobacco chewers, and those with poor oral hygiene, which 
will contraindicate the use of oral mucosa, and, therefore, necessitate a tissue-
engineered graft [80].
To generate new tissues, biomedical engineering investigators have utilized 
three basic tools: cells, scaffold, and growth factor. The earliest use of human cells 
dates back to approximately 30 years ago [81]. Several different tissue-engineered 
grafts have been used for urethral reconstruction. There are two types of urethral 
grafts: (1) those that contain living autologous cells and (2) those that are cell free. 
The latter include grafts obtained from cadaveric or animal sources. This tissue 
undergoes treatment to become completely cell free. The resultant biological 
Figure 21. 
Algorithm of surgical reconstruction of strictures of the meatus, fossa navicularis, and penile urethral shaft. 
FN = fossa navicularis, LS = lichen sclerosus, TIP = tubularized incised plate, and OMG = oral mucosal graft.
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electrical dermatome and is meshed with a mechanical skin mesher using a 1:15 
ratio sheet. The graft is placed on the wound ground lateral to the preserved ure-
thral plate (Figure 20). The graft is fixed by running 5–0 monofilament sutures. 
The second stage (urethral tubularization) is performed in a standard fashion. 
In a study by Carr et al., success was achieved in 80% at a median follow-up of 
38 months [78].
Staged oral mucosa graft urethroplasty: today, staged reconstructions using oral 
mucosal grafts has become a reliable and the most popular procedure to treat 
difficult anterior urethral strictures that are not amenable to single-stage graft or 
flap reconstructions. The indications are similar to the procedures described above. 
The surgical technique is generally similar (to variants) and based on the technique 
used for the Johanson and Schreiter’s operations, that is, urethral marsupialization 
in the first stage followed by urethral tubularization 4–6 months later, the OMG 
being placed at the first stage. At times, it may be necessary to use additional grafts 
at the time of tubularization to optimize the urethral plate. This is the procedure of 
choice for strictures associated with LS. Success rates are very good when compared 
to earlier techniques with an acceptable number of surgical revisions. Multistage 
urethroplasty should replace “two-stage” urethroplasty as the accepted terminology 
as it is not uncommon for patients to require more than two procedures to complete 
Figure 20. 
Mesh graft urethroplasty as described by Schreiter. Meshed skin graft has been placed on the wound ground and 
quilted to the host bed (first stage). The prepared urethral plate is tubularized approximately 6 months later 
(second stage).
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successful tubularization. This may lead to more realistic patient expectations as 
well. Although completion of the second stage may not always be necessary for 
functional improvement, cosmetic outcomes with restoration of a glanular meatus 
can be excellent and achieved in the majority of patients [79]. An algorithm of 
surgical reconstruction of strictures of the meatus, fossa navicularis, and penile 
urethral shaft is suggested (Figure 21).
Tissue engineering, stem cell, and future: the field of tissue engineering 
and scar modulation is an exciting area of research in reconstructive urology and 
is rapidly progressing. Much research has been devoted to the development of 
a tissue-engineered urethral graft. Currently used grafts, when long, can cause 
initial donor site morbidity or may be insufficient. Researchers have investigated 
cell-free and cell-seeded grafts as substitutes for human urethra. There are dif-
ferent approaches to developing these grafts with variable reported successes in 
studies conducted in animal and human models. Further research may improve 
the management of long and complex urethral strictures that usually require 
oral mucosa substitution of urethroplasty with tissue-engineered grafts. These 
grafts have become necessary because the use of oral mucosa may be limited by 
its availability. A combination of buccal (cheek), lingual (tongue), and labial 
(lip) mucosa may be utilized and necessary in some cases. Patients with reduced 
mouth opening or previous oral surgery may have less oral tissue for use. In addi-
tion, longer grafts carry a greater morbidity. The risk of donor site morbidity is 
increased in smokers, tobacco chewers, and those with poor oral hygiene, which 
will contraindicate the use of oral mucosa, and, therefore, necessitate a tissue-
engineered graft [80].
To generate new tissues, biomedical engineering investigators have utilized 
three basic tools: cells, scaffold, and growth factor. The earliest use of human cells 
dates back to approximately 30 years ago [81]. Several different tissue-engineered 
grafts have been used for urethral reconstruction. There are two types of urethral 
grafts: (1) those that contain living autologous cells and (2) those that are cell free. 
The latter include grafts obtained from cadaveric or animal sources. This tissue 
undergoes treatment to become completely cell free. The resultant biological 
Figure 21. 
Algorithm of surgical reconstruction of strictures of the meatus, fossa navicularis, and penile urethral shaft. 
FN = fossa navicularis, LS = lichen sclerosus, TIP = tubularized incised plate, and OMG = oral mucosal graft.
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matrix is then implanted. A good vascular bed is needed to allow take and infiltra-
tion of host cells. As a rule, these techniques would only be expected to be particu-
larly successful for substituting short urethral defects. In contrast, cellularized 
grafts contain a matrix populated with autologous cells, which are obtained from 
a small biopsy from the patient. The cells are cultured, expanded, and seeded onto 
the matrix. The matrix containing cells is then implanted onto the host bed [82].
A critical element required for successful tissue engineering is the cell source. 
Cells can be isolated from autologous urine-derived stems cells, smooth muscle 
cells, adipogenic, chondrogenic, and neural lineages [83]. Because simple cell injec-
tion to a target site is rarely feasible, a scaffold, or a template, also called artificial 
extracellular matrix, is necessary. The major function of a scaffold is to assist 
proliferation, differentiation, and biosynthesis of cells [84, 85].
Scar modulation represents another potential development that may revolution-
ize urethral reconstruction. Antifibrotic injectables, acting as scar inhibitors, may 
be placed into the stricture after stricturotomy. Stents impregnated with tacrolimus 
or paclitaxel have been tried in animal and human models with apparently promis-
ing early results [86, 87].
Regenerative medicine (cell therapy and tissue engineering) has made solid 
progress over the last three decades. We cautiously hope that these technologies will 
finally enter the routine clinical environment and be applicable in the treatment of 
urethral strictures/stenosis.
Sexual impact of anterior urethroplasty: overall, anterior urethroplasty 
appears to have minimal or no impact on long-term sexual dysfunction. One 
study revealed a moderate effect on sexual function, especially transient chordee 
in 25% of patients [88]. In another study, the impact of urethroplasty was not 
worse than circumcision [89]. Another study found a minimal impact on ejacula-
tory function [90]. One further study reported erectile dysfunction (ED) in 
approximately 40% of patients, although recovery occurred in most by 6 months. 
In this study, bulbar urethroplasty affected erectile function more than penile 
urethroplasty, probably explained by the proximity of the bulbar urethra to the 
erectile nerves [89]. Even staged urethroplasty does not seem to influence sexual 
function in patients undergoing penile urethroplasty, although many may experi-
ence de novo penile curvature, reduced penile length, and/or reduced penile 
sensitivity [91]. In conclusion, a meta-analysis conducted by Blaschko et al. 
found that the risk of de novo ED after anterior urethroplasty was low at 1% with 
most of the cases of the de novo ED resolving within 6–12 months; however, the 
possibility of de novo posturethroplasty ED, even if transient from the psycho-
logical impact of surgery or during revascularization, should be discussed during 
preoperative evaluation [92].
8. Lower urinary tract symptoms (LUTS) and urethral strictures
The spectrum of lower urinary tract symptoms (LUTS) at initial presentation 
for urethral stricture disease (USD) is well described. Anterior urethral stricture 
disease most commonly presents as urinary obstruction and may occasionally 
present as acute urinary retention. However, there is little data addressing these 
symptoms in patients after urethroplasty. LUTS after urethroplasty for anterior 
USD and the relationship of these symptoms to USD recurrence has also been 
observed [93]. It was reported that men with a successful outcome after urethro-
plasty tend to remain asymptomatic, whereas those who recur have LUTS, typically 
with weak urinary flow but without dysuria and hematuria. The authors supported 
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the need for a USD-specific validated questionnaire to be used for follow-up after 
urethroplasty.
All men being evaluated for lower urinary tract symptoms (LUTS) should 
include urethral stricture in the differential diagnosis and include a combina-
tion of patient-reported symptom measures, uroflowmetry to assess severity of 
obstruction, and postvoid residual volume by ultrasound to determine degree of 
urinary retention. Patients with urethral stricture typically present a weak flow 
rate. However, evaluation of urethral stricture requires further specific testing to 
delineate the location, length of the stricture, and degree of narrowing such as 
urethroscopy and retrograde urethrogram with or without voiding cystourethro-
gram. LUTS are the usual clinical manifestation of urethral strictures, regard-
less of location, etiology, and severity. However, LUTS after urethral stricture 
repair are not uncommon. Urgency has been reported in 40% of men and urge 
incontinence in 12% of men after anterior urethroplasty. De novo urgency and 
urge incontinence is seen in 9 and 5% of men, respectively, after urethroplasty. 
Once a complication of urethroplasty (such as recurrent urethral stricture or 
diverticulum) has been excluded as a cause, evaluation of LUTS in such patients 
should focus on the differential diagnosis between bladder dysfunction (overactive 
bladder and underactive bladder) and other outlet obstructions (such as benign 
prostatic obstruction), dysfunctional voiding, or medical causes (such as noctur-
nal polyuria). Management of overactive bladder has different treatment options, 
which may include behavioral modification, physical therapy, anticholinergic, 
and/or beta-3 agonist medications. In more severe cases, intravesical onabotuli-
num toxin, sacral neuromodulation, or peripheral tibial nerve stimulation may be 
indicated. Definitive treatment for underactive bladder is limited in number and 
success. Although management of LUTS for patients after urethral stricture repair 
can usually proceed similarly as for patients without prior history of urethral 
reconstruction, special consideration and alterations in management need to be 
made when instrumenting the urethra, as the urethral lumen may be narrower in 
these patients.
Recently, an analysis of risk factors leading to postoperative urethral stricture 
and bladder neck contracture (BNC) following transurethral resection of prostate 
(TURP) has been performed [94]. The authors have found that lower resection 
speed, intraoperative urethral mucosal rupture, and postoperative continuous 
infection were associated with a higher risk of urethral stricture, whereas more 
severe storage symptoms and smaller prostate volumes were associated with a 
higher risk of BNC after TURP.
9. Future directions and goals
Penile urethroplasty has evolved significantly over the last eight decades, since 
the first attempts at reconstruction using preputial tubes or a staged approach 
using penile skin [95]. An improved understanding of the pathophysiology of LS 
and a high complication rate following skin-based reconstructions favored a shift 
to the use of oral mucosal grafts, particularly in LS strictures. To date, very little 
advances have been achieved with conservative/pharmacological therapeutic 
options to stabilize or modulate the scarring process of this recalcitrant cutaneous 
disease.
Currently, one of the critical limitations of penile urethroplasty is the common 
need for a staged reconstruction with all the inconveniences for the patient, and a 
20–31% incidence of graft failure following the first stage, which leads to further 
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matrix is then implanted. A good vascular bed is needed to allow take and infiltra-
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grafts contain a matrix populated with autologous cells, which are obtained from 
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cells, adipogenic, chondrogenic, and neural lineages [83]. Because simple cell injec-
tion to a target site is rarely feasible, a scaffold, or a template, also called artificial 
extracellular matrix, is necessary. The major function of a scaffold is to assist 
proliferation, differentiation, and biosynthesis of cells [84, 85].
Scar modulation represents another potential development that may revolution-
ize urethral reconstruction. Antifibrotic injectables, acting as scar inhibitors, may 
be placed into the stricture after stricturotomy. Stents impregnated with tacrolimus 
or paclitaxel have been tried in animal and human models with apparently promis-
ing early results [86, 87].
Regenerative medicine (cell therapy and tissue engineering) has made solid 
progress over the last three decades. We cautiously hope that these technologies will 
finally enter the routine clinical environment and be applicable in the treatment of 
urethral strictures/stenosis.
Sexual impact of anterior urethroplasty: overall, anterior urethroplasty 
appears to have minimal or no impact on long-term sexual dysfunction. One 
study revealed a moderate effect on sexual function, especially transient chordee 
in 25% of patients [88]. In another study, the impact of urethroplasty was not 
worse than circumcision [89]. Another study found a minimal impact on ejacula-
tory function [90]. One further study reported erectile dysfunction (ED) in 
approximately 40% of patients, although recovery occurred in most by 6 months. 
In this study, bulbar urethroplasty affected erectile function more than penile 
urethroplasty, probably explained by the proximity of the bulbar urethra to the 
erectile nerves [89]. Even staged urethroplasty does not seem to influence sexual 
function in patients undergoing penile urethroplasty, although many may experi-
ence de novo penile curvature, reduced penile length, and/or reduced penile 
sensitivity [91]. In conclusion, a meta-analysis conducted by Blaschko et al. 
found that the risk of de novo ED after anterior urethroplasty was low at 1% with 
most of the cases of the de novo ED resolving within 6–12 months; however, the 
possibility of de novo posturethroplasty ED, even if transient from the psycho-
logical impact of surgery or during revascularization, should be discussed during 
preoperative evaluation [92].
8. Lower urinary tract symptoms (LUTS) and urethral strictures
The spectrum of lower urinary tract symptoms (LUTS) at initial presentation 
for urethral stricture disease (USD) is well described. Anterior urethral stricture 
disease most commonly presents as urinary obstruction and may occasionally 
present as acute urinary retention. However, there is little data addressing these 
symptoms in patients after urethroplasty. LUTS after urethroplasty for anterior 
USD and the relationship of these symptoms to USD recurrence has also been 
observed [93]. It was reported that men with a successful outcome after urethro-
plasty tend to remain asymptomatic, whereas those who recur have LUTS, typically 
with weak urinary flow but without dysuria and hematuria. The authors supported 
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the need for a USD-specific validated questionnaire to be used for follow-up after 
urethroplasty.
All men being evaluated for lower urinary tract symptoms (LUTS) should 
include urethral stricture in the differential diagnosis and include a combina-
tion of patient-reported symptom measures, uroflowmetry to assess severity of 
obstruction, and postvoid residual volume by ultrasound to determine degree of 
urinary retention. Patients with urethral stricture typically present a weak flow 
rate. However, evaluation of urethral stricture requires further specific testing to 
delineate the location, length of the stricture, and degree of narrowing such as 
urethroscopy and retrograde urethrogram with or without voiding cystourethro-
gram. LUTS are the usual clinical manifestation of urethral strictures, regard-
less of location, etiology, and severity. However, LUTS after urethral stricture 
repair are not uncommon. Urgency has been reported in 40% of men and urge 
incontinence in 12% of men after anterior urethroplasty. De novo urgency and 
urge incontinence is seen in 9 and 5% of men, respectively, after urethroplasty. 
Once a complication of urethroplasty (such as recurrent urethral stricture or 
diverticulum) has been excluded as a cause, evaluation of LUTS in such patients 
should focus on the differential diagnosis between bladder dysfunction (overactive 
bladder and underactive bladder) and other outlet obstructions (such as benign 
prostatic obstruction), dysfunctional voiding, or medical causes (such as noctur-
nal polyuria). Management of overactive bladder has different treatment options, 
which may include behavioral modification, physical therapy, anticholinergic, 
and/or beta-3 agonist medications. In more severe cases, intravesical onabotuli-
num toxin, sacral neuromodulation, or peripheral tibial nerve stimulation may be 
indicated. Definitive treatment for underactive bladder is limited in number and 
success. Although management of LUTS for patients after urethral stricture repair 
can usually proceed similarly as for patients without prior history of urethral 
reconstruction, special consideration and alterations in management need to be 
made when instrumenting the urethra, as the urethral lumen may be narrower in 
these patients.
Recently, an analysis of risk factors leading to postoperative urethral stricture 
and bladder neck contracture (BNC) following transurethral resection of prostate 
(TURP) has been performed [94]. The authors have found that lower resection 
speed, intraoperative urethral mucosal rupture, and postoperative continuous 
infection were associated with a higher risk of urethral stricture, whereas more 
severe storage symptoms and smaller prostate volumes were associated with a 
higher risk of BNC after TURP.
9. Future directions and goals
Penile urethroplasty has evolved significantly over the last eight decades, since 
the first attempts at reconstruction using preputial tubes or a staged approach 
using penile skin [95]. An improved understanding of the pathophysiology of LS 
and a high complication rate following skin-based reconstructions favored a shift 
to the use of oral mucosal grafts, particularly in LS strictures. To date, very little 
advances have been achieved with conservative/pharmacological therapeutic 
options to stabilize or modulate the scarring process of this recalcitrant cutaneous 
disease.
Currently, one of the critical limitations of penile urethroplasty is the common 
need for a staged reconstruction with all the inconveniences for the patient, and a 
20–31% incidence of graft failure following the first stage, which leads to further 
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revision(s) prior to the final tubularization [95]. Insufficient oral mucosal grafts 
for panurethral stricture reconstruction, especially in redo cases, add serious 
problems.
Considerable research has been done in the areas of biomaterials, regenera-
tive medicine, including scar modulation, and tissue engineering to overcome the 
limitations of current penile urethral stricture management. These experimental 
technologies appear exciting, revolutionary, and ripe with potential. The main goals 
of these research areas would be to produce scar inhibitors that might be placed into 
the stricture after urethrotomy, on the one hand, and to generate an ideal biomate-
rial in unlimited quantities, easily cultured in laboratory, readily available “off the 
shelf” and without the morbidity associated with graft harvesting, on the other 
hand. Unfortunately, we are not quite there yet.
10. Conclusion
The surgical treatment of penile urethral stricture is continually evolving. No 
one technique is appropriate for all situations, and the successful reconstructive 
urologist needs to be comfortable with a repertoire of different, versatile techniques 
in order to best treat each individual patient’s problem. Since the early 1990s, OMG 
was introduced in urethral reconstructive surgery and has become the first choice 
of most urethral surgeons.
Although all are grouped as anterior urethral strictures, penile urethral stric-
tures are different from bulbar urethral strictures. Flaps are still preferred to 
grafts in long, recurrent penile urethral strictures by some surgeons. Recently, 
one-stage dorsal OMG urethroplasty via perineal approach has been suggested 
for the management of most strictures of the penile shaft urethra with both good 
functional and remarkable cosmetic outcomes. However, in patients who have 
experienced failed hypospadias repair or in whom the penile skin and urethral plate 
are not suitable for urethroplasty, two-stage (usually multistage) urethroplasty is 
recommended. Management of some lengthy, complex strictures remains a great 
challenge even for experienced reconstructive surgeons. Staged urethroplasty, such 
as the Johanson’s technique with or without the use of grafts, is still a good surgical 
option. Regenerative medicine continues to show promise, but further investigation 
is needed to reach clinical application in the future. All in all, these great improve-
ments in penile urethral surgical technique should lead to optimization of the 
surgical treatment algorithm.
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Chapter 7
Lower Urinary Tract Symptoms 
(LUTS) and Sexual Function and 
Dysfunction
Charalampos Konstantinidis, Ioannis Eleftheropoulos  
and Achileas Karafotias
Abstract
In recent years, the coexistence of sexual dysfunction (SD) and lower urinary tract 
symptoms (LUTS) has become a popular topic for researchers. Numerous clinical 
epidemiologic studies have been planned for this reason and have evaluated the rela-
tionship between these seemingly irrelevant urological conditions. The connection 
between SD and LUTS has already been acknowledged, and common pathophysi-
ological pathways have been recognized. In this chapter was attempted to evaluate the 
impact on patient’s quality of life (QoL), common pathophysiological pathways and 
therapy aspects of this condition. SD and LUTS are common problems among the 
general population and affect a great percentage of urological patients. It is a subject 
that affects the community in social, financial, and psychological terms. In this case, 
research for new treatment options has been triggered as phosphodiesterase type 5 
inhibitors established their role as the widely approved combination therapy.
Keywords: lower urinary tract symptoms (LUTS), sexual dysfunction (SD), PDE5i
1. Introduction
In recent years, the coexistence of sexual dysfunction and lower urinary tract symp-
toms has become a popular topic for researchers. Numerous clinical epidemiologic 
studies have been planned for this reason and have evaluated the relationship between 
these seemingly irrelevant urological fields of study. In this chapter, an approach to 
these two fields, their impact on patients’ quality of life (QoL), common pathophysi-
ological pathways and therapy aspects are attempted. Both are common problems 
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potential targets for prevention (e.g., metabolic syndrome) [6]. Most elderly men 
have at least one LUTS [2], which is often mild or not very bothersome [4, 7, 8]. 
LUTS progression is a dynamic procedure. LUTS may persist and upscale over long 
time periods, or they may retreat [2]. LUTS have usually been related to bladder 
outlet obstruction (BOO), which is often caused by an increase of prostatic volume, 
as a result of benign prostate hyperplasia (BPH) [3, 5]. On the contrary, numerous 
studies have shown that LUTS are often not related to the BPH [2, 9]. Bladder dys-
function may also cause LUTS, such as detrusor overactivity or overactive bladder 
syndrome (OAB), detrusor underactivity, and structural or functional abnormali-
ties of the urinary tract and its surrounding tissues [9]. Prostatitis may also cause 
the appearance of LUTS [10, 11]. Furthermore, there are some nonurological 
conditions that may be related to urinary symptoms, mainly to nocturia [2].
The definitions of the most common conditions related to LUTS are presented 
below:
• Acute retention of urine is defined as a painful and palpable bladder when the 
patient cannot urinate [5].
• Chronic retention of urine is defined as a nonpainful bladder, which remains 
palpable even though the patient has urinated. It may also be accompanied by 
incontinence [5].
• Bladder outlet obstruction (BOO) is characterized by reduced urine flow rate 
and increased detrusor pressure. It can be diagnosed by studying the synchro-
nous values of detrusor pressure and urine flow rate [5].
• Benign prostatic obstruction (BPO) is a form of BOO, diagnosed when the 
cause of outlet obstruction is known to be BPH [5].
• Detrusor overactivity (DO) is a urodynamic observation characterized by 
involuntary detrusor contractions during the bladder filling phase [5].
• Overactive bladder (OAB) syndrome is characterized by urinary urgency, with or 
without urinary incontinence, usually with increased daytime frequency and noc-
turia, and in this case, there is no proven infection or other obvious pathology [12].
Patient’s history must be assessed thoroughly [13–15]. A medical history aims to 
identify relevant comorbidities and potential causes, including medical and neuro-
logical diseases. Lifestyle habits, medication, emotional, and psychological factors 
must also be reviewed. When relevant, the sexual function should be assessed, pref-
erably with validated symptom questionnaires such as the International Index for 
Erectile Function (IIEF). The literature recommends, for male LUTS assessment, 
the use of validated symptom score questionnaire [13, 15]. Several questionnaires 
have been developed, which are sensitive to symptom changes. In this case, they are 
helpful in monitoring treatment approaches [16–22]. Symptom scores are helpful in 
quantifying LUTS and identifying the predominant symptoms. Nevertheless, they 
are not disease- or age specific.
3. Sexual dysfunction
It is difficult to identify the prevalence of sexual dysfunction in men, because 
there is no standard definition of sexual dysfunction (SD). Erectile dysfunction 
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(ED) is defined as the persistent inability to attain and maintain an erection suf-
ficient to permit satisfactory sexual performance [23]. Penile erection is a complex 
phenomenon, which implies coordination among the neurological, vascular, and 
smooth muscle compartment. It includes arterial dilation, trabecular smooth 
muscle relaxation, and activation of the corporal veno-occlusive mechanism [24]. 
ED may affect physical and psychosocial health. It might have a significant impact 
on the QoL of sufferers and their partners’ as well [25–27]. Therefore, ED should 
not be regarded only as a QoL issue, but also as a potential warning sign of cardio-
vascular disease (CVD), as it can be an early manifestation of coronary artery and 
peripheral vascular disease [28–30].
The pathophysiology of ED may be vasculogenic, neurogenic, anatomical, 
hormonal, drug-induced, and/or psychogenic [24]. Usually, many pathophysiol-
ogy pathways can be comorbid and concomitant, negatively impacting on erectile 
function. In most cases, ED is the result of more than one organic pathophysiologi-
cal element and, very often, a psychological component. ED was initially classified 
into three categories based on its etiology. These include organic, psychogenic, and 
mixed ED. Nowadays, these are recognized as two categories: the psychogenic and 
the mixed one, as any organic ED has an additional psychogenic impact that inter-
feres with the pathophysiology of ED and causes additional distress to the patient.
Epidemiological data have shown a high incidence and prevalence of ED world-
wide. The Massachusetts male aging study (MMAS) [25] reported, in noninstitu-
tionalized men aged 40–70 years in the Boston area, an overall prevalence of 52% 
ED. Prevalence for minimal, moderate, and complete ED was 17.2, 25.2, and 9.6%, 
respectively. In the Cologne study of men aged 30–80 years, the prevalence of ED 
was 19.2% [65]. The incidence rate of ED (new cases per 1000 men annually) was 
26 in the long-term data from the MMAS study [66] and 19.2 (mean follow-up of 
4.2 years) in a Dutch study [31].
ED shares common risk factors with CVD (e.g., obesity, diabetes mellitus, 
dyslipidemia, metabolic syndrome, lack of exercise, and smoking) [27, 32–34]. The 
association among ED and age, diabetes mellitus, body mass index (BMI) [35, 36], 
obstructive sleep apnea, and hyperhomocysteinemia has been established [37–39]. 
A number of studies have shown evidence that lifestyle modification [29, 40] and 
pharmacotherapy [40, 41] for CVD risk factors may also improve sexual func-
tion in men with ED. Epidemiological studies have also demonstrated consistent 
evidence for an association between LUTS and sexual dysfunction, regardless of 
age, other comorbidities, and behavioral factors [42]. The multinational survey 
on the aging male (MSAM-7) study (performed in France, Germany, Spain, Italy, 
the Netherlands, the USA, and the UK) investigated the relationship between 
LUTS and sexual dysfunction in over 12,000 men aged 50–80 years. From 83% 
of sexually active men, the prevalence of LUTS was 90%, with the prevalence of 
ED being 49%. The complete absence of erection was reported in 10% of patients. 
The prevalence of ejaculatory disorders has been reported in 46% of patients [43]. 
Association between chronic prostatitis or chronic pelvic pain syndrome (CP/
CPPS) and ED is confirmed [44].
Surgical interventions to the prostate also have an impact on erectile function 
according to the type of surgery that was performed [45]. Epidemiologically, there are 
other risk factors that potentially associate to ED, including psoriasis [46–48], gouty 
arthritis [49, 50], ankylosing spondylitis [51], nonalcoholic fatty liver [52], chronic 
liver disorders [53], chronic periodontitis [54], open-angle glaucoma [55], inflamma-
tory bowel disease [56], and complications following transrectal ultrasound (TRUS) 
guided prostate biopsy [57].
World Health Organization (WHO) and International Classifications of 
Diseases-10 (ICD-10) define female sexual dysfunction as “the various ways in 
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muscle relaxation, and activation of the corporal veno-occlusive mechanism [24]. 
ED may affect physical and psychosocial health. It might have a significant impact 
on the QoL of sufferers and their partners’ as well [25–27]. Therefore, ED should 
not be regarded only as a QoL issue, but also as a potential warning sign of cardio-
vascular disease (CVD), as it can be an early manifestation of coronary artery and 
peripheral vascular disease [28–30].
The pathophysiology of ED may be vasculogenic, neurogenic, anatomical, 
hormonal, drug-induced, and/or psychogenic [24]. Usually, many pathophysiol-
ogy pathways can be comorbid and concomitant, negatively impacting on erectile 
function. In most cases, ED is the result of more than one organic pathophysiologi-
cal element and, very often, a psychological component. ED was initially classified 
into three categories based on its etiology. These include organic, psychogenic, and 
mixed ED. Nowadays, these are recognized as two categories: the psychogenic and 
the mixed one, as any organic ED has an additional psychogenic impact that inter-
feres with the pathophysiology of ED and causes additional distress to the patient.
Epidemiological data have shown a high incidence and prevalence of ED world-
wide. The Massachusetts male aging study (MMAS) [25] reported, in noninstitu-
tionalized men aged 40–70 years in the Boston area, an overall prevalence of 52% 
ED. Prevalence for minimal, moderate, and complete ED was 17.2, 25.2, and 9.6%, 
respectively. In the Cologne study of men aged 30–80 years, the prevalence of ED 
was 19.2% [65]. The incidence rate of ED (new cases per 1000 men annually) was 
26 in the long-term data from the MMAS study [66] and 19.2 (mean follow-up of 
4.2 years) in a Dutch study [31].
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dyslipidemia, metabolic syndrome, lack of exercise, and smoking) [27, 32–34]. The 
association among ED and age, diabetes mellitus, body mass index (BMI) [35, 36], 
obstructive sleep apnea, and hyperhomocysteinemia has been established [37–39]. 
A number of studies have shown evidence that lifestyle modification [29, 40] and 
pharmacotherapy [40, 41] for CVD risk factors may also improve sexual func-
tion in men with ED. Epidemiological studies have also demonstrated consistent 
evidence for an association between LUTS and sexual dysfunction, regardless of 
age, other comorbidities, and behavioral factors [42]. The multinational survey 
on the aging male (MSAM-7) study (performed in France, Germany, Spain, Italy, 
the Netherlands, the USA, and the UK) investigated the relationship between 
LUTS and sexual dysfunction in over 12,000 men aged 50–80 years. From 83% 
of sexually active men, the prevalence of LUTS was 90%, with the prevalence of 
ED being 49%. The complete absence of erection was reported in 10% of patients. 
The prevalence of ejaculatory disorders has been reported in 46% of patients [43]. 
Association between chronic prostatitis or chronic pelvic pain syndrome (CP/
CPPS) and ED is confirmed [44].
Surgical interventions to the prostate also have an impact on erectile function 
according to the type of surgery that was performed [45]. Epidemiologically, there are 
other risk factors that potentially associate to ED, including psoriasis [46–48], gouty 
arthritis [49, 50], ankylosing spondylitis [51], nonalcoholic fatty liver [52], chronic 
liver disorders [53], chronic periodontitis [54], open-angle glaucoma [55], inflamma-
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guided prostate biopsy [57].
World Health Organization (WHO) and International Classifications of 
Diseases-10 (ICD-10) define female sexual dysfunction as “the various ways in 
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which an individual is unable to participate in a sexual relationship as she would 
wish” [58]. There are three categories of sexual dysfunction: female sexual interest-
arousal disorder, female orgasmic disorder, and genito-pelvic pain-penetration 
disorder [59]. It is estimated that 10% of women suffer from female sexual interest-
arousal disorder and 3.5–35% present orgasmic problems [60].
Validated psychometric questionnaires, such as the International Index for Erectile 
Function (IIEF) [61] or the sexual health inventory for men (SHIM) [62], are the 
assessment tools needed in different sexual function domains (i.e., erectile function, 
sexual desire, intercourse, orgasmic function, and overall satisfaction), as well as for the 
potential impact of a specific treatment modality. The use of the erectile hardness score 
for the assessment of penile rigidity in practice and in clinical trial research is supported 
by psychometric analyses [63]. Patients should be screened for symptoms of possible 
hypogonadism (testosterone deficiency), libido, fatigue, cognitive impairment, and 
LUTS. Even though LUTS does not represent a contraindication to treat a patient for 
late-onset hypogonadism, screening for LUTS severity is clinically relevant [64].
4. The relationship between ED and LUTS
A lot of epidemiological studies demonstrate the coexistence of ED and LUTS. It 
is also proven that the existence of LUTS is a risk factor for ED. The patient’s age and 
the severity of LUTS are independent prognostic factors for ED, as well. Although it is 
not clear if LUTS lead to ED, or ED results to LUTS, or these conditions are just coex-
isting, their relation is very narrow and clear, especially in older patients. Therefore, 
men who suffer from LUTS should be checked for ED and men who present ED 
should be evaluated for LUTS. There are four theories that try to correlate LUTS with 
ED. These theories include deregulation of NO/NOS system, increased sympathetic 
tone (autonomic hyperactivity (AH)), up-regulation of Rho-kinase, and chronic 
hypoxia. Common vascular risk factors can combine and support these theories.
4.1 Alteration in nitric oxide (NO)
The role of nitric oxide (NO) in erectile function is well known as the main 
regulator of penile corporal smooth muscle relaxation and resultant erection. The 
decrease in NO/cyclic guanosine monophosphate (cGMP) has the effect of reduc-
tion in NO synthase (NOS) due to endothelial dysfunction. Luck or reduction of 
smooth muscle relaxation of the bladder neck, prostate and urethra may lead to 
LUTS. The NO system has been shown to be down-regulated in the transition zone 
of the prostate in BPH when compared with normal controls [67, 68].
4.2 Autonomic hyperactivity (AH)
AH, as a component of the metabolic syndrome, refers to dysregulation of 
sympathetic and parasympathetic tone. Increased sympathetic tone results in flac-
cidity and antagonizes penile erection, due to vasoconstriction. Parasympathetic 
activation can lead to prostate smooth muscle contraction (due to activation of the 
M2 receptors), so nonrelaxing bladder neck, prostatic urethra, and pelvic floor may 
lead to LUTS [67, 68].
4.3 RhoA/rho-kinase-calcium-sensitizing pathway
Smooth muscle tone is adjusted commonly not only through the calcium-
dependent mechanism, but also through the activity of RhoA/ROCK calcium 
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pathway. Activation of RhoA-ROCK pathway can affect smooth muscle relaxation 
and finally increase ED and LUTS. Therefore, penile RhoA/ROCK signaling was 
increased in pathologic situations associated with ED, like diabetes and involuntary 
bladder contractions were associated with increased signaling of the muscarinic 
receptor-activated RhoA/ROCK pathway. Increase in RhoA/ROCK was dem-
onstrated in corpora cavernosa and bladder of spontaneously hypertensive rats 
(SHR), a rat strain genetically prone to develop BPH and OAB. The inhibition of 
ROCK reduces bladder hyperactivity, limits contractions in bladder strips from 
SHR, and improves erectile function [67, 68].
4.4 Pelvic atherosclerosis
Atherosclerosis of the bladder, prostate, and penis serves an extra assumption 
linking LUTS with ED. The theory claims that the risks for ED (smoking, hyper-
tension, hypercholesterolemia, and diabetes mellitus) also affect on LUTS. An 
epidemiologic study was published that supports this theory, all men and women 
who had two risk factors of atherosclerosis (diabetes mellitus, hypertension, 
hyperlipidemia, and nicotine use) and had a statistically higher International 
Prostate Symptom Score (IPSS) compared with those with one or no risk factors 
at all. Smooth muscle changes in the prostate, bladder, and penis of animal models 
of hypercholesterolemia and pelvic ischemia are quite similar. Hypoxia drives to 
overexpression of TGFb1, and converted prostanoid production has been suggested 
as potential mechanisms. Similarly, penile ischemia leads to smooth muscle loss 
in it and ends up with ED. Likewise, the loss of smooth muscle in the bladder may 
decrease compliance and increase the symptoms of LUTS. Additionally, bladder 
ischemia either from BOO or pelvic vascular disease would result in bladder smooth 
muscle loss with the resultant replacement of collagen deposition and fibrosis as 
well as loss of compliance, overactivity, and impaired contractility. Loss of smooth 
muscle in the prostate can induce a less distensible urethra, a decreased urinary flow 
rate, increased flow resistance, and worsening LUTS. Pelvic atherosclerosis associ-
ated with the previously described theories, as pelvic ischemia/atherosclerosis is a 
component of the metabolic syndrome/AH, up-regulates Rk activity, and reduces 
NOS expression. [35, 67, 68].
5. Multifactorial interaction between LUTS and ED
LUTS are significant indicators of a disease when the patient, caregiver, or part-
ner realizes it, and change of them may lead him/her to find help from profession-
als. It is also known (from the 6th International Consultation on Incontinence 2016) 
that from overall world’s population, 46% (of the adults >20 years) experience 
LUTS, 11.8% suffer from OAB symptoms, 8% complain of some type of urinary 
incontinence (UI), and 4% of severe stress urinary incontinence (SUI). Urinary 
incontinence is associated with reduced QoL, higher rates of depression, reduced 
work productivity, and decreased enjoyment of sexual activity [35, 69].
It is well known that sexual life, behavior, and relationships are very impor-
tant for a good and healthy life, and they are affected by attitudes, social models 
and overall health. For sexual health many aspects are necessary and not only 
the absence of infirmity, disease or dysfunction. Sexual practice and habits have 
changed a lot over the last years, it is over also known that the sexual frequency and 
different practices are reducing with age. On the other hand, some sexual behaviors 
are more common in our days, like anal sex. These changes are more likely to be 
attributed to educational status, rather than economic status [69].
Lower Urinary Tract Dysfunction - From Evidence to Clinical Practice
112
which an individual is unable to participate in a sexual relationship as she would 
wish” [58]. There are three categories of sexual dysfunction: female sexual interest-
arousal disorder, female orgasmic disorder, and genito-pelvic pain-penetration 
disorder [59]. It is estimated that 10% of women suffer from female sexual interest-
arousal disorder and 3.5–35% present orgasmic problems [60].
Validated psychometric questionnaires, such as the International Index for Erectile 
Function (IIEF) [61] or the sexual health inventory for men (SHIM) [62], are the 
assessment tools needed in different sexual function domains (i.e., erectile function, 
sexual desire, intercourse, orgasmic function, and overall satisfaction), as well as for the 
potential impact of a specific treatment modality. The use of the erectile hardness score 
for the assessment of penile rigidity in practice and in clinical trial research is supported 
by psychometric analyses [63]. Patients should be screened for symptoms of possible 
hypogonadism (testosterone deficiency), libido, fatigue, cognitive impairment, and 
LUTS. Even though LUTS does not represent a contraindication to treat a patient for 
late-onset hypogonadism, screening for LUTS severity is clinically relevant [64].
4. The relationship between ED and LUTS
A lot of epidemiological studies demonstrate the coexistence of ED and LUTS. It 
is also proven that the existence of LUTS is a risk factor for ED. The patient’s age and 
the severity of LUTS are independent prognostic factors for ED, as well. Although it is 
not clear if LUTS lead to ED, or ED results to LUTS, or these conditions are just coex-
isting, their relation is very narrow and clear, especially in older patients. Therefore, 
men who suffer from LUTS should be checked for ED and men who present ED 
should be evaluated for LUTS. There are four theories that try to correlate LUTS with 
ED. These theories include deregulation of NO/NOS system, increased sympathetic 
tone (autonomic hyperactivity (AH)), up-regulation of Rho-kinase, and chronic 
hypoxia. Common vascular risk factors can combine and support these theories.
4.1 Alteration in nitric oxide (NO)
The role of nitric oxide (NO) in erectile function is well known as the main 
regulator of penile corporal smooth muscle relaxation and resultant erection. The 
decrease in NO/cyclic guanosine monophosphate (cGMP) has the effect of reduc-
tion in NO synthase (NOS) due to endothelial dysfunction. Luck or reduction of 
smooth muscle relaxation of the bladder neck, prostate and urethra may lead to 
LUTS. The NO system has been shown to be down-regulated in the transition zone 
of the prostate in BPH when compared with normal controls [67, 68].
4.2 Autonomic hyperactivity (AH)
AH, as a component of the metabolic syndrome, refers to dysregulation of 
sympathetic and parasympathetic tone. Increased sympathetic tone results in flac-
cidity and antagonizes penile erection, due to vasoconstriction. Parasympathetic 
activation can lead to prostate smooth muscle contraction (due to activation of the 
M2 receptors), so nonrelaxing bladder neck, prostatic urethra, and pelvic floor may 
lead to LUTS [67, 68].
4.3 RhoA/rho-kinase-calcium-sensitizing pathway
Smooth muscle tone is adjusted commonly not only through the calcium-
dependent mechanism, but also through the activity of RhoA/ROCK calcium 
113
Lower Urinary Tract Symptoms (LUTS) and Sexual Function and Dysfunction
DOI: http://dx.doi.org/10.5772/intechopen.86827
pathway. Activation of RhoA-ROCK pathway can affect smooth muscle relaxation 
and finally increase ED and LUTS. Therefore, penile RhoA/ROCK signaling was 
increased in pathologic situations associated with ED, like diabetes and involuntary 
bladder contractions were associated with increased signaling of the muscarinic 
receptor-activated RhoA/ROCK pathway. Increase in RhoA/ROCK was dem-
onstrated in corpora cavernosa and bladder of spontaneously hypertensive rats 
(SHR), a rat strain genetically prone to develop BPH and OAB. The inhibition of 
ROCK reduces bladder hyperactivity, limits contractions in bladder strips from 
SHR, and improves erectile function [67, 68].
4.4 Pelvic atherosclerosis
Atherosclerosis of the bladder, prostate, and penis serves an extra assumption 
linking LUTS with ED. The theory claims that the risks for ED (smoking, hyper-
tension, hypercholesterolemia, and diabetes mellitus) also affect on LUTS. An 
epidemiologic study was published that supports this theory, all men and women 
who had two risk factors of atherosclerosis (diabetes mellitus, hypertension, 
hyperlipidemia, and nicotine use) and had a statistically higher International 
Prostate Symptom Score (IPSS) compared with those with one or no risk factors 
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muscle in the prostate can induce a less distensible urethra, a decreased urinary flow 
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tant for a good and healthy life, and they are affected by attitudes, social models 
and overall health. For sexual health many aspects are necessary and not only 
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From a physiological prospect, the functions of pelvic organ functions are 
related as there is a direct relationship with the neuronal network of the pelvis that 
includes bladder, bowel, and sexual functions. Furthermore, vascular, hormonal, 
cellular, and other factors comprehensively affect pelvic organ functions. LUTS and 
ED in males share common pathophysiological pathways [4].
6.  Effects of LUTS/incontinence on male sexual function: 
epidemiological data
Many large studies over the last years have proved the coexistence of SD in men 
with storage and voiding LUTS. Statistics from the Health Improvement Network 
database showed that from 11,327 men in the UK, there was a rise in the overall 
prevalence of recorded SD from 1.7% in 2000 to 4.9% in 2007. The odds ratio (OR) 
for ED was 3.0 (2.6–3.4) for storage LUTS, 2.6 (2.4–2.7) for voiding LUTS, and 4.0 
(3.4–4.8) for voiding and storage LUTS. The EpiLUTS study (a cross-sectional, 
population-representative survey in the UK, Sweden, and the USA with 6326 men) 
show off an impact of OAB on sexual health. Both OAB wet and OAB dry were 
associated with poor sexual health, diminished enjoyment of sex (P < 0.0001), 
and decreased sexual activity. OAB dry/wet was very significant predictors of ED 
and ejaculatory dysfunction (EjD) in men. According to a study by Rosen et al., 
the attendance and severity of LUTS are independent risk factors for SD in older 
men [69].
LUTS are common in older men. While LUTS have a multifactorial etiology, 
BOO/BPH has traditionally been considered as one of the most common causes of 
LUTS. These symptoms, which include dribbling and urgency with leaking, noctu-
ria, and difficulty in urinating, can also impact the sexual function, probably due to 
impact on QoL [70].
7.  Medical and surgical therapy for LUTS and its impact on sexual 
function
The efficacy of all currently available treatments for LUTS is well studied. 
However, the negative impact of them on erectile function is under evaluation. 
Behavior modification therapies and phytotherapies seem to have minimal or no 
impact on sexual function, and even less efficacy on LUTS treatment. On the other 
hand, α-blockers, 5α-reductase inhibitors, and prostatic surgery are associated with 
improvement in LUTS, but they usually have a negative impact on the sexual func-
tion [68]. Many clinical trials have reported on the efficacy of chronic treatment 
with phosphodiesterase type 5 inhibitors (PDE5-Is), either alone or in combination 
with other therapies, in treating LUTS in men with or without ED [71].
α-Blockers such as alfuzosin, doxazosin, tamsulosin, and silodosin have shown 
similar efficacy, but their effect on sexual function is variable. They seem to have 
a slightly positive impact on erectile function. However, they can have a negative 
impact on orgasmic function and ejaculation [72]. Originally, the abnormal ejacu-
late was thought to be retrograde. However, it seems likely to be due to a decrease 
or absence of seminal fluid, possibly by a central effect. α-Blockers decrease the 
prostate secretion and inhibit the contraction of seminal vesicles as both effects are 
mediated by the sympathetic adrenergic system.
5α-Reductase inhibitors (5-ARIs) are usually offered to men with LUTS who 
have a prostate estimated to be larger than 40 ml and who are considered to be at 
high risk of progression [73–75]. Compared to α-blockers, 5-ARIs have a greater 
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impact on sexual function. The side effects most frequently notified are reduced 
libido, ED, and ejaculation disorders such as dry orgasm, ejaculation failure, or 
decreased semen volume [76–78]. It must be mentioned that the effect of 5-ARIs on 
ejaculatory function is currently poorly studied.
Regarding surgical options, transurethral resection of the prostate (TURP) 
and transurethral incision of the prostate (TUIP) are the gold standard surgical 
techniques for BPH/BOO treatment. Dry orgasm after these operations ranges 
from 30.4 to 96.9% and 6.1 to 55.1%, respectively. Heterogeneous data are reported, 
mainly because only a few studies analyzed these rates [79–81] in a prospective 
fashion. ED has been found ranging from 3.4 to 32.4% [80, 81] after TURP.
Laser procedures, such as GreenLight photoselective vaporization of the prostate 
(PVP) and holmium laser enucleation of the prostate (HoLEP) are widely offered 
for BOO/BPH as well. The impact of GreenLight on sexual function seems to be 
close to that of TURP. One single study, comparing these two prostatic surgery 
techniques, reported no significant difference in the rate of retrograde ejaculation 
[82]. There is also no difference reported between TURP and PVP for erectile func-
tion [83, 84]. HoLEP seems to have comparable results. Specifically, the incidence of 
retrograde ejaculation and erectile dysfunction is comparable between HoLEP and 
TURP [85, 86]. It is reported that almost 75% of sexually active patients have retro-
grade ejaculation after HoLEP. Currently, both GreenLight and HoLEP surgeons are 
trying to develop ejaculation preserving techniques [87, 88].
Transurethral thermotherapy and microwave techniques such as transurethral 
needle ablation (TUNA) seem to have lower rates of retrograde ejaculation com-
paring to TURP. A few studies report that the incidence of retrograde ejaculation 
seems to be much lower compared to TURP, with no reported cases in the TUNA 
cohort, compared to the 45% of the TURP arm [89–91]. Urolift/prostatic urethral 
lift (PUL) is an alternative option and has shown positive results in terms of sexual 
function [92].
Currently, because of the increase in life expectancy, patients with LUTS often 
wish to preserve or to improve their sexual function according to their treatments. 
Physicians may focus on the symptoms without considering patients’ wishes and 
expectations. In those cases, despite successful treatment, many patients still 
complain about their QoL due to the procedure or medication side effects.
8. Medical therapy for ED and its impact on LUTS
Phosphodiesterase type 5 (PDE5) is expressed in the whole of the lower urinary 
tract, including the urethra, prostate, and bladder. All these organs are targets of 
PDE5-Is [93–96]. PDE5 is prominently localized in the stroma and in the vascular 
bed (endothelial and smooth muscle cells), suggesting the action of PDE5-I on 
smooth muscle contraction and blood flow.
McVary et al. [97], in 2007, evaluated the safety and efficacy of tadalafil for the 
treatment of LUTS in men with or without ED, for the first time. A total of 479 
patients were screened. After a 4-week washout and 4-week placebo run-in period, 
281 were randomly assigned to a 6-week treatment with once-daily placebo or 
tadalafil 5 mg. After 6 weeks, the remaining 261 patients were assigned to continue 
with placebo for another 6 weeks (a total of 12 weeks of once-daily placebo treat-
ment) or to dose escalate tadalafil to 20 mg once daily. Of 143 placebo-assigned 
patients, 121 (84.6%) were sexually active, 84 (59.2%) had no erectile dysfunc-
tion, and 76 (53.1%) were sexually active despite ED. On the other hand, 138 men 
treated with 5 or 20 mg tadalafil, 107 (77.5%) were sexually active, 99 (71.7%) had 
normal sexual function, and 80 (58.0%) were sexually active despite ED. The IPSS 
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(including the IPSS-QoL question) and BII questionnaires were used in order to 
evaluate LUTS. Maximum urinary flow rate (Qmax) and average urinary flow rate 
(Qave) of free uroflowmetry were record and post-void residual urine (PVR) was 
measured by ultrasound after uroflowmetry. The erectile function (EF) domain of 
the International Index of Erectile Function (IIEF) questionnaire (questions 1–5 
and 15) was used to estimate the sexual function.
Since 2007, numerous studies proved the safety and efficacy of PDE5s as a medi-
cal therapy for both LUTS and ED. Bora Irer et al. [98] studied LUTS, nocturia, 
SD, and the status of QoL in men with obstructive sleep apnea syndrome (OSAS). 
Patients applied continuous positive airway pressure (CPAP) treatment, which 
is one of the most effective treatments for OSAS, supplying positive air pressure 
for the opening of the respiratory tract and keeping high saturation of oxygen. 
Changes in IPSS, IIEF, Overactive Bladder Syndrome Score (OABSS), International 
Consultation on Incontinence Questionnaire for Male LUTS (ICIQ-MLUTS), 
Neuro-quality of life score (Nqol), 36-item Short Form Health Survey (SF-36), and 
Benign Prostatic Hyperplasia Impact Index (BII); the frequency of nocturia; and 
night-time urine volume were reported. After CPAP treatment, significant changes 
and improvements on these symptoms and QoL were observed. It has been shown 
that the frequency of nocturia decreases and erectile function and QoL improves in 
patients with OSAS under CPAP treatment [99, 100].
9. Conclusion
SD and LUTS are confirmed to have a strong connection. It is implied by com-
mon pathophysiological paths that seem to link these two complications, which 
have a great impact on a significant percentage of urological patients. For men, 
PDE5s inhibitors are the milestone of medical treatment for ED and LUTS. Their 
safety and efficacy are widely accepted. More studies need to support this relatively 
new field of research for both LUTS and SD, and new treatments may be used as an 
alternative in near future.
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Lower urinary tract dysfunction (LUTD) is an umbrella diagnosis that covers the 
abnormalities of anatomy and function in the bladder, urethra, and, in men, the 
prostate. People with LUTD face a number of social, mental, and physical health 
effects due to the symptoms. Despite the increasing evidence in the assessment and 
management of lower urinary tract symptoms, it remains a challenge to bridge the 
gap between research evidence and clinical practice. In this book, each and every one 
of the authors presents a remarkable work for how to apply the evidence to clinical 
practice from different aspects. I hope this book is a key for every reader to open the 
door to LUTD.
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